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ABSTRACT  
Conflicting effects of sex hormones on the immune system could potentially explain the 
increased susceptibility of females to autoimmune diseases. In this study, I wanted to explore 
the regulation of the response to sex hormones in T cells from male and female donors. We 
initially investigated the levels of gene expression for sex hormone receptors and sex 
hormone metabolising enzymes in CD45RA+ /CD4+ T cells from male and female donors at 
baseline and after in vitro stimulation. I found that expression of 5α-reductase 1, an enzyme 
which converts testosterone into the more active dihydrotestosterone (DHT), is upregulated 
both on the mRNA and protein level in T cells from female but not male donors after 
stimulation. Since androgens are generally thought to have an anti-inflammatory role, this 
may be a mechanism that regulates the exposure of stimulated T cells to the inhibitory 
influence of DHT. SLE is a systemic autoimmune disease which mainly affects women. I 
investigated the regulation of 5α-reductase in peripheral blood mononuclear cells from 
patients with active or inactive SLE in comparison to normal controls. I did not observe any 
significant differences in 5α-reductase 1 expression in T cells at the baseline or after 
stimulation between SLE patients and healthy controls. However, I did find a significantly 
higher expression of 5α-reductase in B cells from SLE patients compared to healthy controls, 
suggesting that SLE B cells are increasing their exposure to DHT. In a third section of my 
experimental work I investigated the effects of a range of physiological concentrations of 
testosterone and DHT on T cell stimulation and cytokine production. In vitro treatment of T 
cells from female donors with low doses of testosterone resulted in a significant increase of 
the proportion of IL-2-producing CD4+ T cells. Intriguingly, this effect was neither seen at 
higher testosterone concentrations nor with DHT, suggesting that it may not be mediated 
through the androgen receptor. As testosterone, but not DHT can be converted to 17β-
oestradiol by aromatase, we tested whether tamoxifen, a competitive antagonist of the 
oestrogen receptor could block the increase in IL-2 production induced by low doses of 
testosterone in T cells. These experiments confirmed that low doses of testosterone could lead 
to oestrogen dependent upregulation of IL-2 production in T cells. In conclusion, we have 
observed both long-term effects of the hormone environment the T cells have been generated 
in as well as immediate effects of sex hormones on T cell responses.  Attempts have been 
made to therapeutically target the sex hormone system in patients with autoimmune diseases. 
For the efficient development of these therapies we need to improve our understanding of the 
regulatory effects of androgens and oestrogens on the human immune system.     
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1     INTRODUCTION 
 
 
1.1   The immune system  
1.1.1   Introduction 
The main role of the immune system is to protect the body from infections caused by harmful 
foreign pathogens including bacteria, viruses and fungi.  It can be divided into two arms; the 
innate and the adaptive (also known as acquired) system.  The innate system is usually the 
first to encounter any newly invading pathogens. Both systems involve cell-mediated 
responses, with cells directly removing pathogens by phagocytosis or cytotoxicity, and 
humoral responses, which use soluble immune mediators such as antibodies, cytokines and 
the complement system. The innate immune system rapidly responds to infection by firstly 
recognising the presence of an infection and then secondly removing pathogens. Importantly, 
the response needs to be tightly controlled and down-regulated after the infection has been 
cleared to prevent the initiation of inappropriate inflammatory responses, which could lead to 
tissue and organ damage.   
 
Cellular components of the innate immune system include macrophages, neutrophils, natural 
killer (NK) cells, mast cells, eosinophils and basophils. Phagocytes such as macrophages and 
their precursors monocytes ingest pathogens by a controlled process called phagocytosis. 
Phagocytes recognise pathogens through pathogen-associated molecular patterns (PAMPs), 
which are a group of molecular structures found on pathogens and are recognised by 
pathogen recognition receptors (PRRs). PRRs include a range of receptors that recognise 
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different PAMPs on a diverse range of pathogens. For example, macrophages use toll-like 
receptors (TLRs) to recognise cell wall components of Gram-positive bacteria through 
binding to TLR2, whereas TLR4 binds lipopolysaccharide (LPS) found in the cell wall of 
Gram-negative bacteria. Activation of plasma proteins known as complement mediates the 
recognition of pathogens by coating the surface of bacteria with complement fragments in a 
process known as opsonisation. They are then recognised by complement receptors on 
phagocytes, which subsequently result in the phagocytosis of the bacteria. The process of 
opsonisation is greatly increased by the presence of specific antibodies, a classical example 
for the interaction of innate and adaptive immunity (Mantovani 1975). Activation of 
phagocytes results in the production of other immune mediators such as cytokines and 
chemokines, which are responsible for the recruitment and activation of other immune cells 
such as dendritic cells, natural killer cells, B cells and T cells, and therefore initiating the 
involvement of the adaptive immune system.  
 
While the innate immune system responds rapidly, often within minutes, it only recognises a 
limited number of structures on the surface of pathogens. It recognises groups of pathogens 
but has a limited specificity for individual species. This is in contrast to the adaptive 
response, which is slower in its response to new infectious agents, but can subsequently 
recognize a virtually unlimited number of different structures known as antigens. 
Furthermore, the adaptive immune system will generate immunological memory by 
employing specific cells that recognise pathogens previously encountered by the immune 
system in order to initiate a more rapid response to the infection upon re-exposure. Antigen 
presenting cells (APC) provide a key link between the innate and adaptive immune system. 
APCs such as macrophages, dendritic cells and B cells are able to process pathogens 
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(internalised through phagocytosis or receptor-mediated endocytosis), resulting in the 
production of short peptides generated from the pathogen are then displayed on the cell 
surface associated with cell surface glycoproteins called major histocompatibility complex 
proteins (MHC). These antigenic peptides are then recognised by specific T cells and lead to 
the differentiation, proliferation and effector function of effector and memory T cells. 
Activated B cells recognize antigens through the B cell receptor independently of antigen 
presentation and are able to differentiate into memory B cells or plasma cells, which produce 
antibodies specific to the encountered antigen. Effective antibody production also involves 
specific interaction processes between antigen specific T and B cells, in which T helper cells 
are able to activate B cells through CD40/CD40L interactions.  
 
1.1.2   T cells in adaptive immunity 
 
T lymphocytes (T cells) are antigen specific cells that play a vital role in developing the 
adaptive immune response. Upon stimulation and differentiation, T cells can produce a wide 
range of cytokines; specifically kill virus infected cells; provide memory, and contribute to 
self-tolerance. Immature T cells migrate from the bone marrow to the thymus and after 
development in the thymus; mature naive (not previously encountered antigen) T cells that 
express either CD4+ or CD8+ are released into the periphery. CD4+ T helper cells are involved 
in mediating immune responses either by cytokine production or cognate interaction with 
other immune cells such as B cells once antigen has been recognised. CD8+ cytotoxic T cells 
are involved in removal of virally infected and malignant cells. Further CD4+ T cell lineages 
identified, the first being the CD45RO+ subset (Akbar et al. 1988) Later, Mossman and 
Coffman described the Th1 and Th2 subsets based on the differential cytokine production 
(Mosmann et al. 1986). Differentiation into Th1 cells is driven by cytokines IL-12 and IFN-γ 
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(also produced by Th1 cells), and transcription factors STAT1, STAT4 and T-bet. 
Transcription factors STAT6 and GATA-3, and cytokine IL-4 (produced by Th2 cells, and 
also by mast cells, eosinophils and basophils) promote the development of Th2 cells. Th1 
cells are important in defence against intracellular pathogens such as viruses, intracellular 
bacteria and tumour antigens and are involved in delayed type hypersensitivity reactions. 
They activate macrophages to increase their phagocytic activity and upregulate expression of 
MHC class II and other proteins involved in antigen presentation by these cells.  In contrast 
to Th1 cells, Th2 cells are predominately involved in removal of extracellular based 
pathogens and allergic immune responses via the production of IL-4, IL-5 and IL-13.  
   
In recent years, many more CD4+ T cells subsets have been identified (Palmer and Weaver 
2010), which have been characterised by the transcription factors needed for development of 
these specific T cell lineages and also the signature cytokines each subset produces.  T 
regulatory cells (Treg) differentiation is driven by the transcription factor Foxp3 and cytokine 
TGF-β. Transcription factors RORγt, RORα and STAT3 alongside cytokines; TGF-β; IL-6, 
and IL-23 promote the development of Th17 cells, which produce IL-17, IL-21 and IL-22.  
 
Unlike B lymphocytes, T cells cannot recognise native antigen; thus for T cell stimulation the 
antigen must be presented to the T cell via the major histocompatibility complex (MHC) on 
antigen presenting cells (APC) such as B cells, dendritic cells and macrophages (Bretscher 
1999). Two signals are required for T cell activation: the first signal comes from the 
interaction of the T cell receptor (TCR) on the T cell with the MHC associated antigen. The  
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second signal comes from interaction between co-stimulatory molecules CD80 and CD86 on 
APC and CD28 on the T cell surface. An alternative ligand expressed by the T cells is CTLA-
4, however this mediates an inhibitory signal. This second signal derived from CD80/ CD86 
interaction with CD28 is important in T cell self tolerance since antigen recognition in the 
absence of co-stimulation inactivates naïve T cells, inducing a state of anergy (Sharpe and 
Freeman 2002).  It stimulates the production of IL-2, which is needed in clonal expansion 
after T cell activation. Salomon and colleagues demonstrated the importance of CD80/CD86 
interaction with CD28 in self tolerance and prevention of autoimmune responses through the 
demonstration of significant reduction in regulatory CD4+/CD25+ T cells in CD28 knockout 
mice resulting in exacerbated diabetes in non-obese diabetic (NOD) mice compared to wild 
type mice (Salomon et al. 2000). CTLA-4 (also known as CD152) has also been shown to be 
important in maintenance of self tolerance in peripheral effector T cells. The fatal condition 
of lymphoproliferative disease has been observed in CTLA-4 knockout mice and results in 
significantly elevated levels of T cell stimulation (Ise et al. 2010). CTLA-4 is part of the 
CD28 family and has shown to act as part of a negative feedback system in which T cell 
activation leads to the binding of B7 and CTLA-4. CTLA-4 delivers an inhibitory signal to 
the cell, reducing reducing cell proliferation, IL-2 production and T cell mediated immune 
responses. CTLA-4 has a vital role in preventing self-reactive effector T cells (that have 
escaped negative selection) from clonal expansion, being expressed by both effector T cells 
and regulatory T cells.  
 
1.1.3   Autoimmunity 
 
Autoimmunity is defined as the reaction of the adaptive immune system to self-antigen due to 
loss of immunological tolerance. Autoimmune diseases arise from the organ/tissue damage 
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caused by autoreactive T or B cells through both cell-mediated and humoral immune 
responses resulting in array of clinical manifestations. The immune system has various check 
points in place during lymphocyte development to prevent the maturation of autoreactive 
lymphocytes. The first stage of inducing tolerance is known as central tolerance, in which 
immature B and T lymphocytes undergo negative selection to eliminate autoreactive 
lymphocytes. In the bone marrow, immature B cells expressing IgM antigen receptors that 
strongly cross-link multivalent self antigens such as MHC molecules are subsequently 
induced to undergo programmed cell death, apoptosis. These self-reactive cells can be saved 
from cell death by undergoing receptor editing, in which the light chain of the receptor is 
rearranged resulting in a new receptor specificity being expressed, thus removing self-
reactivity (Hardy and Hayakawa 2001; Tsuiji 2006).  
 
T cell development in the thymus also involves negative selection of self-reactive cells. 
Firstly, immature T cells receive survival signals if their T-cell receptor demonstrates 
compatibility with self-MHC molecules on thymic cortical epithelial cells; this is known as 
positive selection. However, if the TCR expressed by the immature T cell interacts strongly 
with self peptides associated with self-MHC expressed by antigen presenting dendritic cells 
in the medulla, then these self-reactive T cells are not able to enter the periphery but are 
instead removed via apoptosis. This process is known as negative selection. 
 
Once mature lymphocytes have left the central lymphoid organs, autoreactive lymphocytes 
are held in check by peripheral tolerance mechanisms. Mature self-reactive T cells 
recognising self antigen can escape the tolerance checkpoints during the early developmental 
stages as the self antigen they recognise may not be present in the central lymphoid organs, 
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and therefore continued in the development process without deletion. Mechanisms which 
prevent the potential destruction caused by autoreactive lymphocytes include anergy (Rocha 
and von Boehmer 1991), in which self reacting T cells become functionally unresponsive due 
to absence of co-stimulation by APCs, thus resulting in insufficient cell activation and can be 
removed by apoptosis. In the absence of added stimuli, termed “danger signals” (Matzinger 
2002), proinflammatory mediators such as cytokines are not produced and co-stimulatory 
molecules on activated APCs are not expressed, therefore adaptive immune activation is 
suppressed. Another mechanism used in peripheral tolerance is through the use of Tregs that 
suppress effector T cells by anti-inflammatory cytokines such as IL-10 and TGF-β and 
expression of CTLA-4. Self-reactive effector T cells can also be differentiated into induced 
Tregs in the presence of TGF-β (Bluestone and Abbas 2003).  
 
Autoimmunity can occur when mechanisms involved in inducing tolerance are defected or 
absent. Autoimmune diseases can either be organ-specific or systemic, in which multiple 
organs are targeted. Organ specific diseases such as multiple sclerosis (MS), type 1 diabetes 
mellitus and Hashimoto’s thyroiditis arise via inflammation mediated tissue/organ damage in 
the CNS, pancreas and thyroid respectively. Systemic diseases include rheumatoid arthritis 
(RA), which primarily involves inflammation and destruction of joints, and systemic lupus 
erythematosus (SLE), in which organs such as the skin, kidneys, lungs, are targeted by 
autoantibodies and resulting immune complexes. Many autoimmune diseases are 
characterised by the presence of autoantibodies, for example autoantibodies specific for the 
myelin sheath in MS (Genain et al. 1999); anti-citrullinated protein antibodies (ACPA) and 
rheumatoid factor (RF) in rheumatoid arthritis (RA) (de Vries-Bouwstra et al. 2008); and 
autoantibodies specific for double stranded DNA in SLE (Swaak and Smeenk 1985).  A 
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significant discovery was the important involvement of T cells in the pathogenesis of various 
autoimmune conditions. 
 
 
1.1.4   The role of T cells in autoimmunity  
 
T cells for a long time have been viewed as the main instigators in autoimmune diseases due 
to their importance in maintaining self tolerance. The CD4+ T cell lineage in particular has 
been identified as a mediator of autoimmunity (Luger et al. 2008; Palmer and Weaver 2010). 
Many findings support this notion, for example the accumulation of activated CD4+ T cells at 
sites of  inflammation and the association of autoimmune diseases with HLA types (Goronzy 
and Weyand 1993; Viallard 2001). The involvement of T cells in the development of 
autoimmune disease has been demonstrated by the ability of self-reactive T cells to confer 
disease when adoptively transferred from a diseased animal to a healthy one. For example, 
the transfer of autoreactive CD4+ T cells from mice with experimental autoimmune 
encephalomyelitis into healthy mice induces disease (Luger et al. 2008). Autoreactive CD8+ 
T cells have been implicated in autoimmune diseases such as type I diabetes, as pathogenic 
self-reactive CD8+ T cells destroyed insulin-producing beta cells in the pancreas of  NOD 
mice (Nagata et al. 1994). A significant finding, which implicated CD4+ T cells in 
autoimmune diseases, was the observation that susceptibility is associated with MHC 
genotype, as most diseases have been linked strongly to MHC class II alleles. For example, 
the MHC II allele subunit human leukocyte antigen-DR (HLA-DR4) is associated with RA 
(Goronzy and Weyand 1993; Walser-Kuntz et al. 1995). As CD4+ T cells recognise antigen 
associated with MHC class II, whereas CD8+ T cells recognise antigen peptides associated 
with MHC class I, therefore abnormalities within MHC class II associated genes  
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sparked the growing interest of CD4+ T cells in autoimmunity. In addition to the 
identification of MHC genes in controlling susceptibility to autoimmune disease, single 
nucleotide variants (SNP) in gene loci encoding proteins involved in regulation of T cell 
activation such as protein kinase C (PKC)-theta, PTPN22 and CTLA-4 are also associated 
with autoimmune diseases (Barton et al. 2008; Fernandez-Blanco et al. 2004; Menard 2011; 
Rieck 2007). While genetic risk factors for autoimmune diseases have been identified most 
autoimmune conditions are regarded as complex diseases involving both genetic and 
environmental factors (such as smoking) (Padyukov et al. 2004). These factors ultimately 
result in aberrant immune activation and the production of various immune mediators 
responsible for the development of destructive immune responses. For example in RA, 
cytokines contribute to the clinical manifestations seen such as joint synovial tissue 
inflammation and bone destruction (McInnes and Schett 2007). In MS, myelin specific CD4+ 
T cells that have crossed the blood-brain barrier are reactivated, leading to inflammation and 
destruction of the myelin sheath surrounding nerves (demyelination) via the production of 
cytokines and recruitment of other inflammatory cells (Langrish et al. 2005).   
 
Autoimmune diseases such as RA and MS have been thought for a long time to be driven by 
T-helper cell type 1 (Th1). IL-12 is required for the differentiation into Th1 cells and has 
been thought to play a key role in the pathogenesis of Th1 driven autoimmune diseases 
(Leonard et al. 1995; Matthys et al. 1998). However, the role of the Th1 subset in the 
pathogenesis of autoimmunity has been questioned due to the discovery of the Th17 subset 
(Harrington et al. 2005), which has been shown to be important in the development of 
autoimmune conditions. Th17 cells have been characterised by the production of cytokine IL-
17. Th17 differentiation depends particularly on the presence of cytokines such as IL-23, 
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TGF-β, and IL-6. IL-23 has recently been shown to be part of the IL-12 family as it shares 
the p40 subunit with IL-12 (Oppmann et al. 2000). For the cytokine IL-23 the p19 subunit 
dimerizes with the p40 subunit, whereas for IL-12 the p35 subunit dimerizes with p40. Before 
this observation was made, the lower susceptibility to autoimmunity observed in p40 
deficient mice had been attributed to the role of IL-12 in the promotion of Th1 differentiation. 
Now studies have shown that both p40 and p19 promote autoimmune diseases in mouse 
models, but p35 was not necessary for the induction of autoimmunity (Gran et al. 2002). 
Such findings indicate the requirement of IL-23 but not IL-12 for disease development (Cua 
et al. 2003; Langrish et al. 2005). The mouse models experimental autoimmune 
encephalomyelitis (EAE) and collagen-induced arthritis (CIA) have shown that in mice Th17 
cells and the presence of IL-23, which is required for differentiation and proliferation of Th17 
cells, are responsible for the progression of autoimmunity due to the production of pro-
inflammatory cytokines such as IL-6, IL-1 and TNF-α by Th17  cells (Nakae et al. 2003; 
Serada et al. 2008). In contrast, mice deficient in IFN-γ, IFN-γR, IL-12Rβ2, and the IL-12p35 
chains had an increased susceptibility to developing EAE and CIA, thus suggesting a 
protective role for IL-12 and IFN-γ mediated responses  (Ferber et al. 1996; Willenborg et al. 
1996; Zhang et al. 2003).  
 
Due to the important role of the Treg subset; either originated from the thymus known as 
natural Treg or induced in the periphery by transforming growth factor β (TGF-β) known as 
iTreg, in the regulation of effector T cell function by inducing tolerance and having the 
ability to suppress T cell activation and proliferation, various studies have been carried out to 
investigate if Treg activity is suppressed in autoimmune conditions (Haufe 2011; Korn 2007; 
Yan 2008). However, it has been demonstrated multiple times that there are elevated numbers 
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of CD4+ CD25+ FOXP3+ Tregs in the synovial fluid of RA patients (Haufe 2011; Mottonen 
2005; Ruprecht 2005), and this is further supported by the enhanced demethylation status of 
the FOXP3 locus within synovial fluid derived FOXP3+ Tregs (Janson 2011). Therefore, 
Tregs themselves might not be defected but the pro-inflammatory environment could 
suppress Treg responses as various in vitro studies have shown Tregs isolated from inflamed 
RA joints are functional. This theory has been investigated in an animal model for SLE 
(Parietti et al. 2008) and in SLE patients (Yan 2008), in which impaired Treg functions were 
demonstrated in the presence of pro-inflammatory cytokines IL-6 and IFN-α produced by 
APCs. Tregs have also been shown to be responsive to TNF (Chen 2008; Chen 2010), which 
is an interesting finding as TNF plays a pivotal role in the development of RA. However, the 
effects of TNF on Treg responses have conflicting outcomes as mouse models of 
inflammation have shown TNF to mediate the expansion of the Treg population (Chen et al. 
2007). In contrast, human in vitro studies have shown TNF is able to suppress Treg 
proliferation, and in inflamed RA joints there is an inverse correlation between the numbers 
of Treg cells and the levels of TNF (Herrath 2011). Anti-TNF therapy has shown to 
compensate for the defect natural Treg population in RA by increasing the population of a 
Treg subset characterised with a CD4+ CD25high CD62L- FOXP3+ phenotype, which reduced 
the production of pro-inflammatory cytokines through a TGF-β dependent mechanism 
(Ehrenstein 2004; Nadkarni et al. 2007).   
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1.2   Systemic Lupus Erythematosus (SLE) 
 
1.2.1   Introduction  
Systemic Lupus Erythematosus (SLE) is an autoimmune disease involving the breakdown of 
tolerance to nuclear self antigens, leading to the production of autoantibodies and finally 
resulting in systemic inflammation and tissue damage. There are 5 million people worldwide 
suffering from SLE and the most common symptoms include extreme fatigue, joint pain, 
weakened muscles, rashes and hair loss. There is a significant gender bias in SLE with 
females more likely developing the disease with a 9:1 female to male ratio (Washburn et al. 
1965; Whitacre 2001). There is also a prominent association of SLE with ethnic background, 
occurring more often in women from an Afro-Caribbean or Asian background then Caucasian 
women. SLE has an estimated prevalence of 28 per 100,000 in the general adult UK 
population, while in Afro-Caribbean women prevalence is around 206 per 100,000. Flares of 
SLE usually arise during childbearing years (usually between the ages of 15-55yrs) and 
continue on a cycle of flares and remission for many years often leading to multiple organ 
damage. The clinical manifestations of SLE are variable. However, approximately 90% of 
patients present with joint pain, and 75% present with skin rashes. A very well recognised 
clinical feature of SLE is the appearance of a rash described as butterfly-shaped spanning the 
face.  
 
1.2.2   Pathogenesis of SLE  
The presence of high levels of autoantibodies, in particular anti dsDNA (double-stranded 
DNA) and anti-nuclear antibodies, is a common biomarker for the development of SLE 
(Swaak and Smeenk 1985). Many organs are affected in SLE by increased inflammation 
14 
 
which may lead to sometimes life threatening complications such as cardiovascular disease 
and lupus nephritis (Clynes et al. 1998). Also, SLE patients are also likely to develop 
additional autoimmune conditions such as Sjogren’s syndrome, thyroid disease and Hughes 
syndrome (anti-phospholipid syndrome).  
 
A wide range of autoantibodies against ubiquitous cellular constituents are detected in SLE 
patients. The main antigens targeted are intracellular nucleosome particles: the nucleosome 
subunits of chromatin, the spliceosome, and a small cytoplasmic ribunucleoprotein complex 
containing two proteins known as Ro and La (Arbuckle 2003). These autoantigens become 
extracellular when exposed on dead and dying cells and are released from injured tissues. The 
resulting generation of immune complexes comprising autoantibodies and these autoantigens 
occurs continuously due to the wide availability of the antigens (figure 1.1). Immune 
complexes may become deposited in the walls of small blood vessels in the renal glomerulus, 
the glomerular basement membrane, joints, and other organs (Brentjens et al. 1975; Churg et 
al. 1980; Schmiedeke et al. 1989). This leads to the activation of phagocytic cells through 
their Fc receptors, resulting in tissue damage and further release of nucleoprotein complexes 
which initiates further generation of immune complexes. During this process, autoreactive T 
cells become activated and provide important help to B cells, but can also be directly 
pathogenic, forming part of the cellular infiltrates found in the skin and kidney and blood 
vessels. The resultant inflammation in affected tissues may ultimately be sufficient to induce 
patient mortality. 
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Figure 1.1 Formation of immune complexes through ineffective apoptotic cell clearance 
and activation of immune responses. 
Nucleic acid autoantigens become extracellular when exposed on dead and dying cells and 
are released from injured tissues. The resulting generation of nucleic acid containing- 
immune complexes comprising of autoantibodies and autoantigens occurs continuously due 
to the wide availability of the antigens. This leads to the activation of phagocytic cells 
through their Fc receptors and TLRs (toll-like receptors), resulting in the production of pro-
inflammatory mediators and further release of nucleoprotein complexes, which initiates 
further generation of immune complexes. During this process, autoreactive T cells become 
activated and provide important help to autoreactive B cells thus further initiating the 
production of autoantibodies against nucleic acid.  
 
1.2.3  Treatment of SLE 
Treatment options for SLE include non-steroidal anti-inflammatory drugs, antimalarial 
agents, glucocorticoids, and immunosuppressive agents. The choice of therapy is primarily 
determined by disease severity and the function of the organs involved. Non-steroidal anti-
inflammatory medications are often used in the treatment of mild symptoms to reduce 
inflammation and dampen joint and muscle pain.  
Hydroxychloroquine has previously been used in the treatment for malaria but has shown to 
reduce SLE symptoms such as fatigue, muscle and joint pain, and skin rashes. Corticosteroids 
are widely used to reduce inflammation in cases of SLE; however they can lead to many 
unwanted and serious side effects. Corticosteroids are commonly used in combination with 
16 
 
immunosuppressants such as azathioprine and cyclophosphamide to improve symptoms and 
limit organ damage in severe cases of SLE. In addition, rituximab, which was originally 
developed as a cancer drug, has been used off-label and in clinical trials for the treatment of 
SLE (Merrill 2010).  Rituximab is a monoclonal antibody, which depletes CD20-expressing 
B cells. Since large scale clinical trials showed disappointing results it has not yet been 
approved for routine therapy.  
A further example of a drug used to target B cells is Belimumab, a human monoclonal 
antibody raised against a cytokine called B cell activating factor (BAFF) also known as 
BLyS. BAFF is important in many stages of B cell development particularly in the regulating 
the selection of naïve B cell repertoire and the survival of mature B cells (Benson 2008). Low 
levels of BAFF induce the negative selection of early autoreactive B cells, while higher levels 
facilitate their progression into the mature B cell compartment (Lesley et al. 2004). BAFF 
serum levels positively correlate with disease activity and over expression of BAFF in mice 
led to the induction of SLE in a T cell independent manner. Clinical trials involving the 
treatment of SLE patients with Belimumab have shown to decrease disease flares and showed 
to improve serological activity (Furie 2011; Jacobi 2010; Stohl et al. 2012). Although the 
effects were modest, it has now received NICE approval and can be used to treat SLE 
patients.  
 
1.2.4  Genetic basis of SLE 
The events responsible for induction of SLE are not yet understood; however it is thought 
that certain genetic traits along with a yet unknown environmental trigger are responsible for 
the initiation of the disease. Most genetic polymorphisms associated with development of 
SLE been found in immune-response related genes (Graham 2008; Sanchez 2011). 
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Considerable evidence suggests that a key driving factor is an impairment or delay in the 
process of apoptotic clearance (Manderson et al. 2004; Marinez Valle et al. 2008). Persistent 
apoptotic cells may undergo necrotic cell death leading to abnormal innate immune responses 
associated with resultant danger signals, and accessibility to modified autoantigens resulting 
in the production of autoantibodies. These abnormal immune responses can result in 
irreversible tissue damage manifested in the clinical features of SLE.  
 
The increased susceptibility of developing SLE among siblings and first degree relatives of 
SLE patients demonstrates the link between genetic factors and the occurrence of SLE. There 
is a strong association between gene polymorphisms in HLA class II and SLE, in which 
certain HLA class II genes have been associated with autoantibodies such as anti-Sm (small 
nuclear ribonuclear protein) and anti-DNA antibodies. Also, inherited deficiencies in HLA 
genes class III encoding for components of the complement system (C2 and C4) have also 
confer increased risk of developing SLE (Howard et al. 1986; Senaldi et al. 1988). 
 
These abnormalities alongside defects in nucleic acid breakdown by DNase (caused by 
defects in the Dnase1 gene) results in an increased exposure of self antigens and nucleic acids 
and a resulting immune response against antigens, which would not normally be detected by 
the immune system (Shin et al. 2004). Autoantibodies produced are able to form immune-
complexes which are recognised by innate inflammatory receptors such as Fc receptors (FcR) 
and TLRs on or in innate immune cells thus resulting in activation of the innate immune 
system (Katayama et al. 1983).  
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Polymorphisms in genes encoding components of the innate immune system such as TLRs 
and TNF are also associated with SLE (Demirci et al. 2007; Graham 2008). There is a 
significant correlation between type 1 IFN levels and disease severity in SLE (Rönnblom et 
al. 2006), and polymorphisms in type 1 IFN have been associated with SLE (Baechler et al. 
2003). Plasmacytoid dendritic (pDC) cells are a major producer of type 1 IFNs and are 
activated by nucleic acid-containing immune complexes (Båve et al. 2003). Type I IFNs are 
also able to induce genes involved in the TLR signalling pathway thus amplifying the 
inflammatory response (Baccala et al. 2007). 
 
1.2.5  Defects of innate immunity in SLE 
Abnormalities in the innate immune system have been shown to play a key role in the 
induction of the disease before any clinical features of SLE are visible. Targeting of self 
organs/tissue by innate immune cells may stem from the absence of safe and efficient 
clearance of apoptotic cell debris and nucleic acid, which can be opsonised by autoreactive 
IgM resulting in nucleic acid-containing immune complexes (NA-IC). Every day, vast 
numbers of cells undergo programmed cell death known as apoptosis. Therefore, it is 
extremely important that apoptotic cells and their content are effectively removed by 
phagocytosis without inflammation occurring. This involves a sequence of pathways taking 
place to prevent secondary necrosis of the cell and leakage of toxic cell components. In order 
to initiate phagocytosis of the apoptotic cells, apoptotic cells alter their cell membrane by 
exposing cytosolic phosphatidylserine on the surface and thereby signalling to phagocytes 
such as macrophages, monocytes and dendritic cells that the cell is undergoing apoptosis. 
Antibodies and the complement system are also essential for the safe removal of apoptotic 
cells by opsonising cells which initiates phagocytosis. DNases also assist this process by 
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breaking down nucleic acid released by apoptotic cells. Defects of these clearance  
mechanisms such as  polymorphisms in C1q and  DNase1 lead to diseases sharing features 
with SLE (Senaldi et al. 1988). Clearance abnormalities results in activation of innate 
receptors such as FcR, TLRs (inside and on the cell surface) on innate cells for instance 
macrophages, monocytes, dendritic and B cells.  Signalling through internal TLRs can also 
occur when nucleic acid translocates to within the cell by the formation of endosomes, in 
which unprocessed TLRs are cleaved and interact with internalised nucleic acid. This in turn 
results in the activation of transcription factor nuclear factor kappa-light chain enhancer of 
activated B cells (NF-ΚB) and leads to the production of proinflammatory cytokines such as 
type one IFNs (IFN-α and IFN-β), TNF, IL-6, IL-1 and IL-17. These inflammatory mediators 
then activate the adaptive immune system, in which self reactive and long lived T and B 
effector cells further amplify the proinflammatory immune response resulting in organ and 
tissue damage (Yasutomo 2003). This vicious cycle continues as autoreactive effector T cells 
help activate B cells to produce autoantibodies towards double stranded DNA accumulated 
through abnormal clearance mechanisms thus initiating more proinflammatory innate 
responses and the cycle repeats itself.  
 
Recently it has also been reported that IFN-α can increase NETosis in neutrophils, which 
involves dying neutrophils extruding their DNA known as neutrophil extracellular traps 
(NETs) pDCs are then activated by NA-IC formed from NETs which leads to further 
production of IFN-α (Garcia-Romo 2011; Lande 2011).    
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1.2.6  The role of B cells in SLE 
In SLE, B cells play a key role in the pathogenesis of the disease as a result of their 
maturation to pathogenic, autoantibody-secreting plasma cells, and their ability to act as 
APCs for autoreactive T cells, providing co-stimulation and initiating T cell activation and 
through production  pro-inflammatory cytokines such as TNF and IL-6 In healthy individuals 
there is a population of low affinity IgM class autoantibodies responsible for mediating the 
safe clearance of apoptotic cell debris and nucleic acid, however, in SLE this B cell tolerance 
is disturbed meaning harmless self antigens promote sequential proinflammatory responses 
leading to irreversible systemic tissue and organ damage which are responsible for the 
clinical manifestations of SLE. In SLE, the B cell receptor (BCR) on the surface of 
autoreactive B cells is also able to bind to nucleic acid, which leads to activation and 
differentiation, and importantly the upregulation of transmembrane activator and calcium 
modulator ligand interactor (TACI), which binds to important B cell survival factors BAFF 
and April.  BAFF produced by myeloid dendritic cells can also activate survival signals 
within self reacting B cells (Leadbetter 2002). 
 
The breakdown of B cell tolerance may also be due to defects in the B cell developmental 
process, which results in the increased production of anti-double stranded DNA antibodies by 
long-lived autoreactive effector B cells, memory B cells and plasma cells. During B cell 
maturation immature B cells leave the bone marrow into the circulation, in which they are 
transported to secondary lymphoid organs, where they go through various check points to 
prevent maturation of autoreactive B cells, however defects in these checkpoints have been 
observed in SLE (Yurasov et al. 2005).  
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1.2.7  T cell defects in SLE 
 
T cells play an important role in SLE pathogenesis by contributing to B cell differentiation, as 
evidenced by the observation that autoantibodies detected in SLE are class-switched and have 
therefore undergone somatic hypermutation in germinal centres with the help of cognate T 
cells (Odendahl et al. 2000). In addition, T cells directly infiltrate affected organs such as the 
renal parenchyma, causing tissue damage via direct cytotoxicity and recruitment and 
activation of macrophages (Kuroiwa and Lee 1998). Antigen-presenting myeloid dendritic 
cells and B cells with MHC associated with self antigen expressed on their surface are able to 
activate self-reactive T cells. There is a genetic association between risk alleles within the 
MHC region and SLE, which may contribute to the accumulation of self-reactive effector T 
cells. There are potentially genetic defects within the T cell development process as there are 
various check points in place to prevent the survival of self reactive T cells; these include 
negative selection within the thymus involving cell death of self reactive cells, receptor 
editing, induction of anergy to prevent T cell activation, and finally regulatory cells such as 
Tregs responsible for mediating effector T cell responses (von Boehmer and Melchers 2010). 
There are significant amount of risk alleles within the MHC region associated with SLE and 
could be an explanation for the loss of T cell tolerance and the accumulation of self reactive 
effector T cells.  
 
There are also intrinsic defects within T cells from SLE patients that have been demonstrated; 
T cells produce very low levels of IL-2 after antigenic and mitogenic activation and are less 
responsive to IL-2 in comparison to healthy individuals. This may be due to an altered TCR 
complex that has the CD3 ζ subunit abnormally replaced by the homologous FcRγ chain 
(Liossis et al. 1998). Upon activation, signalling therefore occurs through spleen tyrosine 
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kinase (SYK) instead of ζ-chain-associated protein kinase 70 (ZAP70) resulting in an increase 
in intracellular calcium concentration. This then can lead to an imbalance in transcription 
factor activation in which cAMP response element binding protein (CREMB) is favoured 
over cAMP response element modulator (CREM) thus resulting in a decrease in IL-2 
synthesis  (Juang 2005). T cells from SLE peripheral blood also have higher CD40 ligand 
expression, which is important in activating B cells that express CD40 receptor. T cells may 
therefore have an increased capacity for activating self-reactive B cells, leading to enhanced 
proliferation and differentiation to autoantibody-producing plasma cells.  
 
Another key finding associated with abnormal T cell responses  in SLE, is the presence of 
defects in CTLA-4 in SLE T cells (Fernandez-Blanco et al. 2004). As previously mentioned, 
CTLA-4 plays a vital role in the regulation of T cell responses in an inhibitory manner; 
including suppression of prolonged immunological synapse formation, and inhibition of 
activation induced downstream signalling through the high concentrations of CTLA-4  
present in the membrane lipid microdomains that are associated with TCR  (Ise et al. 2010). 
CTL4-4 is also key component in regulatory responses by a large proportion of Tregs.  
CTLA-4 expression has shown to be significantly higher in SLE T cells in both FOXP3+ and 
FOXP3- T cells compared to healthy individuals (Jury et al. 2010), however it’s regulatory 
role in T cell signalling after subsequent TCR activation has shown to be deficient in SLE T 
cells, which was due to the absence of CTLA-4 in lipid microdomains, thus reducing CTLA-
4 interaction with TCR (Jury et al. 2010).   
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1.3   Gender differences in autoimmunity 
 
1.3.1   Introduction 
 
It is well established that the prevalence of autoimmune conditions in females is significantly 
higher in than in males (figure 1.2). There is a significant difference in autoimmune 
susceptibility between genders; the female to male incidence ratio for RA is 3:1, in multiple 
sclerosis it is 2:1, and more drastic differences are observed in autoimmune conditions  such 
as SLE, Hashimoto’s thyroiditis and Sjogren’s syndrome, in which the ratio  is  9:1 (Whitacre 
2001).  However, there are a few exceptions to the higher incidence of autoimmunity in 
females such as Ankylosing Spondylitis, in which males are more susceptible with a male to 
female ratio of 3:1; studies have shown that mutations in androgen-responsive genes have 
been linked to the development Ankylosing Spondylitis (Tsui et al. 2005).  
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Figure 1.2 The incidences of autoimmune diseases by sex.   
This shows the percentage incidence of various autoimmune conditions for both genders and 
the number of incidences (x 1,000,000) in females above each pink bar. Taken from 
Whitacre, ‘Sex differences in autoimmune disease.’ Nature (2001). 
 
 
 
There are various factors that could be responsible for this sex difference, one being that 
females have been demonstrated to having a more robust immune responses,  in comparison 
to their male counterparts, which also has been argued as the reason for significantly longer 
life spans in women compared to men (Aspinall 2000). It has been reported that women have 
stronger humoral and cellular immunity, and respond more robustly to infections, 
vaccinations and trauma by producing higher antibody titres, especially higher levels of 
serum IgM (Lichtman, Vaughan et al 1967) (Michaels and Rogers 1971). Also, females have 
shown to have a higher CD4+ T cell count (Amadori et al. 1995), and predominately Th2 
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immune responses in contrast to males, who have more severe Th1 immune responses. From 
a very young age onwards severe bacterial and viral infections are far more frequent in males. 
 
Environmental factors could also potentially explain the gender differences in autoimmunity.  
A Canadian study showed a rapid and significant increase in the female to male ratio for MS 
over the past 50 years (Orton et al. 2006), thus suggesting the potential role of environmental 
factors in the increased incidence of MS in females. For an example, there is evidence to 
suggest that exposure to chemicals and toxins found in cosmetics could increase the 
susceptibility of autoimmunity in females (Finckh et al. 2006; Wang et al. 2008). Studies 
have also investigated the influence of sunlight especially in MS, as low exposure to sunlight 
has shown to be a risk factor in developing MS (Pugliatti et al. 2002). Females have shown to 
have lower exposure to sunlight compared to males and also males tend to use sunscreen less 
often compared to their female counterparts (Hall et al. 1997). These differences in sunlight 
exposure between the sexes will thus have an effect on the production of steroid vitamin D, 
which has shown to have immune-modulating effects (Smolders et al. 2008). MS sufferers 
have shown be vitamin D deficient (Nieves et al. 1994), and in mice females supplemented 
with vitamin D were protected against the development of EAE (Experimental Autoimmune 
encephalomyelitis) (Spach and Hayes 2005) , which is the mouse model for MS.  
 
Another area that has also been investigated extensively is pregnancy and its effect on 
autoimmune diseases. Lifestyle changes could also be responsible for the increase in female 
to male ratio for certain autoimmune diseases. Throughout evolution, women would have 
been pregnant and breastfeeding throughout their fertile life, and therefore would have been 
protected against the development of certain autoimmune conditions such as MS and RA, 
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which have shown to improve during pregnancy due to high oestrogen levels (Latman 1983; 
Offner and Polanczyk 2006). However, women are now having fewer children and much 
later in their fertile life, thus this protection from certain autoimmune diseases could be 
absent.  Other then the effect of oestrogen (discussed later on in this chapter), there have been 
studies investigating microchimerism, which occurs during pregnancy and involves the 
transfer of haemopoietic cells from the foetus to the mother that then reside there for a short 
term or persist as either stem cells or lymphocytes. An environmental trigger can then break 
the tolerance of microchimeric cells towards the recipient and thus lead to the development of 
autoimmunity in the mother. This has been observed in the autoimmune disease scleroderma 
as it resembles many features of graft-versus host disease (Artlett 2003; Evans et al. 1999).  
 
Trauma is also key area in which a significant sex difference is observed; males recover less 
efficiently from severe traumatic injuries such as haemorrhage and other physical traumas 
leading to more trauma-related deaths compared to females (figure 1.3) (Choudhry et al. 
2007). There is a fine balance in which the immune system operates; it should protect the 
body from potentially harmful foreign antigens through the mediation of various immune 
cells and production of inflammatory mediators without these inflammatory processes 
damaging to tissue and organs. This balance is disturbed through the induction of traumatic 
injuries, thus leaving the body very vulnerable to severe infections.  Firstly, trauma related 
injuries leads to an amplified proinflammatory response followed a significantly suppressed 
immune response (known as immune depression) resulting in severe bacterial or viral 
infections (Choudhry et al. 2006). The observation that males are more vulnerable to 
developing induced subsequent sepsis suggests that they have less robust immune systems 
compared to females. There is a significant reduction in pro-inflammatory cytokines 
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produced by macrophages such as IL-1, IL-6 and TNF-α, antigen presentation to T cells, and 
a decrease in T cell proliferation and production of cytokines such as IL-2 and IFN-γ. In 
contrast, there is a significant increase in anti-inflammatory cytokine IL-10. 
 
 
 
 
 
 
 
 
 
Figure 1.3 The incidence of sepsis in multiple trauma patients between the sexes.  
This shows the incidence of sepsis in males and females according to the patient injury 
severity score (ISS). Error bars show 95% confidence intervals. Taken from Wafaisade et al, 
‘Epidemiology and Risk Factors of Sepsis after Multiple Trauma’. Critical Care Medicine 
(2011) 
 
 
These changes in immune cell responses however are not observed in females and remain 
constant during traumatic stress. This advantageous protection against various infections 
females have acquired is also responsible for disadvantageous increased susceptibility of 
many autoimmune conditions.  
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1.3.2  Genetic factors responsible for sex differences in autoimmunity  
 
The obvious answer to the sex difference in autoimmunity may lie in sex linked genes. 
Various studies have addressed the role of the X chromosome on the immune defects seen in 
autoimmunity.  During early stages of female embryogenesis one X chromosome is randomly 
silenced leading to its inactivation in order to prevent the double dosage of X chromosome 
genes. This process results in cellular mosaicism; this means that in females half the cells 
contain genes originating from the maternal X chromosome and half the cells containing 
genes from the paternal X chromosome. The X chromosome contains genes that directly or 
indirectly involved in the immune system, and therefore having two different sets of X 
chromosome derived genes protects females from deleterious gene-mutations and provides 
them with an increased immunological diversity (Spolarics 2007). This is clearly 
demonstrated in X-linked inherited recessive diseases, in which the phenotypes are more 
prominent in males as they only have one X chromosome. Many of these X-linked diseases 
significantly disrupt immune responses, these are known as X-linked primary 
immunodeficiencies (X-linked PIDs). The X chromosome codes for many genes involved in 
immune processes such as transcription factor forkhead box P3 (FOXP3), CD40L, TLR-7 and 
interleukin-2 receptor-γ (IL2RG). Mutations in these genes lead to various loss of function 
defects within immune function resulting in severe immunedeficiency, thus being responsible 
for recurring viral and bacterial infections, which are often fatal in male newborns. X-linked 
chronic granulomatous disease (X-CGD) occurs from mutations in cytochrome b-245 β-
subunit (CYBB or NOX2) (Teahan et al. 1987), which is important in superoxide production 
during phagocytosis; mutations in CYBB leads to deficient bacterial or fungal killing by 
phagocytes and an increased susceptibility to SLE. Another example of an X-linked PID is 
X-linked severe combined immunodeficiency (X-SCID) which arises due to a mutation in the 
IL-2RG gene which encodes the IL-2 receptor gamma chain common to receptors for several 
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interleukin receptors (Noguchi 1993). Mutations in this gene disrupt cytokine signalling, and 
in the absence of IL-7 and IL-15 signalling, T cell and natural killer cells fail to develop. 
Additionally there is decreased production of immunoglobulins by B cells (also demonstrated 
in X-linked CD40L deficiency). One loss of function mutation in particular is so detrimental 
that males die in utero; this condition is known as incontinentia pigmenti, whereas mutations 
that do not completely inactivate but reduce the activity of the protein lead to a rare 
congenital disease called anhidrotic ectodermal dysplasia. These conditions arise from 
mutations in the inhibitor of NF-κB kinase-γ gene (IKBKG), which is important in various 
innate inflammatory responses (Smahi 2000).    
 
Although, inactivation of one X-chromosome in females occurs in order to prevent double 
dosage of X-linked genes and therefore protects females from lose of function and 
hypomorphic mutations, sometimes genes can escape silencing through cellular mosaicism, 
which can be beneficial as they can escape deleterious X-linked mutations and genes 
involved in immunity can enhance protection against infections in females. Genes found both 
on the X chromosome and the Y chromosome (XY homologous genes) usually escape 
inactivation, but can vary in levels of expression and unequal expression in different tissues 
(Ditton et al. 2004).  
 
In females, a process called skewing of X chromosome inactivation occurs when X 
chromosome inactivation selects for or against alleles on the active X chromosome. This 
results in over-expression of either the maternal or paternal X-chromosome in certain tissues, 
which could be detrimental as this could lead to expression of mutant genes, however cells 
carrying normal X-chromosomes can outgrow cells carrying mutant alleles, thus protecting 
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against potential diseases (Migeon 2006). However, this so-called immune advantage in 
females can also be a disadvantage as seen in the increased susceptibility of autoimmune 
conditions in females, thus a loss in immunological tolerance must have some X-
chromosome involvement.  
There are three main theories as to how X chromosomes might be responsible for this sex 
difference in autoimmunity. Firstly, it has been proposed that loss of mosaicism might be 
associated with loss of tolerance; random X chromosome inactivation results in X 
chromosome mosaicism in females meaning different cells contain certain genetic material 
from the maternal side or from the paternal side (Kast 1977; Migeon 2006). However, if there 
is an imbalance of X-linked gene dosage (more maternal then paternal X-linked genes and 
vice versa) due to skewing of X chromosome inactivation, this can result in loss of tolerance 
as X-linked self-antigens may escape presentation in the thymus or other peripheral sites 
involved in tolerance induction.  Self-reactive T cells and B cells may therefore (either 
specific to maternal or paternal X-linked antigens) escape negative selection depending on 
the specificity of the antigen presenting cells,  thus leading to the breach in tolerance by 
activating B cells specific to X-linked antigen to produce autoantibodies and the induction of 
autoimmunity.  
 
The second hypothesis for the induction of autoimmunity on the genetic level is the 
reactivation of genes on the previously inactivated X-chromosome; this can result in an over 
dose of X-linked such as genes involved in immune responses thus leading to autoimmunity 
(Lu 2007). It has been shown SLE T cells have over-expressed CD40L due to reactivation of 
this gene on the inactive X-chromosome.  This results in enhanced IgG production by self 
reactive B cells, which has been shown to correlate with disease activity (Zhou 2009).  
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The third  hypothesis for the involvement of the X-chromosome in autoimmunity is the 
haploinsufficiency of X-genes meaning when two copies of a gene are required for a 
efficiently functioning protein, however only one copy is present (Invernizzi 2005; Invernizzi 
2007). This can occur due to complete deletion or absence of part of one of the X 
chromosomes (Sybert and McCauley 2004).  
 
Another area of interest alongside sex chromosomes in understanding why women are more 
susceptible to autoimmune conditions is the role of steroid hormones in this sex difference, as 
drastic changes in hormone levels have been associated to disease progression.  
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1.4   Steroid sex hormones 
 
1.4.1   Hypothalamic-pituitary-gonadal axis  
 
Another explanation for the increased susceptibility of women to autoimmune conditions 
may lie in the role of sex-specific steroid hormones. Sex hormones are produced in the 
gonads; the ovaries produce oestrogens such as oestrone and 17β-oestradiol in females and 
the testes in males produce testosterone, and this process is regulated by the hypothalamus-
pituitary-gonadal axis (HPG-axis) (Luu-The and Labrie 2010). This involves the coordination 
of the hypothalamus, pituitary gland and gonads working as a single unit. Gonadotropin-
releasing hormone (GnRH) is produced and secreted by the hypothalamus, which in turn 
stimulates the production of luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH) by the anterior pituitary gland (Silverman and Sternberg 2012). Finally, these 
hormones act on the gonadal organs (ovaries in females and testes in males) and stimulate the 
production and secretion of sex hormones (oestrogen and testosterone) i.e. during the 
menstrual cycle in females. This HPG-axis is controlled by a negative feedback mechanism; 
oestrogen predominately inhibits LH secretion from the anterior pituitary gland, whereas 
testosterone and other androgens modulate the process at the hypothalamus level (Rochira et 
al. 2006).  Although oestradiol levels in men are lower compared to testosterone levels, 
oestradiol is much more potent then testosterone, and therefore oestradiol is the main 
inhibitor of LH and FSH secretion by the anterior pituitary gland. Gonadal organs are also 
able to produce other regulatory factors such as activins and inhibins, both belonging to the 
transforming growth factor (TGF-β) superfamily (Bilezikjian et al. 2006).  Activins and 
inhibins have conflicting roles in regulating the HPG-axis; activins enhance FSH production 
and secretion.  In contrast, FSH stimulated synthesis of inhibins forms a negative feedback 
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mechanism, in which inhibins prevent the production and secretion of FSH by the anterior 
pituitary gland by interacting with specific inhibin receptors (Risbridger et al. 2001).    
                   
1.4.2   Hypothalamus-Pituitary-Adrenal axis 
 
Androgens and oestrogens are predominately produced by gonads, however alongside the 
production of cortisol; sex hormones can also be produced by adrenal steroid 
dehydroepiandrosterone (DHEA) through stimulation of the Hypothalamus-Pituitary-
Adrenal-axis (HPA-axis). DHEA and its sulphated precursor DHEA-sulphate (DHEAS) are 
the most abundant steroid hormones and function as precursors of active androgens and 
oestrogens.  
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Figure 1.4 The HPA-axis in response to stress signals. 
HPA-axis is able to respond to stress signals by stimulating the release of vasopressin and 
corticotrophin-releasing hormone (CRH) from the hypothalamus, which then results in the 
release of adrenocorticotropic hormone (ACTH) from the anterior pituitary gland. ACTH 
stimulates the production of a glucocorticoid hormone called cortisol, which is able to 
modulate its own production through a negative feedback mechanism (red lines). Taken from 
Papadopoulos and Cleare, ‘Hypothalamic-pituitary-adrenal axis dysfunction in chronic 
fatigue syndrome,’ Nature (2012). 
 
 
 
DHEA is produced in the zona reticularis in the adrenal glands and can then be secreted into 
peripheral tissue, where  it acts in an intracine manner meaning most of the androgens and 
oestrogens synthesised from DHEA locally in organs such as skin, liver and adipose tissue, 
can then act on the same tissues that produced them (Labrie et al. 2001). This local 
production of androgens and oestrogens by DHEA metabolism is particularly important in 
post-menopausal women as the ovaries are no longer producing high levels of oestrogen and 
virtually all of the androgen being synthesised is through DHEA metabolism. Labrie and 
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colleagues demonstrated that intra-vaginal DHEA administration to post-menopausal women 
rapidly diminished vaginal atrophy and improved sexual function without raising levels of 
androgen and oestrogen in the circulation (Labrie et al. 2009).   
 
1.4.3  Steroidogenesis  
 
Cholesterol is the main precursor for many active steroid hormones (figure 1.4). Cholesterol, 
a C27 compound is converted by CYP11A1 into the first steroid pregnenolone a C21 
compound, which is then converted to progesterone. These two compounds are then 
responsible for the synthesis for three main groups of steroids: C21 compounds known as 
mineralocorticoids and glucocorticoids, C19 compounds which are classed as androgens, and 
thirdly the C18 compounds that form oestrogens.   
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Figure 1.5   Steroid synthesis via cholesterol metabolism. 
Steroids highlighted in green are glucocorticoids and mineralocorticoids, in blue are 
androgens and in red are oestrogens. 
  
Only low levels of the active sex steroids made locally by peripheral tissues are secreted into 
the circulation, as they are inactivated locally before entering in the circulation, whereas most 
of the active steroids in circulation are secreted by the gonads. Active sex steroids such as 
DHT are usually converted into androsterone (ADT) and then made more water soluble by 
the addition of glucuronide derivatives (ADT-G) (Luu-The and Labrie 2010).  
 
Also, a high concentration of sex hormones (particularly the most biologically active sex 
hormones); testosterone; DHT; oestradiol are transported in the periphery bound to 
glycoproteins called sex hormone-binding globulins (SHBG), which are produced in the 
liver.  Sex hormones can also bind to albumin but with a much lower affinity compared to 
SHBG. Therefore, the levels of bioavailable active sex hormones is determined by the levels 
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of SHBG in circulation; bound sex hormones are no longer lipophilic, thus are unable to 
travel through the cell membrane and bind to inactive sex hormone specific nuclear receptors 
and transcription factors within the cytosol.  When measuring the total concentration of sex 
hormones, both the levels of unbound sex hormones (known as free sex hormones) and 
SHBG bound sex hormones are taken into account.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6  Downstream conversions of DHEA/DHEAS to sex hormones. 
DHEA/DHEAS is metabolised into biologically active androgens via many metabolic 
enzymes. Androgens (testosterone and androstenedione) can be converted into oestrogens; 
oestrone (E1) and oestradiol (E2) by aromatase. Abbreviations: 5α-reductase 1 and 2 (5α-Red 
1, 2); 3β- and 3α-hydroxysteroid dehydrogenase (3β/α-HSDs); 17β-hydroxysteroid 
dehydrogenase (17β-HSDs); androsterone (ADT); 5-androstenediol (5-diol);  4-
androstenedione (4-dione); androstanedione (A-dione); dihydrotestosterone (DHT). Taken 
from Luu and Fernand, ‘The intracine sex steroid biosynthesis pathways.’ Progress in  
Brain Research, (2010).  
 
The family of 17β-HSD enzymes are known as the backbone of androgen metabolism (figure 
1.5), as they are required for synthesis of various androgens and indirectly in synthesis of 
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oestrogens. However, the most potent and active androgen DHT, is produced by the reduction 
of testosterone by the enzyme 5α-reductase and therefore plays a vital role in androgen 
metabolism. 
 
 
1.4.4   5α-reductase 
 
5α-reductase, also known as 3-oxo-5α-steroid 4-dehydrogenase, is an important enzyme in 
mineralocorticoids, glucocorticoids and androgen synthesis. It is responsible for the reduction 
of progesterone to 5α-dehydroprogesterone (5α-DHP) or 3α-, 5α-
tetrahydrodeoxycorticosterone (3α, 5α-THDOC), which then can be converted into other 
glucocorticoids or mineralocorticoids. In androgen metabolism, 5α-reductase reduces 
androstenedione to androstanedione, but more importantly it converts testosterone in an 
NADPH irreversible dependent reaction into DHT, the most potent androgen receptor agonist 
(figure 1.6); as DHT has a 10 fold higher affinity for the androgen receptor compared to 
testosterone (Jin and Penning 2001). Testosterone is essential for the formation of male 
internal sex organs and maintaining sexual function. In contrast, DHT is important in the 
formation of external male genitalia, prostate and also facial/body hair. 
 
 
 
 
 
Figure 1.7  Conversion of testosterone by DHT by 5α-reductase.  
(NADPH) 
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This shows chemical reaction for the synthesis of DHT through the reduction of testosterone 
by 5α-reductase in the presence of co-factor NADPH. Adapted from Yin, ‘Steroid 
5αreductases and 3a-hydroxysteroid dehydrogenases: key enzymes in androgen 
Metabolism.’ Best Practice & Research Clinical Endocrinology and Metabolism, (2001). 
 
 
5α-reductases are members of the aldo keto-reductase family of enzymes and are located in 
the microsomal membrane. They act in a NADPH-dependent manner, in which androgens, 
mineralocorticoids, or progestins with a C3 ketone group and a double bond between C4-C5 
are reduced to form 5α-reduced products. 5α-reductases are low abundance proteins with a 
molecular weight between 28-29kDa (Andersson and Russell 1990). There have been three 
isoenzymes identified; 5α-reductase 1 (gene SRD5A1), 5α-reductase 2 (gene SRD5A2) and 
more recently 5α-reductase 3 (gene SRD5A3), however there has been little evidence of 
androgen metabolism activity by SRD5A3 (Uemura et al. 2008). 5α-reductase  isoforms are 
expressed in a tissue specific manner; 5α-reductase 1 is predominately found in the sebaceous 
glands in skin, hair follicles, and the liver (Berman and Russell 1993; Silver et al. 1994), 
where as 5α-reductase 2 is the main isoform found in the male accessory reproductive 
structures such as the Wolffian ducts, prostate, the epididymis and the seminal vesicles 
(Russell and Wilson 1994). Male pseudohermaphroditism is a rare genetic disorder, 
associated with a mutation in the SRD5A2 gene, which results in the formation of female 
resembling external genitalia and no prostate formation during embryogenesis (Andersson et 
al. 1991; Wilson et al. 1993).  It is not until these individuals reach adolescence, where they 
start to develop characteristic male external genitalia but fail to develop a prostate. There is 
limited homology between the different isoforms, which is around 47%. These three isoform 
genes are located on separate chromosomes with the SRD5A1 gene located on chromosome 5 
in p15, SRD5A2 gene on chromosome 2 p23 and SRD5A3 on chromosome 4 q12 (Jin and 
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Penning, 2001). However, the positions of the introns are the same in both SRD5A1 and 
SRD5A2 genes. 
 
A study showed that human lymphocytes from patients with primary 5α-reductase deficiency 
have significantly higher levels of  cytosine methylated 5α-reductase 2 genes, thus resulting 
in reduced gene expression (Rodriguez-Dorantes et al. 2002). Also, a murine study found that 
there were differential methylation patterns in the 5α-reductase 1 genes within various 
organs. They observed an increase in adenine methylation levels in the 5α-reductase 2 gene in 
the epididymis and in the testis in contrast to the liver (Reyes et al. 1997). Adenine 
methylation is associated with increased gene expression, thus the 5α-reductase 2 gene was 
highly expressed in the epidydimis and in the testis compared to in the liver.  There is no 
evidence of 5α-reductase 1 genetic deficiency, however mice studies have shown that 
removal of 5α-reductase 1 in female mice leads to defects in reproduction (Mahendroo and 
Russell 1999). Also, there is evidence to suggest that 5α-reductase is regulated by levels of 
androgens present; testosterone given to castrated mice reduced 5α-reductase activity (Wright 
et al. 1999).  
 
1.4.5  Steroid nuclear receptors 
Androgens and oestrogens exert their effects through binding of nuclear receptors called 
androgen and oestrogen receptors respectively, in target cells. Both androgen and oestrogen 
receptors are members of the nuclear receptor superfamily of transcription factors and are 
found abundantly in sex hormone responding tissues such as the prostate. There are two 
isoforms of oestrogen receptors; oestrogen receptor-alpha ( ER-α) (the dominate isoform in 
most tissues) and oestrogen receptor-beta ( ER-β), which have been shown to have opposite 
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effects to ER-α on gene transcription depending on the activating ligand, as well as target 
DNA regions (Paech et al. 1997). ER-β is able to control ER-α activation as it can form 
heterodimers with ER-α, thus suppressing ER-α transcriptional activity (Lindberg et al. 
2003). Ligand binding, i.e. when DHT binds to androgen receptor and 17β-oestradiol binds to 
oestrogen receptors, results in translocation from the cytosol into the nucleus (figure 1.8). 
This then leads to receptor dimerization with other nuclear receptors, and subsequent binding 
to specific regions in promoters of target genes (figure 1.8). Receptor activation initiates the 
recruitment of co-activators and co-repressors, which in turn changes the structure of 
chromatin surrounding target genes thus initiating transcription. Both testosterone and DHT 
are able to bind androgen receptors however, DHT has a 10 fold higher affinity for the 
receptor and therefore lower concentrations of DHT compared to testosterone are needed for 
androgen receptor activation.  
 
 
 
 
 
 
 
Figure 1.8 Steroid hormone nuclear receptor activation. 
Ligand binding to inactive nuclear receptors results in detachment from co-repressors and 
translocation from the cytosol into the nucleus. This then leads to receptor dimerization with 
other nuclear receptors, and subsequent binding to specific regions (such as androgen 
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response elements (ARE) in promoters of target genes. Receptor activation initiates the 
recruitment of co-activators and co-repressors, which in turn changes the structure of 
chromatin surrounding target genes thus initiating transcription. 
 
 
Studies have shown that androgen and oestrogen receptors are regulated through epigenetic 
modifications and by exposure to androgens and oestrogens (Imamura 2011). In some tissues, 
AR mRNA expression has been shown to be regulated in a negative feedback manner, in 
which low androgen levels increase AR expression and in contrast, high androgen levels 
decrease AR expression (Khetawat et al. 2000; Sader et al. 2005).  Mutations in steroid 
receptors have shown to have severe impacts on development, as seen in indirect 5α-
reductase deficiency, in which a point mutation in the androgen receptor gene (type 1 occurs 
from a mutation in the 5α-reductase gene), resulting in the absence of the androgen receptor. 
This leads to defects in male embryonic development, in which formation process of external 
male genitalia is defected (Wilson et al. 1993).  
 
1.4.6  Steroid hormones and the immune system 
 
The HPA-axis is the focal point of the body’s stress response system and has a direct effect 
on immune responses. Glucocorticoid hormone, cortisol, is produced by the anterior adrenal 
gland through the HPA-axis and is essential in exerting a suppressive effect on the immune 
system to maintain homeostasis and preventing the development of inflammatory conditions.  
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Figure 1.9  Response to pro-inflammatory cytokines by the HPA-axis. 
Pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6 stimulates the HPA-axis at all 
three levels; the hypothalamus, pituitary gland and the adrenal gland. This stimulates the 
release of cortisol from the adrenal gland, which results cortisol acting on immune cells and 
inhibiting the production pro-inflammatory cytokines. Blue lines represent stimulation and 
red dashed lines present inhibition. Taken from Silverman and Stemberg, ‘Glucocorticoid 
regulation of inflammation and its functional correlates: from HPA axis to glucocorticoids 
receptor dysfunction.’ Annals of the New York academy of sciences (2012) 
 
Cortisol is able to inhibit the production of pro-inflammatory cytokines (figure 1.7), thus 
dampening the pro-inflammatory response (Bethin et al. 2000; Ray et al. 1990). The anti-
inflammatory traits of glucocorticoids have been exploited for decades as treatment with 
synthetically produced glucocorticoids such as prednisolone as been used in treatment of 
many inflammatory conditions including autoimmune diseases. Disregulation of the HPA-
axis has been reported in autoimmune diseases such as RA (Cutolo et al. 2003; Mastorakos 
and Ilias 2000), in which RA patients that are not undergoing treatment with glucocorticoid 
medication and patients with active disease have reduced ACTH synthesis and therefore 
produce very low levels of cortisol and adrenal androgen DHEA/DHEAS. This inefficient 
adrenal activity observed in RA results in reduced stress response signals to maintain 
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homeostasis, and therefore decreased suppression of elevated pro-inflammatory responses 
such as increased levels of IL-6 and TNF, which are in turn contributing to the chronic 
inflammation observed in RA. The reduced adrenal activity within the HPA-axis, which has 
shown to be also due to resistance to ACTH stimulation, has been shown to make individuals 
more susceptible to developing inflammatory and autoimmune conditions. Glucocorticoid 
resistance has also been demonstrated in autoimmunity; in which studies have shown that 
abnormal signalling by nuclear receptor glucocorticoid receptor (GR) expressed in various 
cells (including immune cells), thus preventing glucocorticoids mediated the effects 
(Silverman and Sternberg 2012).  
 
Gonadotropin-releasing hormone (GnRH) has also been investigated in the development of 
inflammatory and autoimmune conditions, as it has been shown to be immunostimulatory. 
The importance of GnRH in thymic maturation has been demonstrated, as treatment of 
neonatal rats with GnRH antagonists resulted in significantly reduced thymic proliferative 
responses, and with a decrease in CD4+ population observed and reduced antigen stimulated 
antibody responses in adult rats (Tanriverdi et al. 2003). In vitro studies, GnRH has shown to 
increase T cell responses through upregulation of IL-2R and increasing production of IFN-γ 
after treatment with GnRH. In models for autoimmunity, there was reduced disease severity 
and decreased anti-DNA antibodies after GnRH antagonist treatment in SLE-prone mice 
(Jacobson et al. 1994), which was observed in both castrated and intact mice suggesting the 
effects of GnRH are independent of gonadal sex hormones.  
 
1.4.7 Sex hormones and autoimmunity 
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The predominance of autoimmune conditions in females has initiated a vast amount of 
research into the role sex hormones play in immune and inflammatory responses, especially 
on the effect of oestrogen on immune responses due to this increased susceptibility in 
females. However, male sex hormones known as androgens have also been shown to mediate 
immune responses. Sex hormone levels are shown to have a significant effect on the severity 
of autoimmune diseases. Any drastic changes in levels of sex hormones can have a profound 
effect on the immune system; pregnancy enhances disease activity in SLE individuals; 
furthermore, menopause, chronic stress, and steroid hormonal replacements may affect 
susceptibility to autoimmunity (Angstwurm et al. 1997; Hirano et al. 2007; Oliver and 
Silman 2009; Verthelyi and Klinman 2000). Decreasing levels of DHEA are characteristic of 
the ageing process and may contribute to an increased susceptibility to some autoimmune 
diseases (Hammer et al. 2005; Straub et al. 1998).  Androgens and oestrogens are known to 
have conflicting effects on the immune system; androgens such as testosterone and the most 
potent androgen 5α-dihydrotestosterone (DHT) have an anti-inflammatory effect (Liva and 
Voskuhl 2001), whereas oestrogens such as 17β-estradiol and oestrone enhance immune 
responses (Maret et al. 2003).  
 
1.4.8  Effect of sex hormones on the immune system: mice studies  
 
Oestrogen has been identified as an immune enhancer especially in responses involving the 
humoral immune system. This revelation could potentially explain the increased 
susceptibility of autoimmunity in females compared to males, thus many studies have 
investigated the role of oestrogen in the development of autoimmune conditions in both 
animal models and in humans. In animal models, treatment of New Zealand brown/New 
Zealand white F1 female mice (model used for SLE in mice), with 17β-estradiol enhanced 
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disease activity (Grimaldi et al. 2006). Physiological concentrations of 17β-estradiol increase 
production of pro-inflammatory cytokines such as IL-1, IL-6 and TNF (Garidou et al. 2004).  
 
Various studies have investigated the effects of oestrogen on dendritic cells, particularly the 
pDC subset due to its important role in the pathogenesis in SLE, as it is the major producer of 
IFN-α, a proinflammatory cytokine found to be significantly elevated in SLE patient sera. A 
study carried out by Seillet and colleagues investigating the role of oestrogen in the 
previously reported higher production of TLR7 mediated IFN-α by pDCs in females 
compared to males (Seillet et al. 2012). They found that transplanting human female CD34+ 
hematopoietic progenitor cells into sublethally irradiated NOD/SCID/β2m-/- female and male 
mice, followed by subsequent in vitro stimulating of harvested human pDCs (identified as 
CD45+ CD123+ BDCA-4+) with TLR7/TLR8 ligands showed that a significantly higher 
frequency of not only IFN-α producing pDCs but also an increase in TNF-α producing pDCs 
was observed in female mice in comparison to the male mice. This suggests that these 
differences in innate immune responses are not just linked to the X-chromosome, but are also 
influenced by sex hormones. This hypothesis was supported with the subsequent finding by 
Seillet el al, that supplementing postmenopausal women with 17β-estradiol increased 
TLR7/TLR-dependent production of IFN-α (Seillet et al. 2012). Stimulation of pDCs with 
NA-IC from SLE sera resulted in an increased IFN-α and TNF-α production by pDCs after 
17β-estradiol treatment. These enhancing effects of oestrogen on innate immune responses 
were all dependent on ERα signalling in pDCs as demonstrated in the ERα knockout mice.  
 
Scotland and colleagues demonstrated the importance of oestrogen in the maintenance of 
resident tissue leukocyte population and the recruitment of more leukocytes during infection 
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in an animal model of sepsis (Scotland et al. 2011). Ovariectomised mice had significantly 
reduced total resident leukocytes, which included F4/80+ macrophages and CD19+ B cells but 
no reduction in the numbers of CD3+ and CD8+ T cells. There was also a reduction in tissue 
expression of chemokines such as CCL2, CXCL1, CXCL12 and chemokine receptors CCR1, 
CCR2 and CXCR4, thus explaining the reduction in the resident leukocyte population. 
Resident leukocyte expression of TLRs such as TLR1, TLR2 and TLR3 has also shown to be 
significantly reduced in the ovariectomised mice, alongside reduced phagocytosis by 
macrophages in vitro.  
However, in some studies oestrogen has been shown to have a protective effect in 
autoimmunity, particularly in T cell mediated autoimmune conditions, through activation of 
ER-α signalling (Yang et al. 2010).  In cell-mediated immune responses high concentrations 
of oestrogen have been shown to have a dampening effect on immune responses as 
demonstrated in T cell driven disease MS, as oestrogen is able to decrease Th1 mediated 
responses and increase Th2 immune responses by decreasing Th1 cytokines such as IFN-γ. A 
study found that ER-α knockout mice induced with EAE did not respond to oestrogen 
(Garidou et al. 2004), thus suggesting ER-α signalling is required to mediate the protective 
effects of oestrogen.  
 
In contrast to oestrogens, the effects of androgens on immune responses have been less 
thoroughly researched, however the small number of studies have shown androgens to be 
anti-inflammatory as there is evidence to suggest androgens are able to dampen inflammatory 
responses. In terms of autoimmune diseases, androgens have shown to reduce disease activity 
in humans and in animal models (Harbour, Pervez-Gill, et al 1995). Previous studies have 
demonstrated the protective role testosterone and DHT in autoimmunity as exogenous 
administration suppressed Th1 mediated autoimmune diseases by initiating Th2 cytokine 
48 
 
production.  Animal studies showed that castration of male mice but not ovariectomy in 
females increases Th1 mediated autoimmunity and decreases Th2 cytokine profile, thus 
exacerbating EAE, in contrast female mice implanted with testosterone pellets reduced the 
severity of EAE. Therefore, low levels of testosterone initiate production of pro-
inflammatory mediators (Gilliver et al. 2006). In a rat model of cutaneous wound healing, 
inhibition of 5α-reductase, which blocks the conversion of testosterone to its more active 
metabolite 5α-DHT, resulted in the upregulation of proinflammatory cytokines by 
macrophages (Gilliver et al. 2006). 
A study looking into an inflammatory condition Orchitis, associated with low testosterone 
levels, which can develop into chronic testicular inflammation within the testes and is 
associated with high levels of pro-inflammatory cytokines leading to tissue damage and 
subsequent infertility in severe cases, used an animal model called experimental autoimmune 
orchitis (EAO) and found that implanting testosterone pellets into mice resulted in reduced 
EAO disease activity, positively correlating with the decrease in macrophage and CD4 T cell 
number, and decrease in proinflammatory cytokines such as IL-6, TNF-α, IFN-γ and IL-2. In 
contrast, there was a significant increase in the number of immunosuppressive CD4+ CD25+ 
Foxp3+ Treg cells (Fijak et al. 2011), thus highlighting the importance of testosterone in 
resolving inflammation.  
 
1.4.9  Effect of sex hormones on the immune system in humans  
 
In terms of humoral immune responses, oestrogen has been shown to increase B cell 
proliferation and differentiation thus elevating IgG and IgM antibody production (anti-
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dsDNA in SLE patients) in both males and females at physiological concentrations (Kanda 
and Tamaki 1999; Kanda et al. 1999). 
 
In RA, changes in oestrogen metabolism have been demonstrated as increased metabolism of 
oestrogens into more potent and inflammatory oestrogen metabolites such as 16αOH-
oestrone has been demonstrated in RA synovial cells, but not in OA patients (Schmidt et al. 
2009). These potent oestrogen metabolites have shown to unsuccessfully inhibit TNF-α 
induced inflammation, thus suggesting a pro-inflammatory role in RA. 
 
Some of the effects of oestrogen seem to be dose dependent, as high concentrations of 
oestrogen have also been shown to decrease IL-2R expression and IL-2 production in 
activated T cells from healthy controls (McMurray et al. 2001), but at low concentrations of 
oestrogen an opposite outcome is obtained.  In innate immune reactions oestrogen has also 
been shown to decrease inflammatory mediators; oestrogen inhibits TNF-α production 
through TLR4 stimulation by LPS in human PBMCs (Rogers and Eastell 2001).   
This suggests that oestrogens have conflicting roles on immune responses. Oestrogens have 
shown to have conflicting effects on different autoimmune diseases; in RA and MS, high 
levels of oestrogens cause disease remission which has been well demonstrated during 
pregnancy and the menstrual cycle (Latman 1983). These autoimmune conditions are also 
more common in older women often developing at menopausal age or postmenopausal.  
However, in SLE pregnancy exacerbates disease activity in which it is common for flares to 
occur (Ruiz-Irastorza et al. 1996) and onset of the disease usually occurs at puberty and child 
bearing ages 20-35yrs in which oestrogen levels are very high. These contrasting effects of 
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oestrogen observed in different autoimmune diseases are thought to be due to the cell types 
involved; RA and MS are predominately T cell (Th1) driven diseases, whereas SLE is 
thought have a higher level of B cell involvement. Thus, oestrogens have been shown to 
increase humoral responses and reduce Th1 driven pathways (Feng et al. ; Polanczyk et al. 
2004), at high concentrations at least, which could be the reason for the difference observed.  
 
Testosterone is also able to decrease IL-1 synthesis in synovial macrophages in vitro and 
potent androgen receptor agonist DHT is able to repress activity and expression of the IL-6 
gene promoter in human fibroblasts (Weidler et al. 2005). In terms of humoral responses, 
there is a complete contrast between oestrogens and androgens as testosterone has shown to 
inhibit IgM and IgG production (Kanda et al. 1996). Enhanced DC proliferation and antigen 
stimulation has been shown in males with hypogonadism, suggesting that testosterone is 
important in regulating immune responses in a suppressive manner.  
 
It is well established that SLE patients have low levels of androgens in serum, which 
inversely correlates with disease activity (Jungers et al. 1982). Male SLE patients have a 
significantly lower androgen levels and increased oestrogen levels in serum (Mok and Lau 
2000; Sequeira et al. 1993). It is not well understood if low androgen levels predispose 
individuals to SLE or if the development of autoimmune disease itself is responsible for these 
reduced levels of androgens. In SLE, glucocorticoid based treatment drastically reduces 
androgen levels in serum thus it is extremely difficult to quantitate androgen levels in SLE 
patients while on medication. However, low androgen levels in men have been associated 
with the development of RA (Cutolo et al. 1988). Also, in male MS patients disease onset is 
much later then their female counterparts, which could be due to the age associated decrease 
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in DHEA and testosterone concentrations in men, thus the protective effect of androgens 
against autoimmune development is absent (Hammer et al. 2005).   
 
Recently, it has been shown that the anti-inflammatory effects of androgens can be mediated 
through androgen activation of peroxisome proliferator activated receptors (PPARs) (Dunn et 
al. 2007) and have shown to protect male mice from developing autoimmunity. Therefore, 
PPARs may play an important role in mediating the sex differences observed in 
autoimmunity.  
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1.5    PPAR 
 
1.5.1   Introduction 
 
Peroxisome proliferator activated receptors (PPARs) are a group of transcription factors that 
are part of the nuclear receptors superfamily. PPARs have primarily been associated with 
regulating expression of genes involved in lipid and glucose metabolism.  Three different 
isoforms have been discovered originally in Xenopus: PPAR-alpha, PPAR-gamma and 
PPAR-delta (also known as PPAR-beta).  PPARs were first discovered in rodents as being 
responsible for peroxisome proliferation in the liver upon treatment with industrial chemical 
such as solvents; peroxisomes are subcellular organelles that are important in lipid 
metabolism via β-oxidation of fatty acids or hydrogen peroxide mediated respiration. PPARs 
are composed of five regions: C and E, which are the most conserved regions and contain the 
DNA-binding domain (DBD) and the ligand-binding domain; A/B region consists of the AF1 
ligand-independent activation domain; the F region contains the AF2 ligand-dependent 
activation domain and finally the variable hinge region D (Daynes and Jones 2002).  
 
1.5.2  PPAR ligand mediated activation 
 
PPARs are activated in a ligand dependent manner, which in turn results in altering the role 
of PPARs to transcription factors, thus targeting specific genes.  Generic for all the members 
of the nuclear receptor superfamily is the presence of a central DNA-binding domain 
essential for recognising PPAR-response elements (PPREs) in promoter regions of target 
genes.  These PPRE regions are made up of repeated sequences separated by one nucleotide 
known as Direct Repeat-1 (DR1). Upon ligand binding, PPAR forms a heterodimeric 
complex with another member of the nuclear receptor family, retinoid X receptor (RXR) 
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(Clark et al. 2000).   After PPAR activation, PPARs are able to dissociate from co repressor 
molecules nuclear receptor co-repressor/silencing mediator for retinoid and thyroid hormone 
receptor, collectively known as NCoR/SMRT. Histone deacetylases (HDACs) are also 
needed alongside NCoR/SMRT to suppress PPAR mediated gene transcription, however, this 
only applies to PPAR Isoforms alpha and gamma as PPAR-delta can bind PPREs still 
associated to the co-repressor complex. The dissociation of co-repressor molecules allows co-
activators such as steroid receptor co-activator 1 (SRC1) and members of the DRIP/TRAP 
(vitamin-D-receptor interacting protein/thyroid-hormone-receptor-associated protein) 
complex and CREB-binding protein (CBP)/p300 to bind to the LBD in the E region of 
PPAR, thus able to translocate from the cytoplasm to the nucleus (Clark 2002).  This then 
allows changes to be made to chromatin structure via histoneacetyltransferase surrounding 
target genes of PPAR thus initiating transcription.  
 
1.5.3  PPARs and the immune system 
 
Many studies have suggested a role of PPARs in the immune system as PPARs have shown 
to be expressed in multiple immune cell subsets, and have acted predominately as anti-
inflammatory mediators. PPAR-α and PPAR-γ have both been investigated to vast depth in 
comparison to PPAR-δ as its effects are still widely unknown. In particular, studies in mice 
have shown that PPAR-α is able to modulate the anti-inflammatory effects of androgens. It 
has been suggested that males are less likely to develop autoimmune diseases due to higher 
expression of PPAR-α then their female counterparts. Early in vitro studies investigating the 
effect of PPAR-α on immune responses using mice models showed that PPAR-α knockout 
mice had a prolonged immune responses (Gocke et al. 2009), when treated with PPAR-α 
activating ligands such as LTB4 and arachidonic acid, compared to the wild type mice, thus 
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suggesting PPAR-α is able to inhibit immune responses . The literature also suggests that 
supplementing experimental mice with ω-3 fatty acids or steroids such as DHT which are all 
agonists for PPAR-α, reduced the production of pro-inflammatory cytokines. A study 
exploring the role of PPAR-α in modulating cellular redox status in aged mice found that 
PPAR-α was able to reduce tissue lipid peroxidation, inhibition of NF-κB activity and 
production of pro-inflammatory cytokines, which are all involved in promoting oxidative 
stress in the ageing process (Hasler and Zouali 2005). PPAR-α can antagonise NF-κB and 
AP-1 signalling thus prevent expression of genes involved in inflammatory responses 
(Poynter and Daynes 1998). PPAR-α ligands are also able to induce apoptosis in activated 
macrophages but not in inactivated macrophages or undifferentiated monocytes.  
 
It was a study by Dunn et al (2007) which suggested that PPAR-α expression was sensitive to 
testosterone, thus mediated the effect of androgens on T helper cell activity (Dunn et al. 
2007). Androgen activated PPAR-α reduced TCR-induced NF-κB and c-jun activity. There 
was also an increase in Th2 mediated cytokine production. They also demonstrated a gender 
difference in PPAR-α expression as it was more abundant in male mice in comparison to 
female mice. Furthermore upon EAE induction, male PPAR-α knockout mice displayed more 
severe disease activity than male wild-type animals, whereas disease severity in female mice 
was not significantly different in knock-out and wild-type animals. MOG p35-55-reactive 
splenocytes from male PPAR-α knock-out mice produced increased levels of IFN-γ and TNF 
compared to their wild-type counterparts (Dunn et al. 2007). This suggests that males are less 
likely to develop Th1-mediated autoimmune diseases due to higher T cell expression of 
PPAR-α.  
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PPAR-γ is also expressed in a wide range of inflammatory mediators such as monocytes, 
macrophages and Th17 cells.  PPAR-γ ligands such as thiazolidinediones have been used for 
the treatment of type-2 diabetes as they were able to lower blood glucose levels and levels of 
circulating fatty acids in insulin resistant mice (Szanto and Nagy 2008). In mice, PPAR-γ has 
been shown to be expressed in macrophages in which it was able to inhibit expression of 
inflammatory mediators such as nitric oxide synthase (iNOS), scavenger receptor A and 
matrix metalloproteinase-9 (MMP-9) (Cunard et al. 2002). These studies also demonstrated 
that PPAR-γ agonists were able to inhibit pro-inflammatory mediators LPS, IFN-γ and 
phorbol ester by interfering transcription factor signalling such as NF-κB AP-1 and signal 
inducers and activators of transcription 1 (STAT-1). This mechanism of PPAR-γ inhibition of 
gene transcription is similar to the action of the PPAR-α isoform.  
 
PPAR-γ ligands are also able to have a pro-inflammatory effect on B cells by stimulating 
plasma cell differentiation and antibody production. PPAR-γ is also expressed in T cells; 
studies have shown that the two ligands 15d-PGJ2 and thiazolidinediones were able to inhibit 
IL-2 production in murine T cell clones but not IL-2 mediated cell proliferation (Clark 2002). 
Also other studies demonstrated the enhancing effect of PPAR-γ ciglitazone on murine 
natural T regulatory cells (nTregs) and inducible Tregs (iTregs) (Szanto and Nagy 2008; 
Wohlfert et al. 2007). This suggests PPAR-γ ligands can be used in the treatment of 
autoimmune diseases by enhancing Treg activity, which is particularly important in 
modulating T-helper cells that may become autoreactive.  PPAR-γ ligands are also able to 
induce apoptosis in activated T cells, which has been demonstrated in both the animal and 
human model (Tautenhahn et al. 2003).  Recently it has been reported that PPAR-γ is 
expressed in the Th17 cells subset, which is has been branded as an important instigator in 
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developing autoimmune diseases. Klotz et al showed that PPAR-γ activation inhibited Th17 
differentiation by preventing TGF-β/IL-6-induced expression of RORγt in T cells (Klotz et 
al. 2009), which is an important transcription factor, needed for Th17 differentiation.   
Therefore, PPARs especially PPAR-α could be responsible for mediating the effects of 
androgens on the immune system, and thus could not only explain the observed robust 
immune responses in females during infection in comparison to males, but also may explain 
the increased incidence in autoimmunity development in females.   
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1.6  Objectives 
 
Androgens and oestrogens have been attributed with conflicting effects on the immune 
system; androgens such as testosterone and the most potent androgen;  5α-
dihydrotestosterone (DHT) have an anti-inflammatory effect, whereas oestrogens such as 
17β-oestradiol and generally enhance immune responses. Therefore, these conflicting affects 
of sex hormones could potentially explain the increased susceptibility of females developing 
autoimmune diseases.  The overarching hypothesis tested in this project was that both long-
term and acute effects of sex hormones will affect T cell responses. 
 
Firstly, this study sought to compare the way T cells from healthy males and females regulate 
the activation of androgens, and how T cells are able to regulate their exposure to sex 
hormones. For this purpose the mRNA and protein expression of sex hormone metabolising 
enzymes and sex hormone receptors in resting and in vitro stimulated naïve CD4+ T cells 
from healthy male and female donors were investigated.  
Secondly, we sought to investigate regulation 5 α-Reductase 1 in T cells and other immune 
cells from patients with SLE in comparison to healthy controls. 
Thirdly, this study aimed to investigate the influence of androgens on in vitro T cell 
responses using physiological concentrations of hormones and to compare this effect between 
male and female donors. 
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2       MATERIALS AND METHODS 
 
 
2.1   Peripheral blood collection from healthy controls and SLE patients. 
Ethical approval to collect blood from healthy volunteers was obtained by the University of 
Birmingham ethics committee under the ‘Regulation of immune cell activation by steroid 
hormones’ study. Healthy volunteers gave consent for blood donation by a signing a written 
consent form before blood was taken by trained phlebotomists. Healthy volunteers recruited 
for this study were aged between 20-35 years and were not undergoing treatment for 
inflammatory conditions, and female volunteers recruited were not taking oral contraceptives. 
For the steroid receptors and 5α-reductase qPCR experiments, blood was obtained from 
female donors, who were 7-10 days into the follicular phase of the menstrual cycle.  
 
Under an ethically approved study, blood samples from SLE patients were taken during 
Consultant Rheumatologist Dr Caroline Gordon’s SLE clinic at Birmingham City Hospital. 
Patients fulfilling the American College of Rheumatology 1987 revised criteria for SLE were 
recruited for this pilot study and gave informed consent. Anti-dsDNA titer and disease 
activity (British Isles Lupus Assessment Group, BILAG) was determined at the time of 
sampling. A BILAG system score of B or more (≥5 points) was considered as a marker of 
active disease. Sex and age-matched healthy blood donors were recruited as controls. Signed 
informed consent was obtained from healthy blood donors and SLE patients prior to 
participation in the study, which was approved by the local research ethics committee.  
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2.2   Cell isolation from peripheral blood  
 
2.2.1   Isolation of peripheral blood mononuclear cells (PBMCs).  
Peripheral blood was obtained from healthy donors in tubes containing heparin at a final 
concentration of 1000 U/l. Peripheral blood taken from SLE patients and matching healthy 
controls were collected using heparin-coated (green-topped) blood collection tubes. 
Peripheral blood was diluted with RPMI 1640 medium (supplemented with 2nM glutamine, 
1% 100U/ml penicillin G, and 10µg/ml streptomycin sulphate (GPS) (Invitrogen, Life 
technologies)) at a 1:1 ratio and then gradually layered on Ficoll-Paque (Amersham 
Biosciences, Bucks UK) at a ratio of 3:1 whole blood to Ficoll-Paque. Tubes were then 
centrifuged at 300 g for 30 minutes at 22°C, with no brake. After centrifugation, the 
mononuclear cells were removed from above the Ficoll-Paque layer using a plastic Pasteur 
pipette and then washed three times in 20ml RPMI, in which cells were then centrifuged at 
300 g at 22°C for 8mins; the supernatant was removed after each wash and cells were 
resuspended in fresh medium. PBMCs were then counted using a haemocytometer and used 
in subsequent experiments. Cell viability of cell cultures were determined using flow 
cytometry as live cells had high forward scatter and side scatter fluorescence, unlike dead 
cells and debris, which appeared in the bottom left area of the plot with low forward scatter 
and side scatter fluorescence. Therefore, only samples with 98% live cells were included in 
subsequent experiments.  
 
2.2.2   Isolation of CD4+ T cells from PBMCs.  
After isolation of PBMCs as described in section 2.2.1; CD4+ T cells were isolated from a 
PBMC population via negative isolation using a CD4+ T cell isolation kit (Miltenyi Biotech). 
Firstly, PBMCs were counted using a haemocytometer and resuspended in 40µl MACS 
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buffer (containing PBS at pH 7.2, 0.5% BSA and 2mM EDTA) per 107 cells in a 1.5ml 
eppendorf tube. 10µl of Biotin Antibody Cocktail per 107 cells was added and cells were then 
incubated at 4°C for 10 minutes. After the incubation period, cells were then washed with 
500µl MACS buffer by centrifuging for 5 minutes at 3000 g. Cells were then resuspended in 
30µl of MACS buffer per 107 cells and 20µl of Anti-biotin MicroBeads per 107 cells and 
incubated at 4°C for 15 minutes. Cells were then washed with 500µl MACS buffer by 
centrifuging for 5 minutes at 3000 g and resuspended in 500µl MACS buffer ready for 
magnetic cell separation. 
 
An LS column (Miltenyi Biotech) was placed in the magnetic MACS separator. Firstly, the 
column was washed with 3ml MACS buffer three times and then the 500µl cell suspension 
was added to the top of the column. The column was then washed with 3ml of MACS buffer 
three times to elute the unlabelled CD4+ cell population. Purity of the CD4+ T cell population 
was determined via flow cytometry.  
 
2.2.3  Isolation of CD4+ RA+ T cells from PBMCs.  
The same protocol as described in section 2.2.2 for CD4+ T cells isolation was used for CD4+ 
RA+ T cells isolation using a Miltenyi magnetic cell separation kit for CD4+ RA+ T cells via 
negative selection. PBMCs were resuspended in 40µl MACS buffer per 107 cells in a 1.5ml 
eppendorf tube. 10µl per 107 cells of Biotin Antibody Cocktail was added and cells were then 
incubated at 4°C for 10 minutes. After washing the cells, the cells were resuspended in 80µl 
of MACS buffer per 107 cells and 20µl of Anti-biotin MicroBeads per 107 cells and incubated 
at 4°C for 15 minutes. Cells were then washed and then preceded to the magnetic cell 
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separation steps described in section 2.2.2. Purity of the CD4+ RA+ T cell population was 
determined via flow cytometry.  
 
2.3    Quantitative PCR (qPCR) 
 
2.3.1  CD4+ RA+ T cells stimulation for subsequent qPCR analysis 
Freshly isolated naïve CD4+ CD45 RA+ T cells with a purity of ≥95% were resuspended in 
500μl of serum-free media (RPMI supplemented with 1%GPS) in duplicate in a 24 well flat-
bottomed plate. 25μl of anti-CD3 and anti-CD28 activation beads (Dynabeads) (Invitrogen, 
Life technologies) were added per 1 x 106 of cells. Control cells that were not stimulated with 
activation beads were also cultured alongside stimulated cells. Cells were incubated for 24 
hours at 37°C with 5% CO2.  
 
2.3.2   RNA extraction 
RNA was extracted from unstimulated or stimulated CD4+ RA+ T cells (assay described in 
section 2.3.1) using the Qiagen RNeasy Mini Kit. Freshly isolated cells or cultured cells were 
lysed with 350μl RLT (lysis buffer) and stored at -81°C if not required immediately. Frozen 
cell lysate (allowed to slowly thaw) or non-frozen lysate was then homogenised by adding 1 
volume of 70% ethanol (350μl), which was mixed well without the requirement of 
centrifugation. 700μl of the sample (including any precipitate that may have formed) was 
transferred to an RNeasy spin column and placed in a 2ml collection tube ,and centrifuged for 
15 seconds at 10000 g. Flow through was discarded and 700μl buffer RW1 was added to the 
column and centrifuged again for 15s at 10000 g. The flow through was discarded and 500µl 
RPE buffer was added to the column to be centrifuged for another 15s at 10000 g; this step 
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was repeated twice. A new 1.5ml collection was then used and 30μl of RNA-free water was 
added to the column and centrifuged for 1 minute to collect the eluted RNA.  
 
2.3.3   DNase I treatment 
Extracted RNA was treated with DNA-free DNase treatment and removal kit (Ambion, Life 
technologies) to remove genomic DNA. 3.5μl 10x DNase I buffer and 1µl DNase I was 
added to RNA samples in 1.5ml eppendorf tubes and then incubated at 37°C for 30 minutes. 
5µl DNase inactivation reagent was then added to each RNA sample and kept at room 
temperature for 2 minutes. Samples were centrifuged for 1 minute at 13000 g. The 
supernatant containing the RNA was then carefully removed without extracting any DNase 
inactivation reagent white coloured precipitate.  
 
2.3.4   Reverse transcription (RT-PCR) 
A Vilo reverse transcription Kit (Invitrogen, Life technologies) was used to reverse 
transcribes RNA samples into cDNA. For a 20µl total reaction volume the following reaction 
mix was made; 4μl 5x Vilo reaction mix; 2µl 10x Superscript enzyme mix and 14μl RNA (up 
to 2.5µg) was used. The samples were then transferred to a thermocycler, which was set up 
for the following protocol; 25°C for 10 minutes, 42°C for 2 hours and finally 85°C for 5 
minutes. After the protocol was completed, cDNA samples were stored at -21°C until they 
were required. 
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2.3.5   PCR (cDNA) clean up 
Buffers and enzymes used in the RT reaction (section 2.3.4) were removed from the cDNA 
samples using a NucleoSpin Extract II kit (Macherey-Nagel). Firstly, one volume of sample 
was mixed with two volumes of NT buffer. The sample was then loaded into a NucleoSpin 
extract II Column placed in a 2ml collection tube and centrifuged for 1 minute at 11000 g. 
The flow-through was discarded and 600μl of NT3 buffer was then added to the column, 
which was then centrifuged for 1 minute at 11000 g. The column was centrifuged for another 
two minutes at 11000 g to remove NT3 buffer quantitatively. The column was placed in a 
new 1.5ml microcentrifuge tube and 50µl elution buffer (NE) was added to the column and 
then incubated for 1 minute at room temperature. Finally, the samples were centrifuged for 1 
minute at 11000 g to elute the cDNA.  
 
2.3.6  Quantitative PCR (qPCR) 
qPCRs were carried out for gene expression for the following; oestrogen receptor-α (gene 
ESR1) and oestrogen receptor-β (ESR2); androgen receptor (gene AR); 5α-reductase 
isoforms 1, 2, 3 (genes SRD5A1, SRD5A2, and SRD5A3); PPAR-α, PPAR-γ and PPAR-δ 
(genes PPARA, PPARG and PPARD) and CYP19A1 (aromatase).  Taqman single gene 
expression assays (Applied Biosystems, Life technologies); containing a ready made mix of 
reverse, forward primers and probes, were used for all the genes investigated.  A duplicate of 
each reaction was set up using a 96 well plate. Each 20μl reaction contained 12.5μl of 2X 
Taqman PCR Master Mix (Applied Biosystems, Life technologies), 30-50ng of cDNA, 1μl of 
Taqman assay and RNase-free water was added to make up the total reaction volume of 20μl. 
Ribosomal RNA (18S) was used as a reference gene and was used in separate reactions. 
Human gene reference cDNA (Stratagene), which contains most of the human genome and 
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prostate RNA (courtesy of the Arlt lab), was used as a positive control for all the genes of 
interest. A MX3000P QPCR System (Stratagene) machine was used and the protocol set was 
as follows; one cycle at 50°C for 2 minutes and one cycle at 95°C for 10 minutes, followed 
by 45 cycles of 95°C for 15 sec and 60°C for 1 minute. After manually setting the threshold 
in the exponential area of the curve, the gene expression of the genes investigated was 
quantified relative to 18S expression (CT value of 18s subtracted from CT value of gene of 
interest to calculate the delta CT). Relative quantification (RQ value) was then calculated 
using the following formula; power (2,-Δct), in which the efficiency of the reactions is 
assumed to be 100%.  
 
2.4   Liquid Chromatography Mass Spectrometry (LCMS) 
2.4.1   5α-reductase enzymatic activity 
To measure 5α-reductase enzymatic activity, a testosterone to DHT conversion assay was 
carried out and the concentration of DHT was measured using LCMS (liquid 
chromatography-mass spectrometry). 3 x 106 freshly isolated CD4+ T cells were resuspended 
in 400μl media (Cellgro) (supplemented with 1% 100U/ml Penicillin G and 10µg/ml 
Streptomycin sulphate) and 50µl of foetal calf serum (FCS) was added to glass TLC tubes. 
Assays were supplemented with FCS to improve the kinetics of the conversion assay, as FCS 
supplementation prevented high numbers of cell death. 25μl (per 106 cells) of anti-CD3 and 
anti-CD28 stimulation beads (Invitrogen, Life technologies) was added (not to unstimulated 
control samples). For a final concentration of 200nM testosterone; 4.75µl of 20uM 
testosterone (made up in 100% ethanol, Sigma) was added to unstimulated and stimulated 
cells, and 4.75µl of 100% ethanol were added to control cell samples. Tubes containing no 
cells and just medium (with and without FCS) were used as control samples to detect any 
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background steroid hormones present in the medium or FCS. Testosterone was not added to 
these control samples. The TLR glass tubes were then placed in a horizontally-rotating 
incubator 37°C and incubated for 24 hours. 
 
2.4.2   Steroid hormone extraction from cell media. 
20 µl internal standards; testosterone-d3 and DHT-d3 were added to all samples before 
extraction, so that any differences between samples that may arise during the extraction 
process can be standardised to the internal standard. To extract the steroid hormones from the 
media, cells were pelleted by centrifuging the tubes at 300 g for 5 minutes and then the media 
supernatant was transferred into a fresh TLC tubes. 3ml dichloromethane was then added to 
each tube so that steroid hormones would move from the media into the dichloromethane 
layer to extract the steroids. The tubes were then centrifuged at 300 g for 5 minutes and 
allowed to stand for 10 minutes. The top layer (media) was removed and the remaining 
dichloromethane was evaporated to dryness using nitrogen gas and heating the tubes to 40-
50°C. Finally, the steroid hormones were reconstituted in 100µl 50/50 methanol (LCMS 
grade)/distilled water and transferred into a 500µl glass vial ready for LCMS analysis.  
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Concentration 
of T and 
DHT (ng/ml) 
Volume of 
testosterone 
(ml) 
Volume of 
DHT 
(ml) 
Internal 
standard 
Testosterone-d3 
(10µl) and 
DHT-d3 (10µl) 
Volume of 
50/50 methanol 
(LCMS grade) 
Distilled water 
(µl) 
200 200 200 20 580 
100 100 100 20 780 
50 50 50 20 880 
25 25 25 20 930 
10 10 10 20 940 
5 5 5 20 970 
1 1 1 20 978 
Table 2.1 Calibration samples used to produce a standard curve to quantitate the 
concentration of DHT produced. The calibration series was produced using the following 
dilutions shown.  
 
2.4.3  Mass spectrometry parameters 
All samples and calibrators were prepared in 50/50 methanol/distilled water (LC/MS grade); 
20µl of each sample was analysed.  A Waters Xero mass spectrometer with Acquity uPLC 
system was used, which was fitted with a HSS T3, 1.8µm, and 1.2x50mm column. The 
column temperature remained constant throughout the experiments. The following settings 
were used: an electrospray source in positive ionisation mode, capillary voltage 2.0kV, cone 
voltage 14-30V, collision energy 8-26eV (depending on the mass transition), a source 
temperature of 150°C, and a desolvation temperature of 600°C.  
 
2.5 Western blotting using SDS-PAGE 
 
2.5.1 Gel electrophoresis 
For a 12% resolving gel; 5.25ml of distilled water, 3.25ml of 1.5M Tris buffer pH 8.8 and 
300µl of sodium dodecyl sulphate (SDS) was added to 6ml of Protogel (30% acrylamide and 
bis-acrylamide). Once the gel was ready to be poured into the cassette, 75µl of ammonium 
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persulphate (APS) and 15µl of tetramethylethylenediamine (TEMED) was added to the 
mixture and left to set in a cassette for 10 minutes. Distilled water was added to the top of the 
cassette to ensure a straight gel line formed and to also prevent the formation of air bubbles in 
the resolving gel. 5% staking gel was made with 1.3ml of protogel, 6.1ml of distilled water, 
2.5ml of 0.5M Tris Buffer pH 6.8, 100µl of 10% SDS, 50µl of APS and 10µl of TEMED. 
Once the resolving gel had set, the distilled water was removed from the top of the cassette 
and staking gel was then loaded on top of the resolving gel. A comb was then immediately 
inserted into the stacking gel form wells. Once the stacking gel had set the comb was 
removed and SDS running buffer was then added to remove any air bubbles present in the 
wells.  The white strip on the cassette was removed and subsequently inserted into a running 
tank filled with SDS running buffer. Freshly isolated naïve CD4+ CD45 RA+ T cells were 
resuspended in loading buffer blue heated at 100⁰C for 10 minutes and centrifuged to pellet 
any undissolved protein. 10µl of Protogel protein ladder was loaded into the first lane using a 
Hamilton glass syringe. 20µl of sample (protein from 2 x 105 cells per well) was loaded in 
subsequent lanes. The electrodes from the gel take were attached to a voltage supplier and the 
gel ran for 2 hours at 190 volts. 
 
2.5.2 Transfer to PVDF membrane 
Once the proteins had been separated using gel electrophoresis, they were then transferred 
onto a PVDF membrane via a wet blotting system. This system involves the formation of a 
membrane sandwich in a tray of blotting buffer. In the tray, a sponge and then filter paper 
soaked in blotting buffer were placed on the black side of a large cassette. A piece of PVDF 
membrane was cut 1cm larger in diameter then the gel. The membrane was activated in 
methanol for 30 seconds and then rinsed in distilled water and blotting buffer. The activated 
membrane was then placed on the filter paper soaked in blotting buffer in the cassette. The 
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gel was then placed on the membrane and covered with filter paper and a sponge both soaked 
in blotting buffer and the cassette was subsequently sealed. This ensures that the PVDF 
membrane and the gel are packaged in a tight sandwich to allow transfer of the protein from 
the gel onto the PVDF membrane. A roller was used to remove air bubbles and folds. The 
cassette was placed in a tank with the black side of the cassette facing the black electrode in 
the blotting tank filled with blotting buffer, as this ensures that the protein from the gel 
transfers onto the PVDF membrane and not onto the filter paper. The transfer was run at 450 
milliamps for 90 minutes. 
 
2.5.3  Antibody probing 
After the transfer, the membrane was removed from the cassette and the gel was discarded. 
To prevent any unspecific binding of the antibody on the membrane, the membrane blot was 
soaked in 1% TBS-Tween (tween 0.5%) with 5% milk, which is used as a blocking reagent, 
for 1 hour before probing the blot with the primary antibody. The blot was then washed three 
times with 1x TBS-Tween for 15 minutes. The blot is probed with the primary antibody 
mouse anti-human androgen receptor (Southern Biotech) at a dilution of 1:5000 (made up in 
0.5% milk TBS-tween) overnight with gentle agitation at 4°C. 
The blot was washed three times with 1x TBS-Tween for 15 minutes. The blot was then 
probed with a HRP conjugated secondary sheep anti-mouse IgG antibody (GE healthcare) at 
dilution of 1:2000 for 1 hour at room temperature with gentle agitation. The blot was then 
washed three times with 1x TBS-Tween for 15 minutes.  
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2.5.4  Enhanced chemiluminescence (ECL plus) 
The proteins were visualised using ECL plus (GE healthcare): the blot is incubated with ECL 
for 1min with gentle agitation. The blot was then wrapped in saran wrap and a roller was used 
to remove air bubbles or folds. The blot was placed in a cassette and taped down ready to 
expose the blot. The blot was exposed onto a film for 1 minute (autoradiography against X-
ray film-Kodak) and developed using a developer in a dark room.  
 
2.5.5  β-actin antibody probing 
For a protein loading control, the membrane was subsequently probed for β-actin protein. 
Firstly, the membrane was washed in three times 1x TBS-Tween for 15 minutes. The blot 
was probed with a primary antibody mouse anti-human β-actin (Southern Biotech) at a 
1:5000 dilution (made up in 0.5% milk TBS-tween) and left overnight with gentle agitation at 
4°C. The membrane was then probed with a secondary HRP conjugated antibody using the 
protocol described previously for androgen receptor and also visualised using ECL (as 
described above).  
 
 
2.6  Flow cytometry  
 
2.6.1  Cell membrane surface staining  
Firstly, the wells of a 96 well round-bottomed flexiplate were coated with FCS. Cells were 
then resuspended in FCS and 5 x 105 cells were added to each well, and then centrifuged at 
300 g at 4°C for 4 minutes. The supernatant was then removed leaving the cells pelleted in 
the wells. Cells were resuspended in directly conjugated antibody (specific for the protein of 
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interest) Isotype and species-matched control antibody, which was made up in final volume 
of 50μl MACS buffer (as used in section 2.2.2). For staining panels containing more than one 
fluorochrome, compensation samples for single colour staining were required. Optimal 
dilutions for all antibodies were determined by titration experiments. One sample was stained 
with species, concentration and isotype-matched controls (irrelevant samples) for the specific 
antibodies to detect any background signals. Cells were then incubated for 15 minutes at 2-
4°C in the dark. The cells were then washed twice in 50μl MACS buffer and centrifuged at 
300 g at 4°C for 4 minutes, and then transferred into FACS tubes and resuspended in 500μl of 
MACS buffer. Flow cytometry was performed using a Dako Cyan flow cytometer (Beckman 
Coulter Ltd). Summit 4.4 software (Dako) was used to analysis the data.  
 
2.6.2   Intracellular staining  
Firstly, the cells underwent surface staining as described in section 2.6.1.  Cells were then 
resuspended in 50µl of medium A (fixation) (Invitrogen, Life technologies) and incubated for 
10 minutes at 2-4°C. The cells were then washed twice in 50μl MACS buffer and centrifuged 
at 300 g at 4°C for 4 minutes. Cells were resuspended in 50µl of medium B (for cell 
permabilisation) (Invitrogen, Life technologies) and incubated for 10 minutes at 2-4°C. The 
cells were then washed twice in 50μl MACS buffer and centrifuged at 300 g at 4°C for 4 
minutes.  Cells were then resuspended in 50μl antibody (made up in MACS buffer) that were 
specific for intracellular proteins (including control samples stained with concentration, 
Isotype-matched irrelevant antibodies) and were incubated for 15 minutes at 2-4°C. The cells 
were then washed twice in 50μl MACS buffer and centrifuged at 300 g at 4°C for 4 minutes. 
50μls of secondary antibody (made up in MACS buffer) was added to wells and incubated for 
15 minutes at 2-4°C. Secondary antibodies were only used for unconjugated primary 
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antibodies. Cells were then washed twice in 50μl MACS buffer and centrifuged at 300 g at 
4°C for 4 minutes. Finally, cells were resuspended in 200µl MACS buffer and transferred 
into FACS tubes containing 300µl MACS buffer. Flow cytometry was performed using a 
Dako Cyan flow cytometer (Beckman Coulter Ltd). Summit 4.4 software (Dako) was used to 
analysis the data.  
 
Table 2.2 shows the antibodies used in intracellular staining for PPARs and 5α-reductase 1. 
Dilutions for the PPARs antibodies were made from a stock concentration of 100µg/ml and 
for the 5α- reductase 1antibody, the dilutions were made from a stock concentration of 
200µg/ml.  
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 Dilution      Antibody 
Clone 
Supplier 
Primary antibodies    
Mouse anti-human CD4 APC 1:100 EDU-2 Immunotools 
Mouse anti-human CD45 RA PE  1:100 4KB5 Dako 
Mouse anti-human PPAR-α 1:50 H0723 R&D systems 
Mouse anti-human PPAR-γ 1:20 K8713 R&D systems 
Mouse anti-human PPAR-δ 1:40 K9436 R&D systems 
Mouse anti-human AR 1:40 523339 R&D systems 
Rabbit anti-human 5α-reductase 1 1:100 H-105 Santa Cruz Biotech 
Isotype-matched control 
antibodies  
 
 
Mouse IgG1 APC * M1-14D12 ebiosciences 
Mouse IgG1 PE * PPV-04 Immunotools 
Mouse IgG2a (for PPARs) * DAK-GO5 Dako 
Mouse IgG2b (for AR) * DAK-GO9 Dako 
Rabbit serum IgG  * - Dako 
Secondary antibodies    
Goat anti-mouse IgG2a FITC 1:100 - Southern biotech 
Goat anti-mouse IgG2b FITC 1:100 - Southern biotech 
Goat anti-rabbit FITC 1:100 - Southern biotech 
Table 2.2  Antibodies used for intracellular staining of PPARs, AR and  5α-reductase 1. 
The same concentration used for the specific antibodies were also used for the Isotype and 
species-matched controls (represented by the asterisks)  
 
 
Table 2.3 shows the antibodies used for 5α-reductase staining in SLE patients and healthy 
controls; using the protocol in section 2.6.1 and 2.6.2. Two separate staining panels were 
used; the first panel includes antibodies used for surface staining; mouse anti-human CD3 
pacific blue, mouse anti-human CD4 APC, mouse anti-human CD45 RO PE, mouse anti-
human CD8 PeCy7, and rabbit anti-human 5α- reductase 1 antibody or the isotype-matched 
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control antibody (rabbit IgG) for  intracellular staining. The second panel includes the 
antibodies used for surface staining of; mouse anti-human CD14 PeCy7, mouse anti-human 
CD19 pacific blue, and intracellular staining with rabbit anti-human 5α-reductase 1 antibody 
or the isotype-matched control antibody (rabbit IgG). 
 
 
 Dilution  Antibody   
Clone 
Supplier 
Primary antibodies    
Mouse anti-human CD3 pacific blue 1:200 UCHT1 Biolegend 
Mouse anti-human CD4 APC 1:100 EDU-2 Immunotools 
Mouse anti-human CD45 RO PE 1:100 UCHL1 Dako 
Mouse anti-human CD8 PeCy7 1:100 RPA-T8 ebioscience 
Mouse anti-human CD14 PeCy7 1:100 61D3 ebioscience 
Mouse anti-human CD19 pacific blue 1:200 HIB19 Biolegend 
Rabbit anti-human 5α-reductase 1 1:100 H-105 Santa Cruz Biotech 
Isotype-matched control antibodies    
Mouse IgG1 pacific blue (for CD3 
and CD19) 
* MOPC-21 Biolegend 
Mouse IgG1 APC * M1-14D12 ebioscience 
Mouse IgG1 PE * PPV-04 Immunotools 
Mouse IgG2a PeCy7 (for CD8 and 
CD14) 
* eBM2a ebioscience 
Rabbit serum IgG  * - Dako 
Secondary antibody    
Goat anti-rabbit FITC 1:100 - Southern biotech 
Table 2.3 Antibodies used for intracellular staining of 5α-reductase 1 in SLE patients 
and healthy controls.  
 
Table 2.4 shows the antibodies used for 5α-reductase staining in B cell subsets from SLE 
patients and healthy controls using the protocol in sections 2.6.1 and 2.6.2. 
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 Dilution   Antibody 
Clone 
Supplier 
Primary antibodies    
Mouse anti-human CD19 
pacific blue 
1:200 HIB19 Biolegend 
Mouse anti-human CD27 APC 1:50 O323 ebioscience 
Mouse anti-human CD38 PE 
Texas-Red  
1:100 HIT2 Invitrogen (Life tech) 
Mouse anti-human IgD PeCy7 1:50 IA6-2 Biolegend 
Rabbit anti-human 5α-
reductase 1 
1:100 H-105 Santa Cruz Biotech 
Isotype-matched control 
antibodies 
   
Mouse IgG1 pacific blue  * MOPC-21 Biolegend 
Mouse IgG1 APC * M1-14D12 ebioscience 
Mouse IgG1 PE Texas-Red * - Invitrogen (Life tech) 
Mouse IgG2a PeCy7  * eBM2a ebioscience 
Rabbit serum IgG  * - Dako 
Secondary antibody    
Goat anti-rabbit FITC 1:100 - Southern biotech 
Table 2.4 Antibodies used for intracellular staining of 5α-reductase 1 in B cell subsets 
from SLE patients and healthy controls.  
 
 
2.6.3  Sex hormone treatment and cytokine production assays   
5 x 105 freshly isolated PBMCs (section 2.2.2) were resuspended in 482μl of serum-free 
media (RPMI supplemented with 1% GPS) per well in a 24 well flat-bottomed plate Cells 
were then incubated for 20 hours at 37°C with 5% CO2. For cytokines IL-10 and IL-17, 
which are produced much later than IL-2 and IFN-γ after stimulation, cells were stimulated 
with CD3 and CD28 activation beads for 20 hours before the addition of sex hormones and 
Brefeldin A (Sigma). After overnight incubation, 18μl of anti-CD3 and anti-CD28 activation 
beads were added to each well except in wells for control cells that were not stimulated with 
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activation beads. Brefeldin A was added to all wells (both cells with or without stimulation 
beads) at a final concentration of 10μg/ml. Both control and stimulated cells were then treated 
with different concentrations of either testosterone; 0.1nM, 1nM, 7nM and 15nM, or treated 
with different concentrations of DHT; 0.0nM, 0.1nM, 0.5nM and 2nM, or different 
concentrations of 17β-estradiol; 0.07nM, 0.13nM, 0.29nM and 0.95nM. In control wells, 
which were not treated with any sex hormones, 1μl 100% ethanol was added instead as a 
vehicle control. All the stock solutions of the sex hormones were made up in 100% ethanol; 
in all the treatments the volume of the sex hormones added to the cells was less than 1.5% of 
the total assay volume. Cells were incubated for 4 hours at 37°C with 5% CO2. After the 4 
hours incubation, the cells are ready to be stained for intracellular cytokines using the 
methods in sections 2.6.1 and 2.6.2 and analysed by flow cytometry.  
 
Table 2.5 shows the antibodies used for intracellular staining of cytokines after treatment 
with sex hormones using the protocol in section 2.6.1 and 2.6.2. Four separate staining panels 
were used; the first panel included surface staining with antibodies; mouse anti-human CD3 
pacific blue, mouse anti-human CD4 FITC, mouse anti-human CD45 RO PE and intracellular 
staining with antibodies anti-human IFN-γ APC and IL-2 PeCy7 or the Isotype-matched 
control antibody. The second panel included surface staining with antibodies; mouse anti-
human CD3 pacific blue, mouse anti-human CD8 PE,  mouse anti-human CD45 RO FITC,  
and intracellular staining with antibody anti-human IFN-γ APC and IL-2 PeCy7. The third 
panel (and fourth panel) were used for cells stimulated for 24 hours, which included surface 
staining antibodies; mouse anti-human CD3 pacific blue, mouse anti-human CD4 APC, 
mouse anti-human CD8 PeCy7, and intracellular staining with antibodies anti-human IL-10 
FITC and anti-human IL-17 PE. The fourth panel included surface staining antibodies; mouse 
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anti-human CD3 pacific blue, mouse anti-human CD4 APC, mouse anti-human CD8 PeCy7, 
and intracellular staining with antibody anti-human TNFα PE.  
 
 Dilution   Antibody Clone Supplier 
Surface antibodies    
Mouse anti-human CD3 pacific blue 1:200 UCHT1 Biolegend 
Mouse anti-human CD3 PE 1:100 UCHT-1 Immunotools 
Mouse anti-human CD4 FITC 1:100 MEM-115 Immunotools 
Mouse anti-human CD45 RO PE 1:100 UCHL1 Dako 
Mouse anti-human CD45 RO FITC 1:100 UCHL1 Dako 
Mouse anti-human CD8 PeCy7 1:100 RPA-T8 ebioscience 
Mouse anti-human CD8 PE 1:100 UCHT-4 Immunotools 
Intracellular antibodies    
Mouse anti-human IL-2 PeCy7 1:100 M-A251 BD biosciences 
Mouse anti-human IL-10 FITC 1:25 BT-10 ebioscience 
Mouse anti-human IL-17A PE 1:25 SCPL-1362 BD biosciences 
Mouse anti-human IFN-γ APC 1:500 B27 BD biosciences 
Mouse anti-human TNF-α PE 1:50 6401.1111 BD biosciences 
Isotype-matched control 
antibodies  
 
 
Mouse IgG1 pacific blue  * MOPC-21 Biolegend 
Mouse IgG1 PE * M1-14D12 ebioscience 
Mouse IgG1 FITC * 203 Immunotools 
Mouse IgG2a PeCy7 * eBM2a ebioscience 
Mouse IgG1 APC * M1-14D12 ebioscience 
Table 2.5: Antibodies used for intracellular staining of cytokines using flow cytometry 
after treatment with sex hormones.  
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2.6.4  Testosterone and 4-hydroxytamoxifen treatment 
5 x 105 freshly isolated PBMCs (section 2.2.2) were resuspended in 482μl of serum-free 
media (RPMI supplemented with 1% GPS) per well in a 24 well flat-bottomed plate. Cells 
were then incubated for 20 hours at 37°C with 5% CO2. After overnight incubation, 18μl of 
anti-CD3 and anti-CD28 activation beads were added to each well except in wells for control 
cells that were not stimulated with activation beads.  Brefeldin A was added to all wells (both 
cells treated with or without stimulation beads) at a final concentration of 10μg/ml.  Both 
control cells and stimulated were then treated with a range of testosterone concentrations; 
0.1nM, 1nM, 7nM and 15nM. Cells treated with different concentrations of testosterone were 
treated with 2nM 4-hydroxytamoxifen (control samples included cells treated with 
testosterone with no further 4-hydroxytamoxifen treatment). Cells were incubated for 4 hours 
at 37°C with 5% CO2. After the 4 hours incubation, the cells are ready to be stained for 
intracellular cytokines using the methods in sections 2.6.1 and 2.6.2 and analysed by flow 
cytometry.  
 
2.6.5  Sex hormone treatment and CFSE proliferation assay  
 
To measure cell proliferation, cells were labelled with carboxyfluorescein diacetate, 
succinimidyl ester (CFSE); as the number of cell divisions increases, the CFSE signal 
decreases. Freshly isolated PBMCs were resuspended in 25μl per 1 x 106 cells in PBS 0.1% 
BSA. 5μM of CFSE (Invitrogen, Life technologies) was diluted in the same volume, in which 
the cells were suspended in, and then added to the cell suspension for a CFSE final 
concentration of 2.5μM. Cells were then incubated in the dark at 37°C for 10 minutes. After 
the incubation period, the cells were quenched with 5 volumes of ice-cold medium and 
incubated on ice for 5 minutes. The cells were then washed twice by adding 15ml medium 
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and centrifuging for 5 minutes at 20°C. 5 x 105 cells were resuspended in 482μl of medium 
(RPMI supplemented with 1% GPS and FCS) per well in a 24 well flat-bottomed plate. 18μl 
of anti-CD3 and anti-CD28 activation beads were added to each well except in wells for 
control cells that were not stimulated with activation beads. Both control cells and stimulated 
were then treated with a range of concentrations of testosterone; 0.1nM, 1nM, 7nM and 
15nM. Cells were then cultured for 4 days at 37°C with 5% CO2. After 4 days, cells were 
stained for flow cytometry analysis of the CFSE signal using the protocol outlined in section 
2.6.1. Cells were stained with mouse anti-human CD4 APC and mouse anti-human CD8 
pacific blue antibodies (both at 1:100 dilutions). Cells were then analysed for cell 
proliferation on the flow cytometer using the CFSE signal (FITC channel).  
 
2.7  Statistical Analysis 
 
Statistical analysis was carried out using non-parametric student T tests such as Mann-
Whitney and paired Wilcoxon T tests. All statistical analysis was performed using Graph Pad 
Prism version 5 software. Data analysis producing a p value of ≤0.05 was deemed statistically 
significant.  
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3     GENDER DIFFERENCES IN HORMONE METABOLISM 
DURING T CELL ACTIVATION.  
 
3.1  Introduction 
Androgens and oestrogens have been attributed with conflicting effects on the immune 
system; androgens such as testosterone and DHT have an anti-inflammatory effect, whereas 
oestrogens such as 17β-oestradiol and oestrone generally enhance immune responses. Sex 
hormone levels have shown to have a profound effect on the severity of chronic inflammatory 
conditions and autoimmune diseases, therefore it is important to investigate the effects of sex 
hormones on the immune system. It is important to consider that the immune system in each 
individual has developed in the context of the hormone environment it is exposed to. So we 
need to distinguish between the effects of male or female hormones have throughout the 
development of the individuals T cell pool and thus investigate the long term and short-term 
effects of sex hormone exposure on T cells in the context of an in-vitro experiment over a 
short time duration. Research into the specific differences in the way T cells respond to 
hormones may help our understanding of autoimmune diseases and could potentially lead to 
new therapeutic developments.  
 
Enzymes involved in sex hormone metabolism such as 5α-reductase have been proposed to 
play an important role in the regulation of immune responses; predominately in a suppressive 
manner. In mouse models for trauma-haemorrhage, 5α-reductase expression in T cells was 
found to be increased compared to controls, which resulted in an increase in DHT production 
and thus suppression of T cell responses (Samy et al. 2001). Androgens and oestrogens 
mediate their effects through binding to nuclear receptors; AR; ER-α and ER-β. These sex 
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hormone receptors have been shown to be expressed in various immune cell subsets 
(Brechenmacher et al. 2008), therefore this suggests that immune cells may be responsive to 
the actions of endogenous or exogenous androgens and oestrogens. AR expression has been 
shown to be higher in macrophages from males in comparison to female macrophages 
(McCrohon et al. 2000); this has been linked to androgen-mediated development of 
atherosclerosis, and higher susceptibility to this disease in males.   
 
One of the aims of this project was to investigate differences in the way T cells from healthy 
males and females regulated the production of androgens and oestrogens, and how T cells 
were able regulate their exposure to sex hormones by investigating the expression of sex 
hormone metabolising enzymes and sex hormone receptors. To accomplish this, we explored 
the differences in mRNA expression of sex hormone receptors genes and sex hormone 
metabolising enzymes between male and female naïve CD4+ T cells at baseline and after in 
vitro. We investigated expression of 5α-reductase isoforms 1, 2 and 3 (genes being SRD5A1, 
SRD5A2, SRD5A3 respectively); as the activity if this enzyme results in the production of 
the most androgen, DHT. We also investigated the mRNA expression of sex hormone 
receptors; AR, ER-α, and ER-β (gene names ESR1 and ESR2 respectively) at baseline and 
after stimulation. 
 
We also wanted to explore the role of PPARs in mediating sex differences observed in 
immune responses as Dunn and colleagues found in mice that androgen activated PPAR-α 
suppressed Th1 cell mediated responses (Dunn et al. 2007). They also demonstrated a sex 
difference in PPAR-α expression, as it was more abundant in male mice in comparison to 
female mice. This was found to protect males in the development of autoimmunity. 
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Therefore, we wanted to investigate if this higher expression of PPARs in males (in particular 
PPAR-α) in comparison to females was present in human naïve CD4+ T cells.  
 
3.2  mRNA and protein expression of androgen receptor, and mRNA expression of 
oestrogen receptors; ER-α and ER-β in naïve CD4+ T cells in males and females. 
We found no significant differences the expression of ER-α or AR in naïve CD4+ T cells 
between males and females (figure 3.1A, C). There was a trend towards a higher expression 
of ER-β in naïve CD4+ T cells from males compared to female naïve CD4+ T cells,  however 
this was not statistically significant (p=0.09). Also, we observed no significant differences in 
ER-α, ER-β and AR expression after in vitro stimulation between males and females. 
However, there was a significant upregulation of ER-β expression in female stimulated naive 
CD4+ T cells in comparison to unstimulated CD4+ T cells (p=0.003) (figure 3.1B). Both 
Western blots (figure 3.2A) and flow cytometry (figure 3.2C, D) confirmed the protein 
expression of AR in naïve CD4+ T cells. In contrast to the mRNA data, we did detect a 
significant upregulation of AR expression upon stimulation in naive CD4+ T cell in 
comparison to the unstimulated cells on the protein level, which was observed in both males 
(p=0.04) and females (p=0.04) (figure 3.2D). Overall, there were few significant differences 
in sex hormone receptor expression between males and females on the baseline or upon in 
vitro stimulation.  
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Figure 3.1  mRNA gene expression of sex hormone receptors in naïve CD4+ T cells. 
Freshly isolated naive CD4+ T cells were separated into three different conditions: freshly 
isolated cells that were immediately lysed, cultured unstimulated cells and cells stimulated 
with anti CD3 anti CD28 activation beads for 24 hours prior to cell lysis. Freshly isolated 
cells were used as control for the unstimulated-cultured cells as artefacts may arise from 
culturing the cells. Relative quantification (RQ) to ribosomal RNA 18s are shown for A) ER-
α (ESR1), B) ER-β (ESR2) and C) AR. Horizontal lines present the median. Wilcoxon 
matched pairs t test; * p<0.05, ** p<0.001. 
 
 
 
 
 
 
       AR
10- 9
10- 8
10- 7
10- 6
10- 5
10- 4
10- 3
10- 2
10- 1
100
          Male                      Female
R
Q
 (r
el
at
iv
e 
to
 1
8S
)
           ESR1
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
          Male                      Female
R
Q
 (r
el
at
iv
e 
to
 1
8S
)
             ESR1
0.000001
0.00001
0.00001
0.0001
0.001
0.01
0.1
1
          Male                      Female
Unstim cells
Stim cells
RQ
 (r
el
at
iv
e 
to
 1
8S
)
          ESR2
10- 9
10- 8
10- 7
10- 6
10- 5
10- 4
10- 3
10- 2
            Male                    Female
R
Q
 (r
el
at
iv
e 
to
 1
8S
)
         ESR2
10- 9
10- 8
0.000001
0.00001
0.0001
0.001
0.01
0.1
1
          Male                      Female
RQ
 (r
el
at
iv
e 
to
 1
8S
)
           AR
10- 1 010
- 9
10- 7
10- 6
10- 5
10- 4
10- 3
10- 2
10- 1
100
           Male                    Female
RQ
 (r
el
at
iv
e 
to
 1
8S
)
 
 
 
 
 
 
A 
 
 
 
 
 
 
B 
 
 
 
 
 
 
C 
  
** 
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2  Protein expression of AR in naïve CD4+ CD45 RA+ T cells. 
A) Protein expression of androgen receptor (AR) in isolated naïve CD4+ CD45 RA+ T cells 
from four donors was detected using Western blotting; β-actin was used as a loading control. 
Naive CD4+ CD45 RA+ T cells were stained for intracellular AR and analysed using flow 
cytometry. All the cells gated as CD4+ CD45 RA+ expressed AR as highlighted in the 
histogram for AR expression (B). C) Accumulative data for AR expression in naive CD4+ 
CD45 RA+ T cells from males (n=10) and females (n=10). D) Naïve CD4+ CD45 RA+ T cells 
from 6 males and 6 females were stained for intracellular AR expression after no stimulation 
(circles) or stimulation with anti CD3 and anti CD28 activation beads for 24 hours (squares) 
and analysed using flow cytometry. Horizontal lines present the median. MFI: median 
fluorescence intensity. Wilcoxon matched pairs t test; * p<0.05. 
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3.3 mRNA expression of 5α-reductase isoforms in naïve CD4+ T cells from males and 
females. 
We could not detect mRNA expression of 5α-reductase isoform 2 in naïve CD4+ T cells or 
PBMCs, however in the prostate RNA positive control, did detect SRD5A2 expression (data 
not shown), and therefore the assays were working efficiently. However, we could detect 
mRNA expression for 5α-reductase isoforms 1 and 3 (figure 3.3A, B). On the baseline, there 
were no significant differences between males and females in 5α-reductase 1 or 3 expression 
in naïve CD4+ T cells. Additionally, there were no significant differences in 5α-reductase 1 
and 3 expression between males and females naïve CD4+ T cells after in vitro stimulation. 
However, we did observe a significant upregulation in of both 5α-reductase 1 and 3 upon 
stimulation in female naive CD4+ T cells in comparison to the unstimulated female naïve 
CD4+ T cells. However, this was not observed in male naive CD4+ T cells upon stimulation.  
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Figure 3.3  mRNA gene expression of 5α-reductase isoforms.  
Freshly isolated naive CD4+ T cells were separated into three different conditions: freshly 
isolated cells that were immediately lysed, cultured unstimulated cells and cells stimulated 
with anti CD3 and anti CD28 activation beads for 24 hours prior to cell lysis. Relative 
quantification (RQ) to ribosomal RNA 18s is shown for A) 5α-reductase 1 (SRD5A1) and B) 
5α-reductase 3 (SRD5A3). Horizontal lines represent the median. Wilcoxon matched pairs t 
test; * p<0.05. 
 
 
3.4  Protein expression and enzymatic activity of 5α-reductase in naïve CD4+ T cells. 
We wanted to confirm our mRNA findings by measuring 5α-reductase 1 on the protein level. 
We repeated the same experiments used for detecting mRNA expression and instead used 
flow cytometry as a readout for protein expression. CD45RA+ CD4+ T cells were stained for 
intracellular expression for 5α-reductase 1 (figure 3.4B). The protein data confirmed the 
mRNA data, as we observed an upregulation of 5α-reductase 1 expression in female 
stimulated CD4+ T cells in comparison to the unstimulated CD4+ T cells. This upregulation of 
5α-reductase 1 expression was not observed in stimulated male CD4+ T cells on the protein 
level, which was in line with the observations made on the mRNA level. A stimulation time 
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course for 5α-reductase 1 protein expression showed an upregulation of 5α-reductase 1 
expression was observed at the 24 hours stimulation time point  in both naïve (CD45 RO-)  
and memory (CD45 RO+) CD4+ T cells (figure 3.4C).  
 
We then wanted to investigate whether the increased gene and protein expression levels of  
5α-reductase 1 in female CD45RA+ CD4+ T cells was reflected in 5α-reductase enzymatic 
activity. 5α-reductase conversion assays determined reduction of the substrate testosterone to 
DHT to as a readout for 5α-reductase activity and DHT concentrations were then measured 
using LCMS. These assays are particularly complicated and took several months to set up as 
extremely low levels of DHT are detected (figure 3.5B), and relatively insensitive assays are 
only available. The DHT levels detected were at the lower end of the detection range and 
therefore there were doubts regarding the validity of the analysis. We did detect a trend 
towards higher DHT production in the stimulated CD4+ T cells compared to the unstimulated, 
but unfortunately we obtained extremely low concentrations of DHT detected by LCMS in 
these conversion assays. Therefore, while we could confirm a trend towards higher 5α-
reductase activity in the stimulated female CD4+ T cells compared to the unstimulated cells, 
because of the low DHT concentration levels a definite judgement cannot be made yet. We 
detected conversion of testosterone to androstenedione (figure 3.5C) but a standard curve for 
androstenedione concentration was not used in the LCMS experiments therefore exact 
concentrations of androstenedione were unknown.  
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Figure 3.4 5α-reductase 1 protein expression in naïve CD4+ T cells.  
A) FACS plots for one  donor showing naive CD4+ CD45 RA+ T cells that were stained for 
intracellular 5α-reductase 1 expression (shown in histogram) after no stimulation 
(unstimulated) or stimulation with anti CD3 and anti CD28 activation beads  for 24 hours and 
analysed using flow cytometry. 5α-reductase 1 expression in CD4+ CD45 RA+ T cells was 
measured in 10 males and 10 females (B). Horizontal lines present the median. C) Female 
CD4+ T cells (n=3) were stimulated for various time durations and then stained for 
intracellular 5α-reductase 1 expression in naïve CD4+ CD45 RO- and memory CD4+ CD45 
RO+ T cells. MFI: median fluorescence intensity. MFI of isotype-matched controls were 
subtracted from the 5α-reductase MFI. Error bars represent SEM. Wilcoxon matched pairs t 
test; ** p<0.001; *** p<0.0001. 
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Figure 3.5  5α-reductase activity in female naïve CD4+ T cells.  
5α-reductase activity in female unstimulated or in vitro anti CD3/anti CD28-stimulated naïve 
CD4+ T cells was measured using a conversion assay of substrate testosterone to DHT. DHT 
concentration was measured using LCMS after 24 hours conversion assays, A) shows 
detected LCMS peaks for testosterone, DHT and androstenedione. B) The concentration of 
DHT detected (n=3). C) Androstenedione was also detected in the assays and is represented 
as area under the curve (n=3). Error bars represent SEM.   
 
 
3.5 mRNA and protein expression of PPARs in naïve CD4+ T cells in males and females. 
We observed no significant differences in baseline mRNA or protein expression of PPAR-γ 
and PPAR-δ in naïve CD4+ T cells between males and females. There was a trend observed, 
in which baseline expression of PPAR-α was higher in male naïve CD4+ T cells compared to 
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to the unstimulated female CD4+ T cells; however this was not observed on the protein level 
(see appendix). Overall, there were no significant differences in the expression of PPARs 
between males and females on the baseline and upon stimulation on both the mRNA and 
protein levels.  
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Figure 3.6  mRNA and protein expression of PPARs in naive CD4+ T cells.  
Freshly isolated naive CD4+ T cells from males (n=10) and females (n=10) were separated 
into three different conditions: freshly isolated cells (baseline) that were immediately lysed, 
cultured un-stimulated cells and cells stimulated with anti CD3 and anti CD28 activation for 
24 hours prior to cell lysis. mRNA gene expression was measured as relative quantification 
(RQ) to housekeeping gene 18s for A) PPAR-α, B) PPAR-γ and C) PPAR-δ.  Naive CD4+ 
CD45 RA+ T cells were stained for intracellular PPARs and analysed using flow cytometry. 
All the cells gated as CD4+ CD45 RA+ expressed all three PPAR isoforms including PPAR-α 
as highlighted in the histogram for PPAR-α expression (D). Accumulative data from males 
(n=10) and females (n=10) are represented as dot graphs for E) PPAR-α, F) PPAR-γ and G) 
PPAR-δ. Horizontal lines present the median. MFI: median fluorescence intensity. Wilcoxon 
matched pairs t test; * p<0.05. 
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3.6  Discussion  
 
One of the aims of this project was to investigate differences in the way T cells from male 
and female healthy individuals regulate response to androgens and oestrogens, and how naïve 
CD4+ T cells are able regulate their exposure to sex hormones. We did this by investigating 
the expression of sex hormone metabolising enzymes and sex hormone receptors. 
The role of sex hormone receptors is important for our understanding of the effects of sex 
hormones on inflammatory responses, as sex hormones are able to exert their influence by 
interaction and activation of sex hormone receptors, which have been previously shown to be 
present in various immune cell  subsets (Brechenmacher et al. 2008). Our mRNA gene 
expression data showed there were no significant differences in the baseline expression of 
ER-α, ER-β or AR in naïve CD4+ T cells between males and females (figure 3.1A, B, C). 
This suggests that naïve CD4+ T cells from both males and females are able regulate their 
exposure to sex hormones in a similar manner. Upon in vitro stimulation, the data showed a 
significant increase in ER-β expression in female naïve CD4+ T cells in comparison to the 
unstimulated naïve CD4+ T cells. ER-β can form heterodimers with ER-α, which has shown 
to result suppressed ER-α transcriptional activity (Lindberg et al. 2003). Evidence of this 
modulating effect of ER-β on ER-α activity has been demonstrated in murine models, in 
which ER-β knock-out mice showed an increased ER-α regulation of progesterone receptor 
expression, and subsequently resulted in increased epithelial cell proliferation in the uterus 
and an exaggerated response to 17β-oestradiol via progesterone receptor activation (Weihua 
et al. 2000). Also, the immune enhancing effects of oestrogens have been shown to be ER-α 
dependent (Maret et al. 2003; Yang et al. 2010). Therefore, a possible explanation for the 
upregulation of ER-β upon naïve CD4+ T cells activation in females could be to prevent the 
induction of inflammatory responses that are dependent on ER-α signalling pathways, and 
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could then be mechanism for preventing the development of chronic inflammatory diseases 
including autoimmune diseases. Increased ER-α expression and reduced ER-β has been 
demonstrated in SLE PBMCs (Lin et al. 2011) and interestingly, the expression of ER-β had 
a significant inverse correlation with disease activity (Inui et al. 2007). We did not see this 
upregulation of ER-β in male stimulated CD4+ T cells; the reason for this could be due to the 
lower circulating oestrogen levels in males compared to females, therefore male CD4+ T cells 
may not need to use this mechanism to reduce the effects of oestrogens exerted on T cell 
responses, as the levels of oestrogen exposure to male CD4+ T cells would be considerably 
lower compared to females.  The down regulation of ER-α expression in male stimulated 
CD4+ T cells was not a statistically significant finding; however it does suggest that this could 
be a mechanism to inhibit pro-inflammatory effects exerted by oestrogen, therefore it would 
be interesting to confirm if this finding is significant on the protein level. As interesting as 
these findings are, it would be important to look on the protein level before drawing any 
conclusions from this mRNA data as previous studies have shown that oestrogen receptors 
are susceptible to post-translational modifications (Cheng et al. 2000; Cheng and Hart 2000; 
Saceda et al. 1998).  
 
Very low levels of AR mRNA gene expression were observed in the qPCR experiments (the 
signal became detectable at around cycle 35-40), however subsequent flow cytometry 
analysis found high expression of levels AR protein in naïve CD4+ T cells (figure 3.2A, C, 
D). The qPCR data suggests there is a trend towards higher expression of AR mRNA in 
female CD4+ T cells compared to male CD4+ T cells, however this is not statistically 
significant. In contrast, macrophages from males have been shown to have higher AR 
expression compared to females (McCrohon et al. 2000). However, we did detect a 
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significant upregulation of AR expression upon stimulation in naive CD4+ T cell in 
comparison to the unstimulated cells on the protein level, which was observed in both males 
and females (figure 3.2D). One explanation for this contrasting mRNA and protein data could 
be that the AR gene does not need to be continually expressed if the protein is relatively 
stable. Also, expression of androgen and oestrogen receptors has been shown to be regulated 
by epigenetic modifications (Imamura 2011), therefore these genes might be silenced by 
these modifications, and post-translational modifications could also be responsible of the 
differences in mRNA and protein expression data. The observation that naïve CD4+ T cells 
are increasing their exposure to androgens after stimulation by upregulating AR expression 
particularly in female CD4+ T cells, where there is lower exposure to circulating androgens in 
comparison to males, shows that female CD4+ T cells could be increasing their exposure to 
the immunosuppressing effects of androgens, but also simultaneously reducing their exposure 
to the immune enhancing effects of circulating oestrogens by upregulating ER-β expression 
after stimulation. Subsequent functional experiments on these sex hormone receptors would 
have to be carried out to investigate the outcome of these differences in expression on T cell 
responses.  
 
5α-reductase is an important enzyme in androgen metabolism as it is responsible for the 
conversion of testosterone into DHT, which is the most potent androgen in the body; as it has 
a 10 times higher affinity for the AR in comparison to testosterone. The importance of DHT 
is demonstrated in 5α-reductase deficiency disorder, in which normal development of male 
external sex organs is obstructed (Andersson et al. 1991; Forti et al. 1996). Therefore, we 
wanted to investigate the expression of 5α-reductase in naïve CD4+ T cells to detect any 
differences androgen metabolism between males and females. 5α-reductase 1 (SRD5A1) and 
5α-reductase 2 (SRD5A2) have both been shown to be involved in androgen metabolism and 
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have distinctly different expression patterns in specific tissues and organs (Berman and 
Russell 1993; Silver et al. 1994). However, unlike SRD5A1 and SRD5A3 we could not 
detect SRD5A2 in naïve CD4+ T cells or PBMCs, but it was detected in the positive control, 
therefore we can conclude that 5α-reductase 2 is not expressed in naïve CD4+ T cells, which 
supports a previous finding in mice (Zhou et al. 1998). In the qPCR experiments, we found 
no significant differences in the baseline mRNA expression of the both isoforms between the 
sexes.  There was no correlation between 5α-reductase expression and the different stages of 
the menstrual cycle (data not shown). However, it did show a significant upregulation of 
SRD5A1 and SRD5A3 mRNA expression in female stimulated naïve CD4+ T cells in 
comparison to the female unstimulated CD4+ T cells. Interestingly, this significant 
upregulation of SRD5A1 and SRD5A3 expression was only observed in female stimulated 
CD4+ T cells and not in male stimulated CD4+ T cells. This finding was also confirmed on the 
protein level, as we found 5α-reductase 1 was upregulated in only female stimulated CD4+ T 
cells and a stimulation time course confirmed that 5α-reductase 1 expression peaked at 24 
hours. Also, on the protein level we found the expression of 5α-reductase 1 in female 
stimulated T cells was significantly higher compared to 5α-reductase 1 in male stimulated T 
cells.  There is evidence to suggest that 5α-reductase expression can be epigenetically 
regulated, as it has been shown that 5α-reductase is susceptible to DNA methylation, in 
particular cytosine methylation, in human lymphocytes (Rodriguez-Dorantes et al. 2002). 
Therefore, female CD4+ T cells could be undergoing reduced cytosine methylation of 5α-
reductase upon stimulation, which increases the gene expression, as this type of methylation 
results in the decrease in gene expression. 
 
We did not confirm the 5α-reductase 3 findings on the protein level as it is not clear from the 
literature if this isoform is involved in androgen metabolism. We also found an upregulation 
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of SRD5A3 mRNA expression in female stimulated T cells only. During the initial discovery 
of the 5α-reductase 3, on the basis of sequence similarity to 5α-reductases 1 and 2  it was 
initially thought that 5α-reductase 3 was also able convert testosterone to DHT (Uemura et al. 
2008). However, in the meantime the role of 5α-reductase 3 in steroid metabolism has been 
questioned (Stiles and Russell 2010). A more recent role has been identified for 5α-reductase 
3, as it has been shown to have a vital role in the initial steps in N-glycosylation (Cantagrel et 
al. 2010). Post-translational modifications to antigens (i.e. glycosylation) have been linked to 
T-cell mediated autoimmunity (Purcell et al. 2008). Therefore, this possible increase in 5α-
reductase 3 activity in female stimulated CD4+ T cells could be defected in self reactive T 
cells, and therefore abnormalities in glycosylation that may arise from insufficient 5α-
reductase 3 activity could lead to the development of autoimmune diseases.  
 
Unfortunately, we were unable to have a definite answer to the question whether the 
increased expression leads to higher 5α-reductase enzymatic activity, as our testosterone 
conversion assays detected very low concentrations of DHT produced by female stimulated 
CD4+ T cells. However, we did see a trend towards an increase in DHT production in the 
stimulated CD4+ T cells compared to the unstimulated cells. We did detect conversion of 
testosterone to androstenedione by CD4+ T cells, therefore suggesting that 17β-HSD 2 
activity is active in CD4+ T cells, which has been previously reported (Milewich et al. 1982; 
Zhou and Speiser 1999). A possible explanation for this increase in 5α-reductase 1 expression 
in stimulated female CD4+ T cells and not in male stimulated CD4+ T cells could be that male 
CD4+ T cells are being exposed to higher levels of testosterone in the long term. Therefore, 
the absence of 5α-reductase 1 upregulation in male CD4+ T cells suggests that DHT 
production may be controlled by a negative feedback mechanism to prevent the excess 
production of more active androgens. Interestingly, 5α-reductase deficiency in pregnant 
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female mice resulted in higher foetal deaths, which was associated with chronically elevated 
levels of oestrogen (Mahendroo et al. 1997). The castration of male mice has been shown to 
increase the mRNA levels and activity of 5α-reductase, and restoration of testosterone 
decreased mRNA levels and activity of 5α-reductase (Pratis et al. 2003). The levels of 
testosterone are lower in females, therefore the upregulation of 5α-reductase 1 in female 
CD4+ T cells allows the potential increase production of DHT the more potent androgen. As 
previously stated, androgens are mainly immunosuppressive and have a protective role 
against the development of autoimmune diseases as observed in many studies (Bebo et al. 
1999; Booji et al.1996; Kanda et al. 1997). Therefore, the upregulation 5α-reductase 1 
expression in female CD4+ T cells could increase the production of androgens, therefore 
enhancing the anti-inflammatory effects of androgens, thus protecting against development of 
autoimmunity. This observation leads to the question whether this mechanism may be 
defected in patients with autoimmune diseases, in particular those with a strong gender bias. 
In the following chapter, we therefore investigated 5α-reductase 1 regulation in patients with 
SLE. 
 
It was a study by Dunn et al that suggested that PPAR-α expression was sensitive to 
testosterone and thus mediated the effect of androgens on Th1 mediated responses. They also 
demonstrated a sex difference in PPAR-α expression as it was more abundant in male mice in 
comparison to the females, which in turn protected males from developing EAE (Dunn et al. 
2007). One of the aims of this project is to investigate if a sex difference in PPAR-α 
expression was present in human CD4+ T cells. The qPCR data showed there were no 
statistically significant differences in any of the PPARs expression at baseline between the 
sexes. This finding suggests that the observations made by Dunn et al in mice are not 
extendable to the human system. However, recently Dunn and colleagues extended their work 
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on PPAR-α into humans and found that PPAR-α mRNA in male CD4+ T cells was 
significantly upregulated (Zhang et al. 2012), this was in contrast to our findings as we found 
there were no statistically significant differences between the unstimulated and stimulated 
CD4+ T cells for PPAR-α and PPAR-δ or in both males and females on the mRNA level. The 
expression of PPAR-γ female stimulated CD4+ T cells was significantly higher in comparison 
to female CD4+ T cells unstimulated cells, however this was not reflected on the protein level, 
even though there was a trend towards an increase in all three PPAR isoforms upon 
stimulation, in both males and females, however these findings were not statistically 
significant (see appendix). Dunn et al also found that female CD4+ PPAR-α expression was 
upregulated upon treatment with DHT (Zhang et al. 2012), however the concentration of 
DHT used was 100 times more than the physiological levels of DHT found in both males and 
females. 
Therefore, according to our findings, the gender differences in susceptibility to autoimmunity 
are not likely to be due to the expression PPAR-α or other PPAR isoforms in human CD4+ T 
cells. It would be interesting to compare the expression of PPARs in autoimmune diseases 
compared to the healthy controls to see if there is a decrease in expression of PPARs in CD4+ 
T cells in patients with autoimmune diseases and therefore resulting in reduction of the anti-
inflammatory properties of PPARs. 
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4     5α-REDUCTASE EXPRESSION IN SLE PATIENTS 
 
 
4.1   Introduction 
 
There is a significant gender bias in SLE with females being more susceptible to developing 
the disease with a female to male ratio of 9:1. The predominance of autoimmune conditions, 
particularly SLE in females has initiated a vast amount of research into the role of sex 
hormones in immune and inflammatory responses, especially the effect of oestrogen on 
immune responses. Drastic changes in sex hormone levels are shown to have a significant 
effect on the severity on disease activity in SLE patients. During pregnancy, when oestrogen 
levels are high, disease activity is enhanced in SLE patients (Ruiz-Irastorza et al. 1996). 
Furthermore, the onset of the disease is predominately observed during the child-bearing 
ages. Oestrogen has been shown to increase B cell proliferation and differentiation, and is 
able to elevate IgG and IgM antibody production (anti-dsDNA in SLE patients) in both males 
and females at both high and physiological concentrations (Kanda et al. 1999). 
 
In contrast to oestrogens, androgens have shown to affect immune responses in a suppressive 
manner, as it has been demonstrated that testosterone can inhibit IgM and IgG production by 
decreasing the production of IL-6 by monocytes (Kanda et al. 1996). It is well established 
that SLE patients have low levels of androgens in serum, which inversely correlates with 
disease activity (Jungers et al. 1982; Lahita et al. 1987; Overman et al. 2012). Male SLE 
patients have significantly lower androgen levels and increased oestrogen levels in serum 
compared to healthy males; this is also observed in RA (Cutolo et al. 1991) . However, it is 
not clear if low androgen levels are able to predispose individuals to developing 
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autoimmunity or if the progression of the autoimmune disease itself is responsible for these 
reduced levels of androgens. Furthermore, glucocorticoid treatment given to patients with 
severely active disease has shown to reduce androgen levels (MacAdams et al. 1986). In the 
experimental work described in the previous chapter, we found that 5α-reductase 1 
expression was significantly upregulated in stimulated CD4+ CD45 RA+ T cells from healthy 
females in comparison to the unstimulated cells, which was detected both on the mRNA and 
protein level. However, this upregulation of 5α-reductase 1 expression after stimulation was 
not observed in male CD4+ CD45 RA+ T cells. Therefore, this possible increase in 5α-
reductase 1 activity in female CD4+ T cells upon stimulation could be a mechanism to 
increase the production of androgens, which have shown to have anti-inflammatory effects 
and suppress T cell responses after activation, thus potentially protect against development of 
autoimmunity. We wanted to investigate if this upregulation of 5α-reductase 1 expression 
after stimulation was defected in SLE patients, in which the majority are female, and 
therefore partially explain the autoreactive responses demonstrated in SLE T cells. If CD4+ T 
cells from SLE patients are incapable of upregulating 5α-reductase 1 expression after 
stimulation, this could potentially prevent the anti-inflammatory effect of androgens on T cell 
stimulation, and in turn limit the suppression of pro-inflammatory responses in autoreactive T 
cells. We also wanted to investigate the expression of 5α-reductase 1 in CD8* T cells, CD19+ 
B cells and CD14* monocytes from SLE patients and compare expression levels to healthy 
controls.  
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4.2  5α-reductase 1 expression in immune cells from SLE patients and age and gender 
matched controls. 
Using flow cytometry, we measured the intracellular expression of 5α-reductase expression 
in T cells gated on CD3+, CD4+ CD45 RO+ or CD45 RO-, CD8+ CD45 RO+ or CD45 RO- 
(figure 4.1B), CD14+monocytes (figure 4.1C), and finally CD19+ B cells (figure 4.1D) from 
SLE patients (n=26) and age and gender-matched healthy controls (n=14).  We found no 
significant differences in 5α-reductase expression in both naïve CD4+ CD45 RO- and memory 
CD4+ CD45 RO+, and in naïve CD8+ CD45 RO- and memory CD8+ CD45 RO+ between 
healthy controls and SLE patients. Also, no significant difference in 5α-reductase expression 
in CD14+ monocytes between healthy controls and SLE patients was observed. Also, we did 
not observe any significant differences in 5α-reductase expression T cell subsets (figure 
4.2A-D) and CD14+ monocytes (figure 4.2E) between SLE patients with inactive and active 
disease. However, the results did show that 5α-reductase expression was significantly higher 
in the memory CD4+ CD45 RO+ T cell subset population in comparison to the naïve CD4+ 
CD45 RO- T cell subset (figure 4.1B). This observation was made in both healthy controls 
and SLE patients.  
 
Interestingly, we also found a significant increase in 5α-reductase expression in SLE CD19+ 
B cells compared to the healthy controls and this positively correlated with disease activity  
(figure 4.1D), as SLE CD19+ B cells from patients with active disease had significantly 
higher expression of 5α-reductase 1 in CD19+ B cells compared to healthy controls.  
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Figure 4.1  5α-reductase expression in immune cells from SLE patients and age 
matched controls.  
PBMCs from SLE patients (n=26) and age and gender-matched healthy controls (n=14) were 
stained for intracellular 5α-reductase 1 expression in different immune cell subsets using flow 
cytometry. A) FACS plots show T cells were gated on CD3+, CD4+or CD8+ cells, and CD45 
RO high or low cells, and B cells as CD19+ and monocytes as CD14+. B) 5α-reductase 1 
expression in CD4+ RO- and CD4+ RO+ T cells, CD8+ RO- and CD8+ RO+ T cells (blue dots 
for healthy controls and red dots for SLE patients), C) CD14+ monocytes, D) CD19+ B cells 
divided into patients with inactive (n=13) or active (n=25) disease. Mann-Whitney T test; ** 
p<0.001; *** p<0.0001 
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Figure 4.2 5α-reductase expression in T cells and monocytes from SLE patients with 
inactive and active disease, and age-gender matched controls. 
PBMCs from SLE patients and age and gender-matched healthy controls (n=16) were 
measured for intracellular 5α-reductase 1 expression using flow cytometry. T cells were gated 
on CD3+, CD4+or CD8+, and CD45 RO high or low cells (as illustrated in figure 4.1), A) 
CD4+ CD45 RO- B) CD4+ CD45 RO+ T cells, C) CD8+ CD45 RO-, D) CD8+ CD45 RO+ T 
cells, E) CD14+ monocytes. Blue dots represent the healthy controls; black dots represent 
SLE patients with inactive disease (n=14) and red dots for SLE patients with active disease 
(n=26).  Horizontal lines represent the median. MFI: median fluorescence intensity. 
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4.3   5α-reductase 1 expression in CD19+ B cell subsets from SLE patients and healthy 
controls. 
We then wanted to investigate which B cell subset population was responsible for this 
significant difference in 5α-reductase expression in SLE patients (figure 4.3B). We used two 
B cell subset classification panels; CD27/IgD and CD38/IgD (figure 4.3A). In the CD27/IgD 
classification  naïve B cells were classed as CD27-IgD+, unswitched memory being 
CD27+IgD+,  switched memory were represented as CD27+IgD- (intermediate) (have 
undergone somatic hypermutation), plasmablasts classed as CD27++IgD- (high), and finally 
double-negative memory B cells were described as  CD27-IgD-.The CD38/IgD panel uses the 
Bm1-Bm5 classification system (Sanz et al. 2008), in which naïve cells are classed as CD38- 
IgD+ (Bm1), pre-germinal cells (GC) and GC presented as CD38+IgD+ (Bm2), memory cells 
as CD38++IgD- (high) (Bm3 and Bm4), CD38+IgD- (early Bm5) and CD38-IgD- (late Bm5). 
We did not detect any significant differences in 5α-reductase expression between SLE 
patients and healthy controls any of the B cell subsets. However, we did find significant 
differences between the B cell subsets in both SLE patients and healthy controls (figure 
4.3B). However, after receiving the disease activity data for the patients we found that only 
two SLE patients out of 13 sampled had active disease. After reanalysing the data we did not 
detect any trends in the active and inactive patients and did not observe any differences 
between the healthy controls, inactive and active SLE patients (graphs not shown).  There 
was a significantly higher expression of 5α-reductase in CD27++IgD- B cells from SLE 
patients compared to; CD27+IgD- (intermediate) (p=0.03); CD27-IgD+ (p=0.01) and 
CD27+IgD+ (p=0.03) (figure 4.3D). There was also a significantly higher expression of 5α-
reductase in CD27++IgD- (high) B cells from healthy controls compared to CD27+IgD- 
(p=0.04); CD27-IgD+ (p=0.007) and CD27+IgD+ (p=0.007) (figure 4.3C). In SLE patients, 
there was a significantly higher expression of 5α-reductase in CD38++IgD- (high) B cells from 
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SLE patients compared to; CD38-IgD- (p=0.0003); CD38+IgD- (intermediate) (p=0.01); 
CD38-IgD+ (p=0.001) and CD27+IgD+ (p=0.003). In healthy controls, there was also a 
significantly higher expression of 5α-reductase in CD38++IgD- B cells from SLE patients 
compared to; CD38-IgD- (p=0.03); CD38+IgD- (p=0.03); CD27-IgD+ (p=0.007) and 
CD27+IgD+ (p=0.01). 
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Figure 4.3 5α-reductase expression in B cell subsets from SLE patients and age matched 
controls.  
PBMCs from SLE patients (n=13) and age and gender-matched healthy controls (n=10) were 
stained for intracellular 5α-reductase 1 expression using flow cytometry. A) FAC plots 
showing the gating strategy for B cell subsets using the markers CD27 vs. IgD and CD38 vs. 
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IgD. Using CD27 vs. IgD, cells were split into the following subsets; double-negative 
memory B cells (1); switched memory (2); plasmablasts (3); unswitched memory (4) and 
naive B cells (5). Using CD38 vs. IgD, cells were split into the following subsets; late 
memory B cells (1); early memory (2); memory B cells (3); pre-germinal and germinal cells 
(4), and naïve and memory B cells (5). B) Intracellular 5α-reductase 1 expression was 
measured in CD19+ B cell subsets using classified markers; CD27 vs. IgD and CD38 vs. IgD 
from SLE patients (blue dots) and healthy controls (red dots). C) 5α-reductase 1 expression in 
healthy controls B cell subsets; CD27 vs. IgD and CD38 vs. IgD and D) 5α-reductase 1 
expression in SLE patients B cell subsets; CD27 vs. IgD and CD38 vs. IgD. Horizontal lines 
represent the median. MFI: median fluorescence intensity. Mann-Whitney T test; * p<0.05; ** 
p<0.001; *** p<0.0001. 
 
 
4.4 5α-reductase expression in T cells upon stimulation from SLE patients and age 
matched controls. 
We wanted investigate if female T cells from SLE patients could also upregulate 5α-
reductase 1 expression after stimulation as demonstrated in healthy females in the previous 
chapter. Freshly isolated PBMCs from both SLE patients and healthy controls were 
stimulated with anti-CD3 and anti-CD28 activation beads for 24 hours (alongside 
unstimulated controls). After the 24 hour incubation period, cells were then measured for 5α-
reductase expression using flow cytometry. The results showed that both CD4+ (figure 
4.4B,C) and CD8+ T cells (figure 4.4D,E)  (naïve CD45 RO- and memory CD45 RO+) cells 
from SLE patients were able to upregulate 5α-reductase 1 expression after stimulation as seen 
in the healthy controls, and the majority of the SLE patients and healthy controls were 
female. Also, we did not observe any significant differences in 5α-reductase expression in 
unstimulated and stimulated T cell subsets between SLE patients with inactive and active 
disease for both CD4+ (figure 4.5A,B) and CD8+ T cells (figure 4.5C,D) 
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Figure 4.4  5α-reductase expression 1 in unstimulated and stimulated T cells from SLE 
patients and age matched controls.  
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PBMCs from SLE patients (n=26) and age and gender-matched healthy controls (n=16) were 
stimulated with anti-CD3 and anti-CD28 activation beads for 24 hours (alongside 
unstimulated controls). Cells were then measured for intracellular 5α-reductase 1 expression 
using flow cytometry. A) FACs plots showing unstimulated and stimulated T cells were gated 
on CD3+, CD4+or CD8+ cells, and CD45 RO high or low. Accumulative data for intracellular 
5α-reductase 1 expression in B) CD4+ CD45 RO- C) CD4+ CD45 RO+ T cells, D) CD8+ CD45 
RO-, and E) CD8+ CD45 RO+ T cells. Blue dots represent the healthy controls and red dots 
for SLE patients. Horizontal lines represent the median. MFI: median fluorescence intensity. 
Mann-Whitney T test; ** p<0.001; *** p<0.0001 
 
 
 
Figure 4.5  5α-reductase expression in unstimulated and stimulated T cells from SLE 
patients with inactive and active disease, and age-gender matched controls. 
PBMCs from SLE patients and age and gender-matched healthy controls (n=16) were 
stimulated with anti-CD3 and anti-CD28 activation beads for 24 hours (alongside 
unstimulated controls). Cells were then measured for intracellular 5α-reductase 1 expression 
using flow cytometry. T cells were gated on CD3+, CD4+or CD8+ cells, and CD45 RO high 
or low cells (as illustrated in figure 4.4), A) CD4+ CD45 RO- B) CD4+ CD45 RO+ T cells, C) 
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CD8+ CD45 RO-, D) CD8+ CD45 RO+ T cells. Blue dots represents healthy controls; black 
dots represent SLE patients with inactive disease (n=8) and red dots for SLE patients with 
active disease (n=19).  Horizontal lines represent the median. MFI: median fluorescence 
intensity. 
 
 
4.5  Discussion  
 
We wanted to investigate if there is a dysfunction in the upregulation of 5α-reductase 1 
expression after stimulation in SLE patients. If CD4+ T cells from SLE patients are not able to 
upregulate 5α-reductase 1 expression after stimulation, this could prevent the anti-
inflammatory effect of androgens on T cell stimulation and in turn limit the suppression of 
pro-inflammatory responses in autoreactive T cells. We also wanted to investigate the 
expression of 5α-reductase in CD8* T cells, CD19+ B cells and CD14* monocytes from SLE 
patients and compare expression levels to healthy controls. There were no significant 
differences in 5α-reductase expression the T cell subsets (figure 4.1B) or in CD14+ 
monocytes between healthy controls and SLE patients (figure 4.1C). Also, we did not see any 
significant differences between healthy controls and SLE patients with inactive or active 
disease for both T cells (figure 4.2A, B, C, D) and CD14* cells (figure 4.2E)   However, the 
results did show that 5α-reductase expression was significantly higher in the memory CD4+ 
CD45 RO+ T subset in comparison to the naïve CD4+ CD45 RO- T cell subset. This 
observation was made in both healthy controls and SLE patients. This is interesting as it 
suggests that CD4+ T cells that have encountered antigen, and therefore respond more rapidly 
to antigens, are potentially upregulating their  production of DHT. This could a mechanism 
used by memory T cells to suppress pro-inflammatory immune responses, in particular the 
production Th2 cytokines such as IL-4 and IL-5; as DHT has shown to inhibit the production 
of these cytokines, which are important in mediating subsequent humoral responses. We then 
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investigated the effect of stimulation on 5α-reductase expression in T cells, and found that 
both CD4+ and CD8+ (naïve CD45 RO- and memory CD45 RO+) cells from SLE patients 
were able to upregulate 5α- reductase expression after stimulation as seen in healthy controls. 
This shows that T cells from SLE patients are not defected in increasing their exposure to 
immunosuppressive androgens.  
However, in CD19+ B cells we found a significant increase in 5α-expression in SLE CD19+ B 
cells compared to the healthy controls and this positively correlated with disease activity 
(figure 4.1D), as SLE CD19+ B cells from patients with active disease had significantly 
higher expression of 5α-reductase in CD19+ B cells compared to healthy controls. SLE is 
considered to be a B cell driven disease as the production of autoantibodies to components of 
the nuclei including dsDNA are key to the loss of tolerance and pathogenesis of the disease 
(Kanda et al. 1997). The upregulation of 5α-reductase and the subsequent increase in 
intracellular androgen production could be an intracellular mechanism used by B cells in SLE 
to suppress their immune responses, as androgens have been shown to suppress antibody 
production by B cells. SLE patients have significantly lower levels of androgens in serum 
compared to healthy females, in which the levels of circulating androgen are already low due 
to being of the female sex. It is however not clear if females with low levels of androgens are 
predisposed to developing SLE as early diagnosed SLE patients are rapidly treated with 
corticosteroids, which reduces the levels of serum androgens. Therefore, B cells in SLE 
patients could be compensating for the reduced exposure to androgens in the serum and 
synthesising endogenous androgens, which can then directly act on androgen receptors within 
the cell cytosol causing translocation of the androgen receptor into the nuclei, where it can 
target genes involved in mediating inflammatory responses. This upregulation of 5α-
reductase expression in B cells could be a mechanism to counteract the pro-inflammatory 
effects of oestrogens, which have shown to promote humoral responses in both B cells 
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healthy females and in models of autoimmune diseases (Erlandsson et al. 2003; Feng et al. ; 
Grimaldi et al. 2001). The production of DHT, which is more potent then testosterone would 
result in direct interaction with the androgen receptor and promote anti-inflammatory 
responses, whereas testosterone can be converted into oestrogen via the enzyme aromatase 
and therefore promote an enhanced inflammatory response. This observation could also give 
us some insight into the regulation of 5α-reductase, as this suggests that low levels of 
androgens present in SLE patients results in a higher 5α-reductase expression, whereas in 
PCOS patients (who have abnormally high levels of androgens) previous data from our group 
found that PBMC expression of 5α-reductase was reduced (unpublished).  A previous study 
has also shown that DHT negatively regulates 5α-reductase activity, thus supporting this 
hypothesis (Samy et al. 2001). We wanted to then investigate the B cell subset that was 
responsible for the upregulation of 5α-reductase expression in SLE B cells from patients with 
active disease, but unfortunately we did not detect any significant differences in 5α-reductase 
expression between SLE patients and healthy controls in any of the B cell subsets (figure 
4.3B). However, after receiving the disease activity data we found that only two SLE patients 
out of 13 sampled had active disease. We did not detect any trends in the active and inactive 
patients and did not find any differences between the healthy controls, inactive and active 
SLE patients.  It was the SLE patients with active disease that upregulated 5α-reductase 
expression, therefore it would be essential to repeat these experiments for the B cell subsets 
with more SLE patients with active disease, and we then might see a difference in 5α-
reductase expression in B cell subsets between SLE patients with active and control. 
 
However, we did find significant differences between the B cell subsets in both SLE patients 
and healthy controls (figure 4.3C, D). There was a significantly higher expression of 5α-
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reductase in CD27++IgD- and CD38++IgD- B cells in comparison to the other B cell subsets 
investigated from both SLE patients and healthy controls. This is particularly interesting as 
has been previously mentioned that androgens are able to decrease the production of 
antibodies and also prevent the generation of autoantibodies against dsDNA. This population 
of CD27++IgD- B cells known as plasmablast cells, which are a subset of short lived IgM 
secreting plasma cells, have shown to be present in increased numbers in SLE patients 
(Dorner et al. 2011). This high expression of 5α-reductase in this B cell subset could be 
mechanism to prevent excessive antibody production and suppress potential production of 
autoantibodies. Androgens have been shown to modulate early B cell development in a 
suppressive manner (Altuwaijri 2009; Viselli et al. 1997); in the bone marrow, androgens are 
able to suppress B lymphopoiesis through AR signalling in bone marrow stromal cells, thus 
resulting in TGF-β production (Olsen et al. 2001). Androgens have also shown to have a key 
role in maintaining B cell tolerance, as mice with global AR deficiency and specifically 
absent AR signalling in B cells have resulted in the presences of anti dsDNA autoantibodies 
(Altuwaijri 2009). Therefore, it would be interesting to investigate the role of testosterone 
and more importantly endogenous production of DHT on antibody production by 
CD27++IgD- and CD38++IgD- B cells by using 5α-reductase inhibitors such as dutasteride and 
finasteride. 
 
It is extremely difficult to investigate the direct effects of sex hormones on SLE disease 
pathogenesis as predominately all the patients with active disease are on glucocorticoid 
treatment, which influences the levels of sex hormones in the treatment. Therefore, this 
observation of 5α-reductase expression in B cells could be influenced by the glucocorticoid 
treatment the SLE patients were undergoing. We wanted to measure the levels of serum 
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androgens in these patients, however glucocorticoid treatment has a drastic effect on serum 
androgen levels. It would also be important to take into account the availability of sex 
hormones in the serum by investigating levels of SHPB, which are responsible for 
transporting sex hormones in the periphery, as high levels of SHPB in SLE patients would 
decrease to bioavailability of androgens to immune cells. A previous study showed that a 
particular genetic polymorphism of  SHPB is associated with SLE and that it has a stronger 
affinity for androgens then oestrogens, therefore reducing the bioavailability to peripheral 
cells in an already low androgen reserve environment (Piotrowski et al. 2010). 
Overall, we found a significant increase in 5α-reductase expression in SLE CD19+ B cells 
compared to the healthy controls and this positively correlated with disease activity, as SLE 
CD19+ B cells from patients with active disease had significantly higher expression of 5α-
reductase in CD19+ B cells compared to healthy controls. We also showed there was a 
significantly higher expression of 5α-reductase in CD27++IgD- and CD38++IgD- B cells in 
comparison to the other B cell subsets from both SLE patients and healthy controls. 
Therefore, it would be important to follow up these experiments with functional assays 
investigating the effect of inhibiting 5α-reductase activity, thus preventing the production of 
endogenous DHT within B cells, on B cell responses.  
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5        THE EFFECTS OF ANDROGENS ON T CELL RESPONSES 
 
5.1   Introduction 
 
In the human system, the influence of androgens on inflammatory responses both in 
homeostatic and disease states is not very well understood. The higher incidence of 
autoimmune conditions in females may not just be due to the immune enhancing properties of 
oestrogens, but may also be attributable to the low physiological androgen levels in females. 
In addition, the even lower androgens levels found in individuals suffering from autoimmune 
diseases may contribute to immune imbalance. Treatment with glucocorticoids is an 
additional confounding factor as these reduce systemic androgen levels (MacAdams et al. 
1986). 
 
In the context of the humoral response, androgens such as testosterone have been shown to 
inhibit IgM and IgG production. On the other hand, enhanced DC proliferation and antigen 
stimulation has been shown in males with hypogonadism, suggesting that testosterone is 
important in regulating immune responses in a suppressive manner (Corrales et al. 2012). In 
mice, testosterone has been shown to directly act on CD4+ T cell to increase the production of 
IL-10 (Liva and Voskuhl 2001). Also, DHT has been previously shown to suppress Th2 
derived cytokines IL-4 and IL-5 but had no effect on IL-2 (Araneo et al. 1991).  Gender 
dimorphism is not only evident in autoimmunity but also in trauma cases, as injured men 
experience much more severe immunosuppression compared to females, leading to a slower 
recovery rate and higher trauma related death rates. Murine models investigating the role of 
sex hormones in trauma-haemorrhage found that oestrogens helped maintain immune 
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responses; in contrast androgens were shown to suppress Th1 cytokine production while 
castration or supplementation with 17β-estradiol in male mice elevated immune responses 
(Angele et al. 2001; Samy et al. 2001). It was also shown that 5α-reductase activity was 
increased post-trauma resulting in an increased production of DHT, thus further suppressing 
immune responses.   
 
However, most of the studies investigating the effects of androgens were carried out in 
animal models and not in humans, and usually involve in vivo treatment of androgens in 
animal models or castration, therefore not fully representing physiological concentrations of 
androgens circulating normally present in humans. As we had previously demonstrated that 
5α-reductase expression is upregulated in T cell subsets upon stimulation in both healthy 
individuals and SLE patients, we wanted to then investigate the effects of androgens on 
human T cell cytokine production and proliferation to understand what effects increased 
androgen levels would have on T cell responses. We wanted use physiological concentrations 
of androgens found in circulation to get a better understanding on the influence of androgens 
on T cell responses. In circulation, sex hormones (particularly the most potent sex hormones 
such as 17β-oestradiol and DHT) are bound to SHPB with a strong affinity or bound to 
albumin to a lesser extent, thus very low levels of active free (unbound) sex hormones are 
detected in the circulation. Therefore, we took this into account when deciding on androgen 
concentrations to use in our in vitro assays.  
 
A range of concentrations were chosen that reflected both the average concentrations of free 
and total (bound and unbound) androgens present in circulation; for testosterone the highest 
concentration we used was 15nM and for DHT the highest concentration used was 2nM, as 
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this reflects the average total concentration of testosterone and DHT found in circulation in 
healthy males. 7nM of testosterone and 0.5nM of DHT was used to reflect the levels found in 
serum from polycystic ovary syndrome (PCOS) patients, in which females have significantly 
higher androgen levels compared to healthy females. 1nM testosterone and 0.1nM of DHT 
were also used to replicate the average levels of these androgens found in healthy females. 
Finally, 0.1nM of testosterone and 0.01nM of DHT was used to reflect the low concentrations 
of androgens found in the serum of SLE patients.  
 
5.2 Cytokine production by T cells in males and females.  
We found that the percentage of CD4+ T cells producing IL-2 and IFN-γ were significantly 
higher in females compared to males (n=6) (figure 5.1B,C), however this was not reflected in 
the CD8+ T cells (figure 5.2A,B). There were no significant differences in the amount of IL-
10, IL-17 and TNF-α produced by either CD4+  or CD8+ T cells  between the sexes, however 
this could be due to the low number of replicates for these cytokines (n=3).  
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Figure 5.1 Cytokine production by CD4+ T cells from males and females.  
PBMCs from females and males (n=6)  were stimulated with anti CD3 and anti CD28 
activation beads and cultured for 4 hours in the presence of  Brefeldin A to measure 
intracellular production of cytokines. A) The FACs plots for % CD4+ T cells producing IL-2 
and IFN-γ for one male and female donor. The graphs summarise data from all six 
experiments B) IL-2, C) IFN-γ, D) IL-17, E) IL-10, and F) TNF-α from CD4+ T cells (n=3)  
using flow cytometry. Error bars represent SEM. Mann-Whitney T test; * p<0.05. 
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Figure 5.2 Cytokine production by CD8+ T cells from males and females.  
PBMCs from females (n=6) and males (n=6)  were stimulated with anti CD3 and anti CD28 
activation beads and cultured for 4 hours in the presence of  Brefeldin A to assess the 
proportion of CD8+ T cells producing cytokines  A) IL-2, B) IFN-γ. (n=3):  C) IL-17, D) IL-
10, and E) TNF-α using flow cytometry. Error bars represent SEM.  
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5.3  T cell cytokine production after testosterone and DHT treatment.  
We observed a significant increase in the proportion of IL-2 producing cells in CD4+ T cells 
from females treated with 1nM testosterone (levels found in healthy women)compared to the 
untreated control (figure 5.3A). There was also a significant decrease in IL-2 production 
when CD4+ T cells from females were treated with 15nM of testosterone (levels found in 
healthy men) compared to the 1nM testosterone treatment. In male CD4+ T cells (figure 
5.3B), there was no significant increase in IL-2 levels between the untreated control and 1nM 
testosterone, however an significant decrease in IL-2 levels was observed between cells 
treated with 1nM testosterone and 15nM testosterone. There was a similar trend in CD4+ T 
cells producing IFN-γ (figure 5.4A) and CD8+ T cells producing IL-2 after testosterone 
treatment, however the differences observed were not significant. We found no significant 
differences on IL-2 production in both males and females when cells were treated with a 
range of physiological concentrations of DHT. There were no significant differences in the 
production of IL-10, IL-17 or TNF-α by CD4+ and CD8+ T cells from both males and females 
upon treatment with testosterone or DHT (see appendix).  
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Figure 5.3  IL-2 production by T cells after testosterone and DHT treatment.  
PBMCs were stimulated with anti CD3 and anti CD28 activation beads and cultured for 4 
hours with different concentrations of testosterone (black bars) and DHT (checkered bars) in 
the presence of  Brefeldin A to measure the proportion of IL-2 producing T cells from A) 
females (n=6) and B) males (n=6) using flow cytometry. Mann-Whitney T test; * p<0.05. 
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Figure 5.4   IFN-γ production by T cells after testosterone and DHT treatment. 
PBMCs were stimulated with anti CD3 and anti CD28 activation beads and cultured for 4 
hours with different concentrations of testosterone (black bars) and DHT (checkered bars) in 
the presence of  Brefeldin A to measure the proportion of  IFN-γ producing T cells from A) 
females (n=6) and B) males (n=6) using flow cytometry. Error bars represent SEM. 
 
 
5.4  IL-2 production after treatment with 17β-oestradiol and 4-hydroxytamoxifen 
We wanted to investigate if the increase in the proportion of IL-2-producing female CD4+ T 
cells at the low concentrations of testosterone (0.1nM and 1nM) was actually due to 17β-
oestradiol activating oestrogen receptors, as testosterone can be converted into 17β-oestradiol 
A 
  B 
    CD4+ T cells     CD8+ T cells 
 
  
 
 y
Control 0.1 1 7 15
0
2
4
6
Testosterone concn (nM)
%
 c
ell
s
 
  
 
 IFN-y
Control 0.01 0.1 0.5 2
0
2
4
6
DHT concn (nM)
%
 c
ell
s
  
 
 y
Control 0.1 1 7 15
0
2
4
6
8
Testosterone concn (nM)
%
 c
ell
s
  
 
IFN-y
Control 0.01 0.1 0.5 2
0
2
4
6
8
DHT concn (nM)
%
 c
ell
s
  
 
  
 
 y
Control 0.1 1 7 15
0
5
10
15
20
Testosterone concn (nM)
%
 c
el
ls
 
  
 
 
Control 0.1 1 7 15
0
5
10
15
Testosterone concn (nM)
%
 c
el
ls
 
  
 
 IFN-y
Control 0.01 0.1 0.5 2
0
5
10
15
20
DHT concn (nM)
%
 c
el
ls
  
 
 IFN-y
Control 0.01 0.1 0.5 2
0
5
10
15
20
DHT concn (nM)
%
 c
el
ls
 
 
124 
 
by aromatase. Firstly, we investigated the effect of 17β-oestradiol treatment on the proportion 
of IL-2-producing CD4+ T cells from females. A range of concentrations were chosen that 
reflected average concentrations of 17β-oestradiol present in circulation; the highest 
concentration we used was 0.95nM as this reflects the average total concentration of 17β-
oestradiol found in healthy females during the preovulatory phase of the menstrual cycle. 
0.29nM of 17β-oestradiol was used to reflect the levels found during the luteal phase of the 
menstrual and 0.13nM of 17β-oestradiol was used to reflect the concentration found during 
the follicular phase of the menstrual cycle. Finally, 0.07nM of 17β-oestradiol was used to 
reflect the serum concentrations found in men and post-menopausal women. We found a dose 
dependent increase in the percentage of CD4+ T cells producing IL-2 (figure 5.5A), which 
was close to reaching statistical significance (p=0.055). We also observed this trend in IFN-γ; 
however this observation was not significant. 
 
We used an oestrogen receptor inhibitor called 4-hydroxytamoxifen, which is the active 
metabolite of tamoxifen to investigate whether 17β-oestradiol was affecting the proportion of 
IL-2-producing CD4+ T cells (figure 5.5C). Treatment of female CD4+ T cells with 4-
hydroxytamoxifen with different concentrations of testosterone abolished the increase in the 
proportion of IL-2 producing cells previously observed when treated with the lower 
concentrations of testosterone. We also wanted to investigate what immune cell type in the 
PBMC population expressed aromatase, which converts testosterone into 17β-estradiol, as the 
literature suggests that T cells express very low levels of aromatase (Zhou and Speiser 1999). 
qPCR experiments were carried out for aromatase expression on the mRNA level (gene name 
CYP19A1) and showed that macrophages had the highest expression of aromatase and this 
observation was statistically significant in comparison to CD4+ T cells (p=0.02), but not 
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compared monocytes (figure 5.5D). Both CD4+ T cells and monocytes had very low levels of 
expression with a signal detectable after cycle 40. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5  IL-2 production by female CD4+ T cells after 17β-estradiol treatment and 4-
hydroxytamoxifen.  
PBMCs from female donors (n=4) were stimulated with anti CD3 and anti CD28 activation 
beads and cultured for 4 hours with different concentrations of A) 17β-estradiol to assess 
subsequent percentage cells producing IL-2 and IFN-γ using flow cytometry B) different 
concentrations of testosterone with additional treatments with C) 2nM 4-hydroxytamoxifen to 
assess the percentage cells producing of IL-2 by CD4+ T cells using flow cytometry. D) Gene 
expression for aromatase (CYP19A1) was measured as relative quantification to 18s in CD4+ 
T cells, monocytes and in vitro differentiated macrophages cultured for 6 days in the presence 
of GM-CSF (courtesy of Nichola Adlard) (n=3) by qPCR. Error bars represent SEM. NS (not 
significant). Mann-Whitney T test; * p<0.05. 
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5.5  CD4+ T cell proliferation after testosterone treatment.  
After observing the significant effects of testosterone on IL-2 production by female CD4+ T 
cells we then investigated the effect of testosterone treatment on female CD4+ T cells 
proliferation (figure 5.6), as IL-2 is an important growth factor for T cell proliferation. 
However, we did not detect any significant differences in the number of cell divisions after 
treatment with different concentrations of testosterone.  
 
 
 
 
 
 
 
 
 
Figure 5.6  Female CD4+ T cell proliferation after testosterone treatment. 
PBMCs from female donors (n=4) were labelled with CFSE and stimulated with anti CD3 
and anti CD28 activation beads and cultured for 4 days with different concentrations of 
testosterone.  At day 4 PBMCs were stained for CD4+ cells and CFSE fluorescence intensity 
was measured using flow cytometry. A) FACs plots for CFSE profiles, in which each bar 
presents a round of division. B) Number of divisions was calculated by multiplying the 
number of cells in each peak by the number of rounds of divisions. Error bars represents 
SEM. 
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5.6  Discussion  
 
We demonstrated in the previous chapters that 5α-reductase expression is upregulated in 
female T cell subsets upon stimulation in both healthy individuals and SLE patients, thus 
potentially increasing their production of DHT. We therefore wanted to investigate what the 
effects of increased androgen production would have on human T cell cytokine production 
and proliferation. We wanted use physiological concentrations of androgens found in 
circulation to get a better understanding on the influence of androgens on T cell responses. A 
series of concentrations were chosen that reflected physiological concentrations of androgens 
present in circulation in healthy males and females, but also lower and higher concentrations 
found in disease. Many of the previous studies investigating the effects of androgens on 
immune response used animal models, which predominately involved the castration and then 
supplementation of androgen or the treatment with 5α-reductase inhibitors such as finasteride 
(an 5α-reductase 2 inhibitor) (Fijak et al. 2011; Gilliver et al. 2006). We wanted to 
investigate the potential consequence of upregulating 5α-reductase 1 in female T cells after 
stimulation on T cell responses. Therefore, we initially investigated the effect of dutasteride 
(a 5α-reductase 1 inhibitor), which is commonly used for the treatment of benign prostatic 
hyperplasia and prostate cancer, on the proportion of IL-2 and IFN-γ-producing CD4+ T cells 
(see appendix). However, we only observed a decrease in the proportion of CD4+ T cells 
producing these cytokines at a concentration of 10μM dutasteride, which is much higher than 
concentrations reached therapeutically (Schröder et al. 2013). To my knowledge, there has 
not been any studies investigating differences in immune function in patients being treated 
with 5α-reductase inhibitors, however finasteride treatment before induction of trauma-
haemorrhage and sepsis in mice has been shown to inhibit the immunosuppressive effect of 
DHT (Zeckey et al. 2011). Therefore, we then investigated the effect of testosterone and 
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DHT on cytokine production by T cells, as previous in vitro studies have often non-
physiological concentrations (often considerably higher concentrations) of androgens (Zhang 
et al. 2012). We found significant differences between males and females in the percentage of 
cells producing certain cytokines; there were significantly higher percentage of CD4+ T cells 
producing IL-2 and IFN-y from females in comparison to the male CD4+ T cells. This 
observation is in agreement with the published literature (Araneo et al. 1991; Zhang et al. 
2012) and confirms that female CD4+ T cells produce higher levels of these Th1 derived 
cytokines in comparison to males in response to stimulation. We did not investigate the 
differences in Th2 derived cytokines such as IL-4 and IL-5 between the sexes, but previous 
studies in humans have found that women produce higher levels Th2 cytokines compared to 
men, which is consistent with the findings that women have higher antibody titers (Giron-
Gonzalez et al. 2000). However, there is some conflicting data generated from mice as a 
study found that male CD4+ T cells produced higher levels of IL-10 compared to females 
(Liva and Voskuhl 2001). We did carry out some preliminary experiments on the production 
of IL-10 by T cells and found a slightly higher level of IL-10 produced by female CD4+ T 
cells and CD8+ T cells compared to the males, which would support the higher Th2 responses 
in females as IL-10 is a potent stimulator of B cell proliferation and differentiation (Cai et al. 
2012). Therefore, higher IL-10 production in females could make them more susceptible to 
increased  autoreactive B cells responses, as elevated IL-10 levels detected in SLE patient 
serum positively correlates with serological disease activity and anti-DNA antibodies 
(Csiszar et al. 2000). However, we would need to carry out more IL-10 experiments to 
investigate if this observation holds up.  Also, we obtained very low proportions of CD4+ T 
cell producing IL-10, which is most likely due to the short 24 hours stimulation assays, as 72 
hour assays are usually required to detect higher levels of IL-10. Also, it may be important to 
investigate the Treg lacking FoxP3 population as they are the main producers of IL-10 within 
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the CD4+ T cell population (Feuerer et al. 2009). We also investigated the levels of pro-
inflammatory cytokines IL-17 and TNF-α and found a trend towards a higher production of 
these cytokines by male CD4+ T cells, however this was not statistically significant, possibly 
due to the low number of repeats as previously mentioned. However, if this trend is 
confirmed then this would be in line with the literature as human whole blood stimulated with 
LPS results in higher TNF-α in males compared to females (Aulock et al. 2006). The role of 
IL-17 has been clearly demonstrated in the pathogenesis of T cell driven autoimmune 
diseases (Nakae et al. 2003; van den Berg and Miossec 2009), therefore it would be expected 
that IL-17 production is higher in females then in males, as females are more susceptible to 
developing these autoimmune conditions.    
 
We then wanted investigate the effects of testosterone and DHT on production of these 
cytokines, particularly DHT as we had previously found that female T cells were 
upregulating 5α-reductase 1 expression after stimulation, therefore we wanted to investigate 
what effects this increase in DHT levels would have on T cell cytokine responses. For IL-2, 
we observed an interesting pattern creating a bell-shaped curve, in which low concentrations 
of testosterone (0.1nM to 1nM) significantly increased the percentage of IL-2 producing 
female CD4+ T cells compared to the untreated control and in contrast the higher testosterone 
concentrations (7nM and 15nM) in particular 15nM significantly decreased the IL-2 levels in 
comparison to the CD4+ T cells treated with 1nM testosterone. This pattern was also 
observed in female CD8+ T cells; however the differences observed were not statistically 
significant. Also, a similar trend was seen in female CD4+ T cells producing IFN-γ; however 
none of the differences were statistically significant. In male CD4+ T cells, an increase in IL-
2 levels between the control and 1nM testosterone was not observed, however a significant 
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decrease in IL-2 levels in cells treated with 7nM and particularly 15nM testosterone as seen 
in female CD4+ T cells was also observed in male CD4+ T cells. Therefore, we observed what 
appears to be a dual effect of hormones on IL-2-producing CD4+ T cells; firstly a long term 
effect on the T cells that leads to a different behaviour of T cells depending on whether they 
have been generated in a “female” or “male” hormone environment and secondly a short term 
effect of hormones present at the time of stimulation. The long term effects are most likely to 
be involving hormone-dependent epigenetic modifications as hormones have been shown to 
influence sex hormone receptor expression through epigenetic modifications (Imamura 
2011), while the short term effects are more likely to be mediated through the oestrogen or 
androgen receptors respectively. This effect of testosterone on proportion of IL-2-producing 
CD4+ T cells suggests that low testosterone levels found in healthy females and SLE patients 
could be responsible for more robust immune responses seen in females in both health and 
disease. In contrast, high testosterone concentrations seen in healthy males and PCOS 
patients seem to be able to suppress the proportion of IL-2-producing CD4+ T cells, thus 
potentially reducing subsequent CD4+ T cell proliferation and differentiation. High levels of 
testosterone could also be protecting males from generating proinflammatory responses, and 
possibly prevent the development of chronic inflammation and autoimmunity. There is 
evidence to suggest testosterone is able to dampen immune responses in models of 
autoimmunity and trauma-haemorrhage, the latter resulting in a severe decrease in the rate of 
wound healing and increase mortality in males (Gilliver et al. 2006). The actions of 
androgens are mediated through the classical androgen receptor signalling pathway, in which 
androgen receptor translocation after subsequent activation leads to the transcription of target 
genes with androgen response elements in their promoter regions. DHT is the most potent 
androgen in the body as it has an affinity for the androgen receptor in comparison to 
testosterone. Therefore, we also investigated the effect of DHT on cytokine production, 
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however there were no significant differences in the treatment of DHT on CD4+ and CD8+ T 
cell cytokine production from both males and females, in contrast to the findings in the 
testosterone treatment on IL-2 production. As these differential effects of low and high 
testosterone concentrations on IL-2 production were not observed upon DHT treatment, 
which directly activates the androgen receptor, it questioned if a direct effect of testosterone 
on the androgen receptor could be responsible for the increase in IL-2 production at these 
lower concentrations. However, testosterone can be converted into 17β-oestradiol by 
aromatase, therefore is conceivable that the increased proportion of IL-2-producing CD4+ T 
cells treated with the low but physiological concentrations of testosterone may be explained 
by conversion of testosterone to 17β-oestradiol. This would also be in agreement with the 
lack of effect of DHT, which cannot be converted to 17β-oestradiol. Therefore to investigate 
this further so we used an oestrogen receptor inhibitor, 4-hydroxytamoxifen (the active 
metabolite of tamoxifen) to investigate if 17β-oestradiol was responsible for the increase in 
IL-2 production in female CD4+ T cells. Treatment of female CD4+ T cells with 4-
hydroxytamoxifen in conjunction with different concentrations of testosterone abolished the 
increase in proportion of IL-2-producing CD4+ T cells previously observed with the lower 
concentrations of testosterone. This suggests that it was 17β-oestradiol and its activation of 
oestrogen receptors, which was responsible for this increase in proportion of IL-2-producing 
CD4+ T cells at the lower testosterone concentrations. However, T cells have been shown to 
have very low expression of aromatase suggesting that T cells are not able to produce 
endogenous oestrogens, but can respond to oestrogens as they express both isoforms of 
oestrogen receptor.  However, 4-hydroxytamoxifen treatment had no effect on the decrease of 
IL-2 production observed when CD4+ T cells were treated with high concentrations of 
testosterone (7nM and 15nM), thus suggesting this observation was not mediated by 
oestrogens and could be testosterone activating the androgen receptor. 
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 In experiments testing whether oestrogens have an effect in our cell culture system, we found 
that the percentage of female CD4+ T cell producing IL-2 and IFN-y showed a concentration 
dependent increase under influence of 17β-estradiol.  If the low testosterone effect was 
mediated by 17β-oestradiol, it remained to be tested whether the testosterone was converted 
in the T cells or in other cells in the PBMC cultures, as T cells have been reported to have 
very low aromatase activity. Previous publications by Straub and colleagues  have suggested 
that monocytes and macrophages are able to convert testosterone to 17β-oestradiol  (Schmidt 
et al. 2000). To answer this question we used qPCR to investigate aromatase gene expression 
(CYP19A1) in CD4+ T cells, monocytes and in vitro differentiated macrophages. The results 
showed that both CD4+ T cells and monocytes had very low levels of mRNA expression for 
aromatase; in contrast macrophages had significantly higher gene expression for aromatase 
compared to CD4+ T cells. This is an interesting observation, but it does not explain why at 
higher levels of testosterone the effect is reversed.  It has been previously shown that at high 
concentrations testosterone is able to activate androgen receptor with high affinity in a similar 
manner to DHT (Grino et al. 1990). Also, there is evidence to suggest that high 
concentrations of testosterone can inhibit aromatase activity; human synoviocytes isolated 
from RA patients that were treated with 250nM testosterone showed a significant decrease in 
testosterone conversion to oestrone and 17β-oestradiol due to decreased aromatase activity 
(Schmidt et al. 2005). Also, the treatment of healthy men with exogenous testosterone, which 
results in an increase in serum testosterone levels from 22nM to 35nM, showed a significant 
reduction in aromatase activity after testosterone treatment (Vottero et al. 2006). As our 
findings were only observed in female CD4+ T cells, possible explanation may be differences 
in the aromatase activity in male and female individuals, however this is not reported in the 
literature.  However, we did detect a higher aromatase expression in in vitro differentiated 
monocytes to macrophages compared to undifferentiated monocytes, which suggests that 
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differentiation of monocytes into macrophages results in an increased exposure of 
endogenous oestrogens.  Oestrogen has shown to increase MHCII expression through the 
upregulation of IL-1 production in mice (Ruh et al. 1998). Therefore, it would be interesting 
to investigate when this upregulation of aromatase occurs in macrophage differentiation 
through time course analysis, and effect of aromatase inhibitors on macrophage responses. 
 
IL-2 is an important cytokine and growth factor needed for T cell survival, proliferation and 
differentiation. The initial encounter of antigen by naïve T cells induces activation through 
TCR and co-stimulation signalling pathways, resulting in the rapid production of IL-2. IL-2 
produced by the T cells in turn acts on the T cell itself in an intracine manner by interacting 
with the IL-2 receptor (IL-2R) on the surface of the T cells, thus driving subsequent 
proliferation and differentiation. To further  investigate if the increase in IL-2  production 
was down to testosterone conversion into 17β-oestradiol, we treated female CD4+ T cells 
with physiological concentrations of 17β-oestradiol detected at various stages of the 
menstrual cycle in order to get both low and high physiological levels present. We found that 
there was a dose dependent in increase in IL-2 and IFN-γ production, which positively 
correlated with increasing concentrations of 17β-oestradiol. In contrast to our initial findings, 
previous studies have shown oestrogen is able to decrease IL-2 production and IL-2 mRNA 
expression in a dose dependent manner (McMurray et al. 2001). There are several mediators 
involved in the transcription and therefore the synthesis of IL-2, the most important being the 
transcription factors; AP-1, NFAT and NF-κB, which bind to specific regions within the IL-2 
gene promoter. Oestrogen receptors upon ligand activation have shown to not only target 
oestrogen response elements in promoter regions of specific genes but also target non-ERE 
regions such as AP1 enhancer elements specific for AP1 transcription factors thus suggesting 
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the influence of oestrogens on IL-2 transcription (Paech et al. 1997). The exact mechanisms 
of which oestrogen is able to mediate these effects is not very well understood, however 
McMurray and colleagues also showed that oestrogen activated oestrogen receptors are able 
to prevent the binding of transcription factors AP1 and NFκB to the promoter regions of the 
IL-2 gene by in part increasing the levels of IκBα, an cytoplasmic inhibitor of NFκB which 
prevents its translocation into the nucleus (McMurray et al. 2001).  IL-2 transcription is also  
modulated by two transcription factors with contrasting roles that bind the same region of the 
IL-2R promoter (cyclic AMP response element (CRE); cyclic cAMP response element 
binding (CREB) in its phosphorylated form activates IL-2 transcription and in contrast cyclic 
AMP response element modulator (CREMα) once phosphorylated suppresses IL-2 
transcription. An imbalance of these two conflicting transcription factors have been 
demonstrated in SLE T cells, in which CREMα transcriptional activity is elevated and levels 
of phosphorylated CREB are reduced, thus an increased suppression of IL-2 production is 
observed (Juang 2005; Solomou et al. 2001). Moulton and colleagues found that oestrogen 
was able to increase CREMα mRNA expression and activity in T cells (Moulton et al. 2012).  
However, in both of these studies extremely high and non-physiological concentrations of 17-
β-oestradiol were used, ranging from 100nM to 10μM and both studies found a significant 
effect of 17-β-oestradiol at 10μM, which is significantly higher than the maximum 
physiological concentration range of 1nM-2nM found in women. Therefore, these inhibitory 
effects of oestrogen in these studies will need to be verified using physiological 
concentrations. It could be that at lower concentrations of oestrogens that the reverse is 
observed and that decreases IκBα levels and therefore elevating IL-2 transcription, which 
would support our observations of 17β-oestradiol treatment on proportion of IL-2-producing 
CD4+ T cells. Also, there is evidence to suggest that CREMα is able to mediate silencing of 
the IL-2 gene through epigenetic modifications; histone deacetylation and cytosine phosphate 
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guanosine (CpP)-DNA hypermethylation (Hedrich et al, 2011). Therefore, if oestrogen is are 
able to decrease CREMα activity at physiological concentrations then it would be interesting 
to see if oestrogen could indirectly abrogate IL-2 gene silencing through epigenetic 
modifications.  
 
To confirm our findings, an important experiment that needs to be done in future is to 
establish the levels of 17β-oestradiol in our culture system. Prof Arlt’s laboratory is currently 
establishing the necessary techniques. It would also be necessary to confirm these findings by 
measuring the concentration of IL-2 produced by CD4+ T cells after testosterone treatment. 
Tamoxifen, through its metabolite 4-hydroxytamoxifen, is a well established as a competitive 
antagonist binding to the oestrogen receptor. It is frequently prescribed to women with 
oestrogen sensitive breast cancer. The action of tamoxifen on oestrogen receptors has been 
previously questioned, therefore, it will be important to repeat the experiments with novel 
inhibitors which target aromatase directly such as anastrozole or exemestane.  
 
After observing the significant effects of testosterone on the proportion of  female CD4+ T 
cells we then investigated the effect of testosterone treatment on female CD4+ T cells 
proliferation (figure 5.5), as IL-2 is an important growth factor for T cell proliferation and the 
effect of androgens in humans is unclear. However, we did not detect any significant 
differences in the number of cell divisions after treatment with different concentrations of 
testosterone. In mice, castration has shown to increase the number of T cells in peripheral 
lymphoid tissues and in the thymus, which resulted in a significant increase in thymus mass 
as a result of castration, thus suggesting that androgens exert a suppressive affect on T cell 
proliferation. A possible explanation for our data is that there were vast amount of 
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heterogeneity between the proliferation assays as T cells from some donors had much higher 
number of cell divisions compared to others. Therefore it would be important to repeat these 
proliferation experiments with a higher number of donors. Also, it would be interesting to 
investigate T cell differentiation as IL-2 has a vital role in Th1 differentiation. 
 
In summary, we found that the percentages of IL-2 and IFN-γ producing CD4+ T cells from 
females were significantly higher compared to their male counterparts, which confirms 
previous findings in the current literature. The most interesting finding was the dual effect of 
testosterone treatment on proportion of IL-2 CD4+ T cells from females only, in which at low 
concentrations of testosterone the proportion of IL-2 producing CD4+T cells, which was not 
observed after DHT treatment. This was later confirmed to be oestrogen mediated (through 
potential conversion of testosterone into 17β-oestradiol by aromatase present in 
macrophages), as treatment with tamoxifen abrogated this increase in proportion of IL-2 
CD4+ T cells after treatment with low concentrations of testosterone suggesting that 
testosterone is being converted into but did not prevent the decrease the proportion of IL-2 
producing CD4+ T cells when cells were treated with high concentrations of testosterone, 
which suggests these are oestrogen independent affects. It would be important to confirm 
these findings using specific aromatase inhibitors and measuring 17β-oestradiol levels in 
these assays after testosterone treatment.   
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6       GENERAL DISCUSSION  
 
6.1   Sex hormone metabolism and activation in T cells 
 
The increased risk of autoimmune conditions such as SLE and RA in females has initiated a 
considerable amount of research into the role sex hormones play in immune and 
inflammatory responses. A large proportion of this research has focussed on the effect of 
oestrogen on immune responses. Sex hormones have substantial effects on the pathogenesis 
of chronic inflammatory disorders including autoimmunity, and this is clearly demonstrated 
during events of drastic changes in sex hormone levels (particularly oestrogens) including 
pregnancy, menstrual cycle and menopause. Endometriosis is a chronic inflammatory 
condition, in which oestrogen production in local tissues positively correlates with disease 
severity, and the onset of the disease occurs in predominately in woman of a reproductive age 
(Jones et al. 1995). Pregnancy has been associated with increased incidence of disease flares 
in SLE (Ruiz-Irastorza et al. 1996; Tengstrand et al. 2002). Androgen levels have also been 
associated with changes in immune responses and androgen deficiency has been associated 
with enhanced immunostimulatory responses and increased susceptibility to autoimmune 
diseases (Cutolo et al. 1991; Forsblad-d'Elia et al. 2009). Low androgen levels have been 
detected in both female and male SLE (and RA) patients (Lahita et al. 1987), and have been 
shown to be associated with disease activity . In contrast to oestrogens, the effects of 
androgens on immune responses have been less thoroughly researched, however the general 
consensus seems to be that androgens have predominately anti-inflammatory effects and 
therefore able to dampen inflammatory responses . 
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The initial aim of this project was to investigate differences in the way T cells from male and 
female healthy controls respond to androgens and oestrogens, and how they regulate their 
exposure to these hormones, as this could explain the enhanced T cell responses in females. 
To accomplish this, we explored the differences in the expression of a range of proteins 
including hormone receptors, downstream signalling molecules such as PPARs and enzymes 
involved in sex hormone metabolism between naïve CD4 T cells from healthy male and 
female donors. Our results showed that there were no significant differences the expression of 
sex hormone receptors in resting naïve CD4+ T cells between males and females. We would 
have suspected that the different levels of sex hormones seen in males and female (higher 
androgen levels verses oestrogen in males and vice versa in females) might be able to 
influence to expression of sex hormone receptors within CD4+ T cells, however this was not 
the case, thus suggesting that circulating sex hormone levels do not influence the expression 
of sex hormone receptors in T cells. Therefore, any differences in T cell responses between 
sexes are unlikely to be due to differences in sex hormone receptor availability; nevertheless, 
exposure of T cells to higher levels of androgens and oestrogens will increase overall sex 
hormone receptor mediated signals and therefore may influence T cell responses. It is well 
established that females and males have significantly different levels of androgens and 
oestrogens. These differences could be responsible for a large proportion of the differences in 
immune responses demonstrated between the sexes both in health and disease.  
 
While we did not observe any significant differences in baseline expression of sex hormone 
receptors, we did observe an upregulation of ER-β in female CD4+ T cells upon stimulation, 
which is interesting as others have shown that ER-β is able to mediate anti-inflammatory 
responses, in part by suppressing ER-α activation, which is the predominate isoform in 
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mediating the pro-inflammatory effects of oestrogens. Also, it has been shown that SLE 
CD4+ T cells have significantly higher ER-β mRNA levels compared to healthy controls (Inui 
et al. 2007), suggesting that SLE CD4+ T cells are suppressing their exposure to the pro-
inflammatory affects of oestrogens.  
In this study, we have largely focussed on the adaptive immune response. Sex hormones do 
not only exert their influences on adaptive immune responses, but have also been shown to 
influence innate immune responses (Seillet et al. 2012). Therefore it would be interesting to 
investigate any differences in sex hormone receptor expression and responses between the 
sexes in the cells of the innate immune system such as neutrophils, macrophages, NK cells 
and dendritic cells. As we did detect a significant upregulation in ER-β expression in female 
naïve CD4+ T cells after stimulation it would be interesting to follow this up by investigating 
the effects of specific agonists and antagonists for ER-α and ER-β to investigate their 
individual roles in T cell responses.  
 
One of the most important findings in this study was the upregulation of 5α-reductase in 
female T cells after stimulation, which was not observed in the male T cells. This is 
particularly interesting as 5α-reductase is responsible for the synthesis of the most potent 
androgen in the body, DHT.  Circulatory levels of DHT are significantly lower in females 
compared to males, therefore this observation suggested it may be advantageous for the 
female organism if T cells can increase their exposure to androgens by producing their own 
DHT in an intracine manner. DHT is the most potent androgen receptor agonist, therefore any 
DHT produced within the cell can directly act on the androgen receptor within the cell, thus 
initiating transcription of target genes. DHT among other androgens such as testosterone have 
shown to exert mainly anti-inflammatory effects, therefore suggesting that the increase in 5α-
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reductase 1 expression in female T cells may be a mechanism to prevent excessive 
stimulation. Clinical trials have been carried out for the treatment prostate cancer with 5α-
reductase inhibitors (Schröder et al. 2013). No publications on the effect of this drug on the 
immune system have emerged from these trials. It would be interesting to investigate the 
effect of dutasteride in healthy males in order to get a in vivo insight of the influences of DHT 
on the immune system in a human model on immune responses such as T cell cytokine 
production and proliferation; innate responses such as phagocytosis and respiratory burst by 
phagocytes. 5α-reductase knockout mice have also been used in studies to investigate the 
effect of DHT (Osborne and Frye 2009), therefore 5α-reductase knockout mice could be used 
to investigate changes in immune responses.  
 
 An interesting future series of experiments could  investigate changes in intracellular 
signalling after T cell stimulation that are able to regulate 5α-reductase 1 gene expression, 
and also if these mechanisms differ between males and females, as this might be responsible 
for this upregulation of 5α-reductase 1 in stimulated female T cells only. The regulation of 
5α-reductase transcription has been shown to be dependent on DHT-activated androgen 
receptor in a cell-type specific manner (Berman and Russell 1993; Hellwinkel et al. 2000; 
Kuhnle et al. 1994), therefore differences in this mechanism could explain our observations. 
Although, we were able to confirm this mRNA finding on the protein level, unfortunately 
even after months of carrying out optimisation experiments, it was extremely difficult to 
detect high concentrations of DHT in 5α-reductase activity assays, as most of the testosterone 
substrate was converted into androstenedione via 17β–HSD and the total detectable levels of 
DHT were at the lower limit of the sensitivity of the assay. Furthermore these assays require 
high concentrations of substrate to detect any subsequent metabolites, these extremely high 
141 
 
concentrations of testosterone (200nM) would not be found in circulation and the assay is 
therefore not reflecting the physiological situation. Also, extremely high concentrations of 
testosterone have shown to inhibit 5α-reductase activity (Pratis et al. 2003). Therefore, an 
alternative method to detect DHT would have to be developed to further confirm the 
increased enzymatic activity of 5α-reductase in activated T cells from female donors.   
This initial observation led us to hypothesise that this mechanism of upregulating androgen 
exposure by upregulation of  5α-reductase expression in immune cells could be deficient in 
SLE patients and might explain the deregulated immune responses in these patients. 
 
6.2   5α-reductase expression and regulation in peripheral blood mononuclear cells from 
SLE patients. 
 
We did not observe any significant differences in 5α-reductase expression in T cells on the 
baseline or after stimulation between SLE patients and healthy controls. However we did find 
a significantly higher expression of 5α-reductase in B cells from SLE patients compared to 
healthy controls. This is interesting for two reasons; firstly, B cell activation plays an 
important role in SLE, as our current understanding of this disease suggests that 
autoantibodies greatly contribute to the immune complex-driven complement activation seen 
in these patients (Stohl et al. 2012). Secondly, SLE patients have been shown to have very 
low androgen levels (positively correlating to disease severity) and in contrast, an increase in 
oestrogen metabolites has been observed in these patients. Most studies looking at the effects 
of sex hormones on B cells responses have mainly focused on oestrogen as it has shown to 
enhance humoral responses, however androgens have also shown to be able to exert 
immunosuppressant effects on B cells (Corrales et al. 2012).  
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In clinical trials for the potential use of sex hormones for the treatment of various 
autoimmune diseases, has been investigated. Most commonly DHEA has been used as many 
autoimmune disorders have shown an inverted correlation of DHEA/DHEA with disease 
severity (Straub et al. 2003). Low DHEA levels have been linked to high IL-6 levels in older 
people, and this has been suggested to play an important part in the increased incidence of 
autoimmune conditions such as RA as individuals over the ages of 60 (Hammer et al. 2005). 
However, the effects of DHEA, which have shown to be anti-inflammatory (Straub et al. 
1998), is more likely due to the downstream metabolites of DHEA, as DHEA itself is an 
inactive precursor for active androgens and oestrogens. For this reason, testosterone has been 
investigated as a potential treatment for SLE. However, a trial treating SLE patients with 
testosterone patches did not see any significant differences in disease activity or patient 
symptoms (Gordon et al. 2008). Our observation of conversion of testosterone into 
oestrogens, which have shown to exacerbate disease severity in SLE patients, could be an 
explanation for the lack efficacy of testosterone therapy in SLE.  However, the use of DHT as 
treatment for SLE may be beneficial as DHT is more potent than testosterone and therefore 
binds to the androgen receptor with greater affinity, and also cannot be converted in 
downstream to oestrogens.  
 
6.3  Regulation of IL-2 production by sex hormones 
 
In CD4+ T cells from women, we observed an interesting pattern of regulation of IL-2 
production at low concentrations of testosterone, which are physiologically found in women, 
the percentage of IL-2 producing female CD4+ T cells significantly increased compared to 
the untreated control and in contrast the higher testosterone concentrations significantly 
decreased the IL-2 levels in comparison to the CD4+ T cells treated with low concentrations 
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of testosterone. This decrease in IL-2 production at high testosterone concentrations was also 
observed in male CD4+ T cells. We did not find this pattern with DHT. This observation of 
increased proportion of IL-2-producing CD4+ T cells from females was completely 
unexpected as androgens have been shown to suppress pro-inflammatory responses. 
However, as testosterone can be converted into 17β-oestradiol, it suggested that testosterone 
was being converted into oestrogen at the lower concentrations. This was later confirmed as 
tamoxifen treatment abolished the increase of IL-2 at low testosterone concentrations. We 
also found that IL-2 and IFN-y showed a 17β-oestradiol dose dependent increase, however 
this just short of being statistically significant for IL-2, therefore it would be important to 
increase the number of repeats. However, the question still remains to why do only low, but 
not higher levels of testosterone increase production of IL-2. A possible explanation may be 
that the conversion of testosterone to estradiol by aromatase is saturated at these 
concentrations and the androgenic effect of testosterone tilts the balance towards an 
inhibitory signal, as this inhibition of aromatase activity by high concentrations of 
testosterone has been previously demonstrated (Schmidt et al. 2005). Other explanation could 
be due to higher aromatase activity in female macrophages compared to males, this as of yet 
has not been previously reported.  
 
One of the key defects of SLE T cells is that they produce significantly lower levels of IL-2 
in response to TCR stimulation and even after in vitro treatment with exogenous IL-2, SLE T 
cells remain unresponsive. IL-2 knockout mice have been shown to develop lethal 
autoimmune diseases, which has been partly explained by the reduction of regulatory T cells 
in an environment lacking IL-2, which has been shown to be vital for the development and 
survival of regulatory T cells (Malek and Bayer 2004). The interesting finding that Tregs 
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cannot produce IL-2 upon TCR stimulation and rely on IL-2 produced from other cells 
further supports this argument. Therefore, if the main producers of IL-2 (T cells) are defected 
and produce very low levels of IL-2 as seen in SLE, then this would result in reduced Treg 
responses, thus peripheral tolerance may be lost resulting in the development of 
autoimmunity. A possible explanation for this reduced IL-2 production by SLE T cells is the 
observation that CREMα transcriptional activity is elevated and levels of phosphorylated 
CREB are reduced in SLE T cells, thus an increased suppression of IL-2 production is 
observed (Juang 2005). It still remains unclear if oestrogen is able mediate this process of IL-
2 transcription by modulating CREMα activity at physiological concentrations, but 
additionally the effect of androgens on CREMα and CREB activity should also be 
investigated, which to my knowledge has not been previously done and could explain the 
mechanism behind the contrasting affects of androgens and oestrogens on IL-2 transcription. 
Androgens are able to negatively regulate target gene expression in an androgen receptor-
dependent manner, in which upon ligand activation of AR, AR is able to bind to negative-
androgen responses elements (nARE) in the promoter regions of the target genes (Li et al. 
2011; Qi et al. 2012). Interestingly, androgen receptors have shown to negatively regulate 
TGF-β transcription in prostate cells, as nARE regions are present in the TGF-β promoter 
region (Qi et al. 2012). Therefore, another interesting possibility could that nARE regions 
could be present in the IL-2 promoter and can mediate androgen receptor-dependent 
suppression of IL-2 transcription.  
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Figure 6.1 illustrates the main findings of the project.  
Firstly, it was demonstrated that female not male T cells were able to upregulate 5α-reductase 
1 expression upon stimulation, which could potentially lead to an increase in conversion of 
testosterone to the more potent androgen 5α-dihydrotestosterone (DHT). Secondly, this 5α-
reductase 1 expression regulation upon stimulation was also observed in Systemic Lupus 
Erythematosus (SLE) T cells and interestingly SLE B cells expressed higher 5α-reductase 1 
expression compared to healthy controls. Thirdly, in vitro treatment of female CD4+ T cells 
with low concentrations of testosterone, which was being converted into 17β-estradiol by 
macrophages, resulted in an increase in IL-2 upon oestrogen receptor activation in female 
CD4+ T cells by 17β-estradiol.  
 
 
6.4   Future work 
 
In this study, we made a novel discovery that female T cells were upregulating their 
expression of 5α-reductase 1 upon stimulation, and therefore may be increasing their 
exposure to the anti-inflammatory effects of androgens. It would be interesting to see if the 
inhibition of 5α-reductase 1 activity by transfection with dominant negative enzyme or 
knockdown by SiRNA has any effect on T cell responses. The differences we have seen in 
the gene regulation of 5α-reductase expression between T cells from male and female donors 
is most likely caused by gender specific epigenetic modifications. This could be further 
investigated in a follow-on project. 5α-reductase protein expression showed that expression 
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peaked at 24 hours; therefore it would be interesting to measure IL-2 production at this time 
point, which coincides with potentially increased DHT levels. However, our method limited 
our incubation duration to 4 hours, as our the time course for time period as brefeldin A is 
toxic and incubation longer than 6 hours is not recommended and in a cytokine time course 
(data not shown) we did see a decrease in both IL-2 and IFN-y producing cells after 24-48 
hours treatment with brefeldin A, which was predominately due to the increase in dead cells. 
Another method such as detection by ELISA must be adopted in order to investigate effects 
of androgens on cytokine production for longer time durations.  
 
To further characterise the outcomes of 5α-reductase upregulation in SLE B cells, it would be 
important to investigate the effects of DHT on B cell responses such as antibody production 
and antigen presentation to T cells, as previous studies have studied the effects of testosterone 
on B cell responses but not DHT (refs), which directly activates the androgen receptor; 
whereas testosterone can be converted to oestrogens, thus it would be important to establish if 
androgens are mediating these affects observed on B cell antibody production or oestrogens. 
 
We did not see a dramatic effect of dutasteride treatment on IL-2 and IFN-γ production, very 
high concentrations were necessary to observe any changes. It is however difficult to 
establish how much dutasteride actually enters the cells. The concentration needed to reduce 
IL2 production are unlikely to be reached in vivo in patients treated for hormone dependent 
prostate cancer. It would also be interesting to repeat more IL-10, IL-17 and TNF-α assays to 
see if any of the preliminary differences observed after androgen or oestrogen treatment are 
statistically significant. Also, it would be interesting to see if dutasteride treatment has any 
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affect on these cytokines, as they might be more sensitive to this dutasteride treatment 
compared to IL-2 and IFN-γ.  
To confirm the differences in IL-2 production observed after testosterone treatment, it would 
be important to use an aromatase inhibitor to confirm that the low concentrations testosterone 
is being converted into 17β-estradiol. It would also be important to use an androgen receptor 
inhibitor to completely dismiss the effects of androgens on IL-2 production at the lower 
concentrations, and confirm the role of androgen on IL-2 production at the higher 
concentrations of testosterone. Also, it would be important measure oestrogen levels in 
samples treated with androgens, to confirm the conversion into oestrogens. We currently have 
no technique to do this at the necessary level of sensitivity available to us, but the Arlt 
laboratory is currently working on establishing an assay. It would also be necessary to repeat 
the IL-2 and testosterone assays with purified T cells in the presence or absence of 
macrophages to confirm that these cells, through their aromatase activity, mediate the effects 
of low testosterone concentrations on IL-2 production. It would also be important to 
investigate the changes in signalling and transcription pathways that results in this increase 
and decrease IL-2 production in response to androgens/oestrogens treatment.  
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8      APPENDIX  
 
8.1   Protein expression of PPARs naiveCD4+ T cells upon stimulation.  
 
 
 
 
 
 
 
 
Naive CD4+ CD45 RA+ T cells from males (n=6) and females (n=6) were stimulated with anti 
CD3 and anti CD28 stimulation beads (alongside unstimulated cells) for 24 hours and then 
stained for intracellular expression of  A) PPAR-α, B) PPAR-γ and C) PPAR-δ. Samples 
were analysed using flow cytometry. Horizontal lines represent the median. MFI: median 
fluorescence intensity. 
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Table 8.1   Clinical data for SLE patients. PBMCs taken from these patients were measured for 5α-reductase expression using flow cytometry 
(Chapter 3). 
 
Age Gender GEN  
L 
GEN 
N 
MUC 
L 
MUS 
N 
NEU  
L 
NEU 
N 
MSK  
L 
MSK 
N 
CAR  
 L 
CAR  
N 
VAS  
 L 
VAS  
N 
REN  
L 
REN 
N 
HAE  
L 
HAE 
N 
COM
P 3 
COM
P 4 
DNA 
Quan 
BILAG 
S 
35 Female D 0 C 1 D 0 B 5 D 0 D 0 D 0 C 1 1.12 0.26 0 7 
59 Female D 0 C 1 D 0 D 0 D 0 D 0 C 1 D 0 1.47 0.51 0 2 
52 Female D 0 C 1 D 0 B 5 D 0 D 0 D 0 D 0 1.19 0.36 0 6 
64 Female D 0 D 0 D 0 C 1 D 0 C 1 D 0 D 0 1.02 0.10 0 2 
43 Female C 1 C 1 C 1 C 1 D 0 D 0 D 0 C 1 1.19 0.20 30 4 
53 Female D 0 C 1 D 0 B 5 D 0 D 0 D 0 D 0 1.51 0.35 0 6 
52 Female D 0 C 1 D 0 D 0 D 0 D 0 D 0 C 1 0.39 0.05 383 2 
37 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 1.04 0.25 0 0 
36 Female D 0 B 5 D 0 D 0 D 0 D 0 D 0 D 0 1.16 0.42 0 5 
67 Female D 0 C 1 D 0 D 0 D 0 D 0 D 0 D 0 1.16 0.23 0 1 
66 Female D 0 C 1 D 0 D 0 B 5 D 0 D 0 C 1 1.17 0.33 42.9 7 
32 Female D 0 C 1 D 0 A 12 D 0 D 0 D 0 D 0 1.06 0.20 0 13 
27 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 0.99 0.13 0 0 
41 Female D 0 C 1 D 0 C 1 D 0 D 0 C 1 D 0 1.08 0.28 103.1 3 
38 Female D 0 C 1 D 0 C 1 D 0 D 0 C 1 D 0 1.12 0.34 0 3 
42 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 1.03 0.30 0 0 
51 Female D 0 C 1 D 0 C 1 D 0 D 0 C 1 B 5 ND ND ND 8 
66 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 B 5 0.91 0.16 0 5 
47 Female D 0 C 1 D 0 D 0 D 0 D 0 D 0 D 0 1.25 0.21 0 1 
66 Female D 0 C 1 D 0 C 1 B 5 D 0 C 1 C 1 0.92 0.24 41.5 9 
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35 Female D 0 C 1 D 0 D 0 D 0 D 0 D 0 D 0 1.24 0.25 45.0 1 
43 Female D 0 B 5 D 0 B 5 D 0 B 5 D 0 C 1 1.32 0.20 22.1 16 
32 Female C 1 C 1 D 0 B 5 D 0 D 0 D 0 D 0 1.15 0.20 0 7 
21 Female D 0 D 0 D 0 C 1 B 5 D 0 D 0 B 5 0.94 0.15 91.9 11 
38 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 1.22 0.35 0 0 
25 Female B 5 B 5 D 0 B 5 D 0 D 0 D 0 D 0 1.50 0.29 0 15 
49 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 0.85 0.10 88 0 
66 Female D 0 C 1 D 0 C 1 C 1 D 0 D 0 C 1 0.98 0.27 33.8 4 
41 Female D 0 D 0 D 0 B 5 D 0 C 1 D 0 D 0 1.04 0.13 250.6 6 
41 Female D 0 D 0 D 0 C 1 D 0 D 0 D 0 C 1 0.86 0.19 0 2 
38 Female D 0 D 0 D 0 D 0 D 0 D 0 C 1 C 1 1.44 0.43 0 2 
44 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 0.95 0.17 0 0 
60 Female D 0 D 0 D 0 B 5 D 0 D 0 D 0 D 0 1.39 0.32 0 5 
46 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 1.22 0.33 0 0 
47 Female D 0 C 1 D 0 C 1 D 0 D 0 D 0 D 0 1.55 0.31 0 2 
59 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 1.21 0.18 0 0 
46 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 1.51 0.2 0 0 
59 Female D 0 C 1 D 0 C 1 D 0 D 0 D 0 D 0 1.59 0.55 0 2 
26 Female D 0 C 1 D 0 C 1 D 0 D 0 C 1 C 1 0.6 0.04 206.6 4 
45 Female D 0 C 1 D 0 C 1 D 0 D 0 D 0 D 0 1.41 0.42 0 2 
67 Female D 0 D 0 D 0 D 0 D 0 D 0 C 1 D 0 1.03 0.24 232.5 1 
58 Female D 0 C 1 E 0 D 0 D 0 D 0 D 0 C 1 1.13 0.19 257.6 2 
52 Female D 0 D 0 D 0 D 0 D 0 D 0 D 0 D 0 1.26 0.14 324.9 0 
43 Female E 0 D 0 E 0 D 0 E 0 E 0 E 0 D 0 1.07 0.22 0 0 
33 Female D 0 D 0 E 0 D 0 D 0 D 0 D 0 D 0 1.11 0.22 51.1 0 
35 Female D 0 D 0 D 0 D 0 E 0 D 0 D 0 D 0 1.11 0.22 20.8 0 
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47 Female D 0 B 5 E 0 D 0 D 0 D 0 D 0 D 0 0.84 0.16 34.4 5 
66 Male E 0 C 1 E 0 D 0 E 0 E 0 E 0 C 1 1.28 0.20 0 2 
45 Female D 0 C 1 E 0 C 1 E 0 E 0 E 0 D 0 1.37 0.33 0 2 
48 Female D 0 D 0 E 0 C 1 E 0 E 0 E 0 C 1 1.24 0.18 0 2 
43 Female D 0 D 0 E 0 D 0 E 0 D 0 E 0 B 5 0.91 0.10 0 5 
31 Male D 0 D 0 E 0 D 0 D 0 E 0 D 0 C 1 1.13 0.17 24.9 1 
36 Female D 0 D 0 E 0 D 0 D 0 E 0 D 0 C 0 0.75 0.08 163 0 
28 Female D 0 D 0 E 0 D 0 E 0 D 0 E 0 D 0 0.93 0.11 0 0 
BILAG scoring system, which examines multiple clinical features, was used to determine disease severity in patients. Abbreviations: General (GEN);  Mucocutaneous 
(MUC); Musculoskeletal (MUS); Neurological (NEU); Cardiovascular (CAR); Vasculitis (VAS); Renal (REN); Haematology (HAE); Non-detectable (ND). 
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Table 8.2   Clinical data for SLE patients.  Treatment information for SLE patients used in the study for 5α-reductase expression in immune 
cells (Chapter 3). 
Age Gender Treatment 
35 Female Prednisolone 
59 Female Hydroxychloroquine, methotrexate 
52 Female Hydroxychloroquine, prednisolone, zathioprine 
64 Female Hydroxychloroquine, prednisolone, methotrexate 
43 Female Hydroxychloroquine, prednisolone, cyclophosphamide (3 weeks) 
53 Female Hydroxychloroquine, prednisolone, zathioprine 
52 Female      Hydroxychloroquine 
37 Female Hydroxychloroquine, prednisolone, zathioprine 
36 Female Hydroxychloroquine, prednisolone, mycophenolate mofetil 
67 Female Hydroxychloroquine, prednisolone  
66 Female Hydroxychloroquine, prednisolone, zathioprine 
32 Female Prednisolone, mycophenolate mofetil 
27 Female Hydroxychloroquine, prednisolone 
41 Female Prednisolone, ciclosporin 
38 Female Hydroxychloroquine, prednisolone, zathioprine 
42 Female Hydroxychloroquine, prednisolone, mycophenolate mofetil 
51 Female Hydroxychloroquine, prednisolone, zathioprine 
66 Female      Hydroxychloroquine 
47 Female Hydroxychloroquine, prednisolone 
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66 Female Hydroxychloroquine, prednisolone, zathioprine 
35 Female Hydroxychloroquine, prednisolone, methotrexate 
43 Female Hydroxychloroquine, prednisolone, zathioprine 
32 Female Hydroxychloroquine, prednisolone, zathioprine 
21 Female      Hydroxychloroquine, prednisolone 
38 Female Hydroxychloroquine 
25 Female Hydroxychloroquine, prednisolone 
49 Female Hydroxychloroquine, prednisolone 
66 Female Hydroxychloroquine, prednisolone 
41 Female Hydroxychloroquine, prednisolone 
41 Female Hydroxychloroquine, ciclosporin 
38 Female Hydroxychloroquine 
44 Female Hydroxychloroquine, prednisolone 
60 Female Hydroxychloroquine, prednisolone, azathioprine 
46 Female Hydroxychloroquine, prednisolone, methotrexate 
58 Female Hydroxychloroquine, prednisolone, azathioprine 
52 Female Hydroxychloroquine, prednisolone, methotrexate 
43 Female Hydroxychloroquine 
33 Female Hydroxychloroquine 
35 Female Hydroxychloroquine, prednisolone, azathioprine 
47 Female Hydroxychloroquine 
66 Male Hydroxychloroquine, prednisolone, mycophenolate mofetil 
45 Female Hydroxychloroquine 
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 48 Female Hydroxychloroquine, prednisolone, methotrexate 
43 Female Hydroxychloroquine, ciclosporin 
31 Male Hydroxychloroquine 
36 Female Hydroxychloroquine, prednisolone, azathioprine 
28 Female Hydroxychloroquine, mycophenolate mofetil 
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8.2   The proportion of IL-2 and IFNγ producing CD4+ T cells after 
dutasteride treatment.     
 
 
 
 
 
 
PBMCs were stimulated with anti CD3 and anti CD28 activation beads and cultured for 4 
hours with different concentrations of dutasteride in the presence of  brefeldin A to measure 
the proportion of  A) IL-2 producing CD4+ T cells and B) IL-2 producing CD4+ T cells using 
flow cytometry (n=3). Error bars represent SEM.   
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 8.3     Cytokine production in T cells after testosterone and DHT 
treatment. 
 
 8.3. 1    IL-10 production by T cells after testosterone and DHT treatment. 
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PBMCs were stimulated with anti CD3 and anti CD28 activation beads and cultured for 4 
hours with different concentrations of testosterone (black bars) and DHT (checkered bars) in 
the presence of  brefeldin A to measure the proportion of  IL-10 producing T cells from A) 
females (n=3) and B) males (n=3) using flow cytometry. Error bars represent SEM.   
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8.3. 2    IL-17 production by T cells after testosterone and DHT treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PBMCs were stimulated with anti CD3 and anti CD28 activation beads and cultured for 4 
hours with different concentrations of testosterone (black bars) and DHT (checkered bars) in 
the presence of  brefeldin A to measure the proportion of  IL-17 producing T cells from A) 
females (n=3) and B) males (n=3) using flow cytometry. Error bars represent SEM.   
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8.3. 3    TNF-α production by T cells after testosterone and DHT treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PBMCs were stimulated with anti CD3 and anti CD28 activation beads and cultured for 4 
hours with different concentrations of testosterone (black bars) and DHT (checkered bars) in 
the presence of  brefeldin A to measure the proportion of  TNF-α  producing T cells from A) 
females (n=3) and B) males (n=3) using flow cytometry. Error bars represent SEM 
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